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ABSTRACT 
The prevalence of nitrogen heterocycles in medicinally important compounds has, for 
years, inspired synthetic chemists for developing strategies to form new heterocyclic 
scaffolds and methods that streamline the syntheses of complex heterocycles. Giving into the 
cause, this dissertation primarily focuses on development of transition-metal catalyzed 
hydroacylation of alkenes as a platform for enantioselective synthesis of multiple classes of 
polycyclic nitrogen heterocycles.  
Development of catalytic, enantioselective intramolecular hydroacylation of N-
vinylindole-2-carboxaldehydes that occur in the presence of a readily accessible rhodium 
catalyst and form chiral, non-racemic 2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-ones in high 
yields and enantioselectivities has been described. The dihydropyrroloindolone products can 
be readily transformed to dihydropyrroloindoles that are core structures present in a variety 
of natural products and biologically relevant compounds. This methodology could be 
extended to hydroacylations of N-allylindole- and N-allylpyrrole-2-carboxaldehydes in 
construction of six-membered rings that generated 7,8-dihydropyrido[1,2-a]indol-9(6H)ones 
and 6,7-dihydroindolizin-8(5H)-ones in moderate to high yields with excellent 
enantioselectivities. In contrast to many alkene hydroacylations that form six-membered 
rings, these endo-selective annulative processes occur in the absence of ancillary 
functionality to stabilize the acylrhodium(III) hydride intermediate.  
Our protocol for rhodium-catalyzed hydroacylation of N-vinylindole-2-
carboxaldehyde could be leveraged for installation of stereochemical triad in 2,3-dihydro-
1H-pyrrolo[1,2-a]-indole core of putative structure of yuremamine. The enantioselective 
model synthesis was achieved in 39% overall yield and 96% ee over 5 steps. An 
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enantioselective synthesis of a densely functionalized dihydropyrroloindolone that maps onto 
the putative structure of yuremamine is demonstrated in 26% yield and 97% ee over 8 steps. 
Additionally, exo-selective nickel- and NHC-catalyzed hydroacylations could be 
coupled with catalytic enantioselective -(hetero)arylation reactions in a sequential synthetic 
strategy to form a wide variety of nitrogen-containing heterocyclic ketones bearing -chiral 
quaternary stereogenic centers. Exo-selective, intramolecular Ni-catalyzed hydroacylations 
of N-homoallylindole- and N-homoallylpyrrole-2-carboxaldehydes form -substituted six-
membered heterocyclic ketones in up to 95% yield, while N-heterocyclic carbene (NHC)-
catalyzed hydroacylations of N-allylindole- and N-allylpyrrole-2-carboxaldehydes form -
substituted five-membered heterocyclic ketones in up to 99% yield. The racemic five- and 
six-membered products of Ni- and NHC-catalyzed hydroacylation reactions are readily 
transformed into heterocyclic ketones containing an -chiral quaternary stereogenic center 
by enantioselective Ni-catalyzed -arylation and -heteroarylation reactions. The identity of 
the precatalyst for Ni-catalyzed -(hetero)arylation is dictated by the identity of the –
substituted heterocyclic ketone starting material. -(Hetero)arylations of six-membered 
heterocyclic ketones occur at 65-85 °C in the presence of a catalyst generated in situ from 
Ni(COD)2 and (R)-BINAP or (R)-DIFLUORPHOS. -(Hetero)arylation of five-membered 
heterocyclic ketones must be conducted at room temperature in the presence of an [((R)-
BINAP)Ni(2-NC-Ph)] precatalyst or a catalyst generated in situ from Ni(COD)2, (R)-
DIFLUORPHOS and benzonitrile. 
Finally, studies on Ni2P nanocrystal catalyzed hydrogenation of phenylacetylene have 
been reported. The model reaction is studied with both hollow and solid Ni2Ps in two 
different solvents (1,4-dioxane and 1-propanol). Recycling studies in both solvents 
ix 
 
 
demonstrated increase in catalytic activity of Ni2P nanocrystals over reaction cycles.  
Structural characterization of recycled Ni2P nanocrystals via powder XRD, TEM and XPS 
analyses revealed reduction in size of hollow nanoparticles along with the formation of Ni(II) 
species after hydrogenation reactions. Systematic characterization of Ni2P nanocrystals 
isolated after each reaction throughout the lifetime of recycling study (in both 1,4-dioxane 
and 1-propanol) has been demonstrated. 
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THESIS ORGANIZATION 
This thesis comprises of six chapters. Chapter 1 is a brief literature survey on 
progress of transition-metal catalyzed hydroacylation of olefins over last four decades. A 
portion of the review presented in Chapter 1 was published as a highlight in Organic 
Chemistry Frontiers with contributions from Kirsten F. Johnson, Kevin L. Vickerman and 
James A. Walker. Chapter 2 describes our studies on synthesis of indole- and pyrrole-based 
chiral, non-racemic polycyclic nitrogen heterocycles via rhodium-catalyzed intramolecular 
hydroacylation reactions. Rhodium-catalyzed hydroacylation of N-allylindole-2-
carboxaldehydes was developed by Dr. Xiang Wei Du (Postdoctoral fellow in Stanley group) 
based on the initial results obtained by the author of this thesis. Chapter 3 describes an 
enantioselective model synthesis of the core and progress toward the total synthesis of the 
putative structure of yuremamine utilizing enantioselctive hydroacylation methodology as 
described in Chapter 2 as the key synthetic step. David T. Bainbridge is an undergraduate 
student at ISU who helped with the synthesis of TBS-protected tryptophol. Chapter 4 
describes a sequential protocol involving exo-selective nickel or NHC-catalyzed 
hydroacylation and enantioselective -arylation reactions that constructs a wide variety of 
highly enantioenriched nitrogen containing heterocyclic ketones bearing -chiral quaternary 
stereogenic centers. James A. Walker Jr. is a graduate student in Stanley group who 
developed the NHC-catalyzed hydroacylation protocol and helped with the identification of 
nickel catalyst for -arylation of five-membered nitrogen heterocycles. Iowa State 
University’s crystallographer, Dr. Arkady Ellern collected all X-ray data and determined the 
absolute configuration of the structures. Chapter 5 describes our studies toward nickel 
phosphide (Ni2P) nanocrystal catalyzed hydrogenation of phenylacetylene. This work has 
xi 
 
 
been performed in close collaboration with Himashi Andaraarachchi, a graduate student in 
Prof. Javier Vela’s group. Chapter 6 is general conclusion and outlook. It summarizes the key 
findings in each chapter and identifies areas for further research.
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CHAPTER I 
 A SNAPSHOT INTO FORTY YEARS OF TRANSITION-METAL CATALYZED 
HYDROACYLATION OF ALKENES 
 
A portion of the review is published as a Highlight in Organic Chemistry Frontiers
1
 
1.1 General Introduction and Scope 
Transition metal-catalyzed alkene hydroacylation, the formal addition of an aldehyde C-
H bond across an unsaturated C-C bond (Equation 1.1 and 1.2), has emerged as a powerful, 
catalytic process to synthesize ketones over the past four decades.
1
 The identification and 
development of new catalysts has greatly expanded the scope and synthetic utility of these 
hydroacylation reactions in recent years. Intramolecular alkene hydroacylation reactions are now 
 
well-established methods to synthesize carbocyclic and heterocyclic ketones, often with high 
enantioselectivities. These transformations generally occur in the presence of transition-metal or 
NHC catalysts, and the selection of the specific catalyst type determines the regiochemical 
outcome of the reaction. NHC-catalyzed intramolecular hydroacylations occur with exo-
selectivity (formal Markovnikov selectivity), while transition metal-catalyzed hydroacylations 
can occur with either endo-selectivity (formal anti-Markovnikov selectivity) or exo-selectivity 
(Equation 1.3). The potential for complementary regioselectivity can be utilized for synthesis of 
                                                 
1
 Ghosh, A.; Johnson, K. F.; Vickerman, K. L.; Walker Jr., J. A.; Stanley, L. M. Org. Chem. 
Front., 2016, 3, 639-644. 
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two distinct ketone products from the same substrate. In addition, the development of 
intermolecular hydroacylations of new combinations of alkenes and alkynes with aldehydes 
continues to rapidly expand and provide direct routes to new ketones from simple starting 
materials.  
Despite recent advances in catalytic alkene hydroacylation reactions, many challenges 
remain to fully harness the synthetic potential of these valuable processes. These challenges 
include: intramolecular hydroacylations to form medium and large rings in the absence of 
functional groups to stabilize catalytic intermediates; intermolecular hydroacylations that 
encompass a much broader array of substrates; and new catalyst types that improve activity, 
complement the selectivity, and reduce the cost of widely studied rhodium complexes of 
bisphosphine ligands.  
Since the initial report by Sakai and co-workers in 1972,
2
 hydroacylation of alkenes has 
evolved to encompass reactions catalyzed by not only transition metal complexes, but also N-
heterocyclic carbenes (NHCs)
3
 and photocatalysts.
4
 This review will focus on recent 
developments in transition metal-catalyzed alkene hydroacylation reactions. The discussion is 
divided by catalyst type and includes highlights of rhodium-, cobalt-, ruthenium-, iridium-, and 
nickel-catalyzed processes. 
1.2 Rhodium-Catalyzed Alkene Hydroacylation 
The first transition metal-catalyzed olefin hydroacylation reaction was reported by Sakai 
and co-workers in 1972 in which reaction of a variety of 4-enals generated cyclopentanones in 
3 
 
presence of a stoichiometric amount of Wilkinson’s complex along with the formation of 
cyclopropanes as byproducts via a decarbonylative pathway (Equation 1.4).
2
  
 
Since the first report of transition metal-catalyzed olefin hydroacylation, rhodium-catalyzed 
alkene hydroacylation reactions have remained at the forefront of studies in the area. A generally 
accepted mechanism for rhodium-catalyzed hydroacylation is illustrated in Figure 1.1. The key 
steps involve oxidative addition of Rh(I) across the aldehyde C-H bond to form an acyl 
rhodium(III)hydride intermediate, coordination of alkene to the metal center followed by 
migratory insertion. Finally reductive elimination yields the ketone product with regeneration of 
the Rh(I) catalyst.  
 
Figure 1.1 Reaction mechanism of rhodium-catalyzed hydroacylation and decarbonylation 
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An unproductive catalyst decomposition pathway involving decarbonylation and reductive 
elimination is often competitive with hydroacylation pathway. Strategies to stabilize the acyl 
rhodium(III)hydride intermediate by utilizing additional chelating functionality often reduce the 
extent of decarbonylation (Discussed in detail later).  
After the first report on hydroacylation, subsequent examples of hydroacylative 
cycloisomerizations using sub-stoichiometric amounts of rhodium catalysts (up to 50 mol%) 
were reported by the Miller and Larock groups that employed ethylene saturated solvents for the 
synthesis of cyclopentanone derivatives from substituted γ-pentenals.5 They noted formation of a 
considerable amount of byproducts from a reductive decarbonylation pathway. The first 
enantioselective example of hydroacylation, a serendipitous discovery by James and Young in 
1983 during their attempt toward kinetic resolution of 4-pentenals by aldehyde decarbonylation, 
generated -quaternary cyclopentenones in 40-50% yield and up to 52% ee.
6
 However, the most 
significant advancement in early alkene hydroacylation came from the laboratory of Bosnich in 
1988. Bosnich and co-workers developed catalyst systems involving cationic rhodium species in 
combination with bisphosphine ligands that significantly reduced the formation byproducts 
arising from competing reductive decarbonylation pathway even in the presence of 1 mol % 
catalyst.
7
 Ever since this discovery, a large number of reports including many recent ones 
effectively utilized cationic rhodium species as the catalyst for hydroacylation of varied substrate 
classes. Both Bosnich and Sakai groups independently illustrated catalytic enantioselective 
intramolecular hydroacylation of 4-substituted-4-pentenals using cationic rhodium perchlorate 
catalysts derived from BINAP or Me-Duphos.
8
 Identifying the appropriate chiral ligand for 
particular substrates was the key for obtaining high enantioselectivity. A number of reports 
5 
 
including desymmetrizations and kinetic resolutions for synthesis of enantiopure 3,4-
disubstituted cyclopentanones followed this report.
9
 
Inspired by Tanaka and Suemune’s report on desymmetrization of β-
bis(alkenyl)aldehydes to generate cyclopentanones bearing β-quaternary stereogenic centers,10 
Dong and coworkers recently developed an enantioselective desymmetrization of α-trisubstituted 
aldehydes to form cyclopentanones with α-quaternary stereogenic centers (Scheme 1.1).11 A 
catalyst generated in situ from [Rh(coe)2Cl]2, (R)-DTBM-MeO-BIPHEP and AgBF4 facilitates 
the desymmetrization of the α-quaternary center through an isomerization-hydroacylation 
cascade.  Key to this isomerization-hydroacylation cascade is a rare endocyclic -hydride 
elimination for which this study provides experimental evidence that supports previous 
theoretical studies. The chiral Rh catalyst enables selective formation of a variety of -
vinylcyclopentanones (R = alkyl, aryl, heteroaryl) in high yields (73-91%) with excellent 
enantioselectivities (91-99% ee). 
Scheme 1.1 Desymmetrization of α-quaternary centers by isomerization-hydroacylation  
 
6 
 
Morehead and coworkers reported enantioselective hydroacylation of -substituted 2-
vinyl benzaldehydes to access a range of chiral 3-substituted indanones with high yield (88-98%) 
and high enantioselectivity (70-99%).
12
 They noted that 2-vinyl benzaldehyde with no 
substitution at the double bond formed the dimerized product in up to 75% yield (Scheme 1.2). 
However, the hydroacylation product, 1-indanone was isolated in up to 95% yield when the 
substrate was added slowly over 18 hours.  
Scheme 1.2 Access to chiral 3-substituted indanones via asymmetric intramolecular 
hydroacylation  
 
 
In 2011, Carriera and co-workers reported highly enantioselective, intramolecular 
hydroacylation of 4-pentenals catalyzed by cationic rhodium complexes featuring 
phosphoramidite-alkene ligands and an achiral phosphine co-ligand (Scheme 1.3).
13
 
Scheme 1.3 Asymmetric intramolecular hydroacylation catalyzed by 
rhodium(I)phosphoramidite-alkene complex 
 
 
Examples of intramolecular hydroacylation reactions to form larger rings were often 
limited due to catalyst decomposition by reductive decarbonylation becoming prominent as the 
7 
 
ring size increases and rate of cyclization decreases. Thus, hydroacylation to form rings of 
greater than five atoms are often driven by strain release or rely on heteroatom functionality 
contained at specific sites within the substrate molecules to stabilize acylrhodium(III) hydride 
intermediates and prevent catalyst decomposition. Gable and co-workers in 1991 reported 
formation of six-membered cyclohexanone derivatives by hydroacylation of hexenals with a 
rigid carbohydrate backbone.
14
 They hypothesized that formation of a cyclopentanone ring was 
disfavored due to the ring strain that would be present in the resulting 5,5,5-tricyclic product.  
Shair and co-workers in 2000 showed that intramolecular hydroacylation could be 
extended to the synthesis of eight-membered rings by strategically placing in the substrate a 
cyclopropane ring capable of fragmentation (Scheme 1.4).
15
 The principal step in this 
transformations involved fragmentation and isomerization of rhodacycle I to ring-expanded 
rhodacycle II, followed by reductive elimination to generate eight-membered cyclic product.  
Scheme 1.4 Synthesis of eight-membered rings via intramolecular hydroacylation 
 
In 2002, Mori and co-workers reported the first example of synthesis of cycloheptanones 
via intramolecular hydroacylation of 4,6-dienals.
16
 In the same year, Bendorf et. al reported 
synthesis of medium ring sulfur heterocycles from ω-alkenals and alkynals containing a sulfur 
tether atom appropriately positioned in the substrate to stabilize the acyl rhodium(III)hydride 
intermediate (Scheme 1.5).
17
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Scheme 1.5 Synthesis of seven- and eight-membered sulfur heterocycles via chelation-assisted 
intramolecular hydroacylation 
 
 
In 2009, Dong and co-workers developed the first asymmetric hydroacylation strategy 
that synthesized enantiopure medium-sized rings (seven and eight-membered) utilizing 
coordinating heteroatoms (ether, sulfide and sulfoxide) in the tether to promote hydroacylation 
over decarbonylation.
18
 Furthermore, they illustrated a switch in the regioselectivity of the 
transformation by modulating the ligand structure. Thus, they could access both seven- (endo-
selectivity) and eight-membered (exo-selectivity) rings from the same substrate with excellent 
regio- and enantiocontrol by using two different chiral ligands in combination with the 
rhodium(I) precursor (Scheme 1.6).  
Scheme 1.6 Accessing formal Markovnikov and anti-Markovnikov products by a ligand switch 
 
Douglas and co-workers utilized Jun’s strategy of metal-organic cooperative catalysis to 
access six- and seven-membered cyclic ketones.
19
 These hydroacylation reactions involved in 
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situ formation of imines to install chelating functionality to stabilize the resulting 
iminorhodium(III) hydride intermediate (Schem1 1.7). 
Scheme 1.7 Synthesis of medium-sized rings by intramolecular hydroacylation via cooperative 
catalysis  
 
 
Even though six-, seven- and eight-membered carbocycles and oxygen or sulfur 
containing heterocycles were accessible from alkene hydroacylation reactions, alkene 
hydroacylations to generate nitrogen-containing heterocycles were rare. Bendorf and co-
workers reported amine-directed, intramolecular hydroacylation of 2-
(homoallylamino)benzaldehydes (Scheme 1.8, Equation 1).
20 
These amine-directed 
hydroacylation reactions occur in the presence of 10 mol % of Wilkinson’s catalyst, and 
the efficiency of the reactions is greatly influenced by the identity of the substituents on 
the nitrogen atom. Douglas reported hydroacylation of N-allylindole-2-carboxaldehydes 
and N-allylpyrrole-2-carboxaldehydes (Scheme 1.8, Equation 2). These hydroacylation 
reactions involved in situ formation of imines to install chelating functionality to stabilize 
the resulting iminorhodium(III) hydride intermediate.
19
 The heterocyclic ketone products 
are formed in good yields, but the requirement for chelation assistance leads to poor atom 
economy and efforts to develop a highly enantioselective catalyst were unsuccessful.  
 
 
10 
 
Scheme 1.8 Hydroacylation of olefins to generate nitrogen heterocycles 
Our group investigated alkene hydroacylation reactions as a strategy to synthesize 
polycyclic nitrogen heterocycles with high enantioselectivity and without the need for strategies 
to stabilize the acylrhodium(III) hydride intermediate. We initially reported highly 
enantioselective, intramolecular hydroacylation of N-vinylindole-2-carboxaldehydes to generate 
dihydropyrroloindolones in high yield with excellent enantioselectivities (Scheme 1.9).
21
 More 
recently, we reported catalytic, enantioselective hydroacylations of N-allylindole-2-
carboxaldehydes and N-allylpyrrole-2-carboxaldehydes to form dihydropyridoindolones and 
dihydroindolizinones in moderate-to-high yields with high enantioselectivities.
22
  These reactions 
represent the first examples of highly enantioselective, transition metal-catalyzed hydroacylation 
to form six-membered rings in the absence of chelation-assistance and encompass an array of N-
allylindole- and N-allylpyrrole-2-carboxaldehydes substrates.  These studies will be discussed in 
detail in Chapter 2 of this dissertation. The ability to form six-membered rings in the absence of 
11 
 
chelation-assistance led to the development of a related catalyst system for endo- and 
enantioselective hydroacylation of ortho-allylbenzaldehydes.
23
  
Scheme 1.9 Enantioselective hydroacylation to access polycyclic nitrogen heterocycles 
 
The coupling of alkene and alkyne hydroacylation reactions in sequence or in tandem 
with additional bond-forming processes has expanded the types of heterocyclic ketones that are 
readily accessible from simple starting materials. Nguyen and coworkers reported a sequential 
approach to the synthesis of dihydroquinolinones and tetrahydrobenzo[b]azepinones involving 
Rh-catalyzed asymmetric allylic amination followed by intramolecular alkene hydroacylation 
reactions.
24
 The enantioenriched allylic amine, formed by Rh-catalyzed dynamic kinetic 
asymmetric transformation (DYKAT) of racemic allylic trichloroacetimidates with 2-
aminobenzaldehyde, is a suitable substrate for alkene hydroacylation to form six- or seven-
membered ring aza-ketones based on the choice of the rhodium catalyst (Scheme 1.10). 
 
 
 
 
 
 
 
 
12 
 
Scheme 1.10 Sequential allylic amination and hydroacylation reactions to access six- and seven-
membered nitrogen heterocycles 
 
 
Intermolecular hydroacylation is considered to be more challenging compared to 
intramolecular hydroacylation owing to faster catalyst decomposition via reductive 
decarbonylation pathway.
1c
 In 1978, Suggs revealed that decarbonylation could be suppressed by 
employing β-chelating aldehydes as that would lead to the formation of a highly strained four-
membered metallacycle.
25
  
Following Suggs’ report, numerous studies with substrates containing various chelating 
functionalities including olefinic aldehydes,
26
 salicyldehydes,
27
 β-sulfido aldehydes28 and (N-2-
pyridyl)aldimines
29
 were found to be effective in diminishing decarbonylative products. The first 
enantioselective intermolecular hydroacylation was reported by Bolm and co-workers in 2007 
where salicyldehydes were coupled with strained alkenes like norbornadienes. A ligand-
controlled switch in diastereoselectivity (exo vs endo) was observed by the authors in this report. 
Exo-selectivity was observed by use of the bidentate bisphosphine ligand Walphos, while the 
monodentate phosphoramidite ligand (S)-Monophos facilitated endo-selective hydroacylation by 
13 
 
promoting norbornadiene to coordinate to the metal center in a bidentate manner (Scheme 
1.11).
30
 
Scheme 1.11 Intermolecular enantioselective hydroacylation of salicylaldehydes with 
norbornadienes 
 
 
 
The Willis group in 2008 reported intermolecular hydroacylation of β-sulfur chelating 
aldehydes with racemic allenes with excellent regio- and stereocontrol in the presence of a 
cationic rhodium catalyst derived froma  Rh(I) precursor and Me-Duphos ligand (Scheme 
1.12).
31
 The Willis and Weller groups further identified a catalyst for general linear-selective 
intermolecular hydroacylation of β-sulfur chelating aldehydes.28, 32 
Scheme 1.12 Enantioselective intermolecular hydroacylation of allenes 
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Development in the Willis and Weller labs of catalysts containing small-bite-angle 
bisphosphine ligands with the general structure [Rh(R2PCH2PR2)(
6
-C6H5F)][BArF4] has 
substantially improved the activity and stability of rhodium catalysts in intermolecular 
hydroacylation of alkenes with -substituted aldehydes. Recently, these groups reported a 
catalyst with this general structure based on the non-symmetrical ligand tBu2PCH2P(o-
MeOC6H4)2 that enables intermolecular hydroacylation of a wide range of functionalized internal 
alkenes with -substituted aldehydes (Scheme 1.13).33  Detailed mechanistic studies suggest that 
the o-MeOC6H4 group on phosphorous plays a key role in the stability and activity of the catalyst 
by increasing the rate of olefin insertion in to the rhodium hydride bond, which prevents 
decarbonylation by maintaining a low concentration of the acyl hydride intermediate.  This 
catalyst system enables hydroacylations of a range of both 1,1- and 1,2-disubstituted alkenes, 
including cycloalkenes, cyclic and acyclic vinyl ethers, and α,β-unsaturated esters, with aryl and 
non-aryl aldehydes.  
Scheme 1.13 Intermolecular hydroacylation of internal alkenes with β-substituted aldehydes 
 
The Suemune and Dong groups in 2009 and 2010 independently reported 
enantioselective, intermolecular hydroacylation strategies with salicylaldehydes that generated -
15 
 
branched ketone products.
27b, 27d, 34
 Suemune’s work employed 1,5-hexadienes as the chelating 
alkene partner. While the coordinating heteroatom functionality in salicylaldehyde suppressed 
decarbonylation, coordinating dienes facilitated formation of branched products over linear 
ketone products (12:1 branched:linear selectivity with achiral ligand). However, hydroacylation 
in presence of the chiral ligand (S)-BINAP formed ketone products in 84% ee and 1:1 
branched:linear selectivity.
27d
  Dong’s report employed homoallylic sulfides as the chelating 
alkene partner and generated ketone products in >20:1 branched:linear selectivity. Reactions in 
the presence of rhodium(I) precursor in combination with a chiral spiro-phosphoramidite ligand 
generated chiral, non-racemic branched ketone products with excellent enantio- and 
regioselectivity.
27b
 Interestingly, the selectivity of the reaction switched with non-chelating 
alkene acceptors at higher temperature (70 °C) and formed highly linear ketone products under 
similar reaction conditions (Scheme 1.14).
35
 These reactions encompassed a variety of both 
terminal and 1,2-disubstituted olefins.  
Scheme 1.14 Intermolecular hydroacylation of salicylaldehydes with homoallylic sulfides and 
unactivated terminal alkenes 
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Dong and co-workers also reported highly enantio- and diastereoselective 
desymmetrization reactions via strain-release driven hydroacylation reactions of salicylaldehydes 
and strained cyclopropenes in the presence of a catalyst generated in situ from [Rh(COD)Cl]2 
and Josiphos ligand (Scheme 1.15).
27a
  
Scheme 1.15 Enantio- and diastereoselective desymmetrization reaction of salicylaldehydes 
 
Aldehydes containing -heteroatoms are privileged substrates in transition metal-
catalyzed alkene and alkyne hydroacylation reactions due their ability to coordinate acylmetal 
hydride intermediates and suppress catalyst deactivation pathways.  Often these -chelating units 
are viewed as a limitation to the scope of alkene and alkyne hydroacylation processes. Recent 
reports from Willis and our laboratory demonstrated sequential and tandem reaction strategies 
that utilize these -heteroatom functional groups as synthetic handles for the construction of 
dihydroquinolones and chromanones (Scheme 1.16). Willis and coworkers reported a sequential 
protocol for the hydroacylation of alkynes with 2-aminobenzaldehydes followed by Lewis acid-
catalyzed, intramolecular aza-Michael addition that gave rapid access to dihydroquinolones.
36
 
Later, our group developed a tandem process for the synthesis of trans-2,3-disubstituted 
chroman-4-ones involving hydroacylation of symmetrical alkynes with salicylaldehydes 
followed by oxo-Michael addition reactions.
37
 The trans-2,3-disubstituted chroman-4-ones could 
be readily fluorinated to form trans-3-fluoro-2,3-disubstituted chroman-4-ones in high yields 
(67-93%) and excellent diastereoselectivities (up to >20:1). 
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Scheme 1.16 Sequential and tandem alkyne hydroacylation aza- and oxo-Michael addition 
reactions to form dihydroquinolones and chromanones 
 
 
Willis, Weller and co-workers also reported a traceless hydroacylation cascade involving 
Rh-catalyzed hydroacylation of alkenes, allenes, and alkynes coupled to a Rh-catalyzed, silane-
mediated sulfide reduction (Scheme 1.17).
38
 These cascades utilize the methyl sulfide 
functionality in the aldehyde substrate to stabilize the acylhydride intermediate formed during 
the hydroacylation cycle, and removed the chelating sulfide group in the Rh-catalyzed reduction. 
The same group also successfully sequenced alkyne hydroacylation to Suzuki coupling with the 
methyl sulphide group functioning as a pseudohalide for cross-coupling with aryl and alkenyl 
boronic acids.
39
 The utility of this approach was further illustrated through a three-component 
hydroacylation/Suzuki coupling cascade using a single rhodium catalyst. 
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Scheme 1.17 Traceless chelation-assisted hydroacylation and alkyne hydroacylation/Suzuki 
coupling cascade 
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 While much progress has been made in the development of alkene and alkyne 
hydroacylation reactions with aldehydes containing functional groups capable of coordinating 
the rhodium center, intermolecular alkene hydroacylations with simple aromatic and aliphatic 
aldehydes remain challenging.  
In 2009, Tanaka and co-workers reported a rare example of enantioselective 
intermolecular hydroacylation of aldehydes without any chelating functionality and acrylamide 
acceptors catalyzed by cationic a rhodium(I)/QuinoxP complex.
40
 The presence of amide 
functionality in alkene acceptors was instrumental to the success of these reactions as the amide 
group is involved in stabilizing the acyl rhodium(III) intermediate (Scheme 1.18). The strategy 
worked great for aliphatic aldehydes without any chelating group and formed linear selective 
ketone products with excellent enantioselectivity (96-99%). Reaction of benzaldehyde was 
sluggish and formed the ketone product in modest yield and enantioselectivity.  
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Scheme 1.18 Enantioselective intermolecular hydroacylation of acrylamides and non-chelating 
aldehydes 
 
 
Dong and co-workers recently reported highly branched-selective intermolecular 
hydroacylation reactions of a variety of non-chelating aliphatic, aromatic, and alkenyl aldehydes 
with ortho-vinylphenols (Scheme 1.19).
41
 [Rh(COD)(OMe)]2 and a small-bite-angle 
bisphosphine ligand, bis(dicyclohexylphosphino)methane (dcpm), combine with the ortho-
vinylphenol substrate to generate an electron-rich and neutral rhodium complex that has a lower 
barrier for the turnover-limiting, non-directed oxidative addition of Rh to the aldehyde C-H 
bond. This catalyst promotes reactions of an array of non-chelating aldehydes with a wide range 
of substituted ortho-vinylphenols to form branched ketone products (typically >20:1 selectivity) 
in 50-99% yield. The -aryl ketone products can readily undergo acid-catalyzed 
cyclocondensation to form benzofurans in high yields. 
Scheme 1.19 Hydroacylation of vinylphenols with non-chelating aldehydes 
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1.3 Cobalt-Catalyzed Alkene Hydroacylation 
The use of cobalt complexes as catalysts for alkene and alkyne hydroacylation is 
attractive due to the abundance and cost of cobalt relative to the 2nd- and 3rd-row group metals 
rhodium and iridium. Brookhart and coworkers demonstrated the first examples of cobalt-
catalyzed alkene hydroacylations nearly twenty years ago.
42
 However, the utility of cobalt 
catalysts in alkene hydroacylation reactions remained limited until a recent flurry of reports. 
 In 2014, Dong and coworkers developed Co-catalyzed hydroacylations of 1,3-dienes that 
occur with regioselectivity that is distinct from previously reported ruthenium catalysts.
43
 Based 
on the identity of the bisphosphine ligand, cobalt complexes catalyze the C1-selective 
hydroacylations of 1,3-dienes with aromatic and aliphatic aldehydes to form products of 1,4-
addition and 1,2-addition respectively (Scheme 1.20).  These cobalt-catalyzed hydroacylations 
proceed in the absence of chelation assistance without significant decarbonylation of the 
aldehyde starting materials.  Mechanistic studies support a pathway involving an oxidative 
cyclization step, which contrasts the traditional mechanism of transition metal-catalyzed 
hydroacylation and prevents decarbonylation of the aldehyde substrate by avoiding the formation 
of an acylmetal hydride intermediate.  
Scheme 1.20 Cobalt-catalyzed intermolecular hydroacylation of 1,3-dienes 
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 Yoshikai and Yang reported the first enantioselective, Co-catalyzed intramolecular 
hydroacylations of alkenes and ketones.
44
 A catalyst generated by in situ reduction of a Co(II)-
BDPP complex with zinc metal promotes highly enantioselective hydroacylations of 2-
alkenylbenzaldehydes to form indanone derivatives (Scheme 1.21). Although the scope of 
enantioselective, Co-catalyzed alkene hydroacylation is limited relative to related 
enantioselective, rhodium-catalyzed hydroacylations of 2-alkenylbenzaldehydes, this work is 
likely to serve as a foundation for the development of new Co-catalyzed, enantioselective alkene 
hydroacylation reactions.  
Scheme 1.21 Enantioselective hydroacylation of 2-alkenylbenzaldehydes 
 
 Yoshikai and coworkers subsequently developed chelation-assisted, Co-catalyzed 
intermolecular hydroacylation of alkenes with aldimines generated from 2-amino-3-
methylpyridine.
45
 The formal hydroacylation process encompasses a wide range of alkenes, 
including styrenes, vinylsilanes, allylsilanes, and simple alkenes, and forms, after hydrolysis, the 
corresponding ketone products in moderate-to-good yields with high linear-to-branched ratios 
(Scheme 1.22). 
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Scheme 1.22 Cobalt-catalyzed hydroacylation of alkenes with aldimines 
 
Cheng and coworkers recently reported a cobalt-catalyzed cyclization of 1,6-enynes with 
aldehydes (Scheme 1.23).
46
 The scope of these reactions included a variety of N-, O-, and 
malonate-tethered enynes and an array of aromatic, heterocyclic, and aliphatic aldehydes. The 
formal hydroacylation is proposed to proceed via a novel cobaltacycle intermediate that is 
generated from the reaction of the enyne substrate with the cobalt catalyst. Interestingly, the 
cobalt catalyst system demonstrated switchable C-H functionalization activity depending on the 
electronic nature of the ancillary ligand enabling the authors to achieve either hydroacylation or 
hydroarylation processes. 
Scheme 1.23 Cobalt-catalyzed formal hydroacylation of enynes 
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1.4 Ruthenium-, Iridium- and Nickel-Catalyzed Alkene Hydroacylation 
 Although rhodium complexes are the most common transition metal catalysts employed 
for alkene hydroacylation reactions, the competition between hydroacylation and 
decarbonylation pathways observed with rhodium catalysts has led to a growing interest in the 
use of alternative transition metals for these processes.  In particular, recent developments have 
been made in ruthenium-, iridium- and nickel-catalyzed alkene and alkyne hydroacylations.  
Work on Ru-catalyzed hydroacylation of dienes by Krische and coworkers showed that 
these processes do not proceed through an acylmetal hydride intermediate.
47
 The absence of this 
intermediate precludes the decarbonylation pathway that has historically plagued olefin 
hydroacylation reactions.  
Recently, Nagamoto and Nishimura reported the iridium-catalyzed hydroacylation of 
bicyclic alkenes with salicylaldehydes (Scheme 1.24).
48
 A readily available iridium complex, 
[Ir(OH)(cod)]2, catalyzes the hydroacylation of a variety of bicyclic alkenes with 
salicylaldehydes, and the ketone products are formed in high yields (91-99%) with nearly perfect 
exo-selectivity. The authors note that in contrast to the previously reported rhodium-catalyzed 
hydroacylation of norbornadiene with salicylaldehyde,
49
 the iridium-catalyzed reaction is highly 
exo-selective and generates the mono-acylation product in 85% yield. The authors also 
demonstrate an enantioselective variant of these reactions using an iridium catalyst containing a 
chiral diene ligand to form the corresponding ketone product in 97% yield with 86% ee. 
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Scheme 1.24 Iridium-catalyzed hydroacylation of bicyclic alkenes 
 
Reports on nickel-catalyzed alkene hydroacylation are becoming more frequent. In 2012, 
Ogoshi and coworkers reported exo-selective hydroacylations of ortho-allyl- and ortho-
homoallylbenzaldehydes in the presence of a Ni(0)/NHC complex (Scheme 1.25).
50
 -
Substituted indanones and tetralones are readily prepared from these reactions, including 
products containing a quaternary carbon center.  
Scheme 1.25 Nickel-catalyzed hydroacylation of o-allyl- and o-homoallylbenzaldehydes 
 
Inspired by Ogoshi’s report on intramolecular hydroacylation to generate carbocyclic 
ketones, our group has recently reported exo-selective, intramolecular nickel(0)-catalyzed 
hydroacylation of N-allylindole, N-homoallylindole- and N-homoallylpyrrole-2-carboxaldehydes 
that generated a range of -substituted polycyclic, nitrogen containing heterocyclic ketones. The 
exo-selective nickel(0)-catalyzed hydroacylation was further coupled with enantioselective, 
intermolecular nickel(0)-catalyzed -arylation/heteroarylation reactions that provided access to 
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a wide range of highly enantioenriched nitrogen-containing heterocyclic ketones with -chiral 
quaternary stereocenters (Scheme 1.26).
51
 These sequential hydroacylation and -arylation 
studies will be discussed in detail in Chapter 4 of this dissertation. 
Scheme 1.26 Sequential exo-selective hydroacylation and enantioselective -arylation reaction 
 
 
Recently, Xu, Zhou and coworkers reported intermolecular hydroacylation reactions of 
styrenes and simple aldehydes that do not require any chelating functionality.
52
 These reactions 
occur in the presence of a catalyst generated in situ from a 1:3 mixture of Ni(COD)2 and PCy3 
ligand and form highly branched-selective ketone products (up to >99:1) in high yields (up to 
99%). Both computational studies and experimental evidence suggests involvement of a ligand-
to-ligand hydrogen transfer (LLHT) pathway that includes the aldehyde hydrogen transfer to a 
coordinated alkene to form an acyl-nickel-benzyl intermediate without oxidative addition 
(Scheme 1.27). 
Scheme 1.27 Nickel-catalyzed intermolecular hydroacylation of styrenes with simple aldehydes 
via LLHT pathway 
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1.5 Conclusions 
The development of new transition metal-catalyzed alkene hydroacylation reactions has 
progressed rapidly in the past few years. Rhodium-catalyzed hydroacylation remains an active 
area of study with new intermolecular alkene and alkyne hydroacylation reactions and 
applications to the synthesis of new heterocyclic ketones emerging in recent years.  However, the 
field of alkene and alkyne hydroacylation is rapidly expanding beyond rhodium catalysts. Cobalt 
catalysts hold great promise for the discovery of new hydroacylation reactions and as a 
replacement for traditional rhodium catalysts. In addition, ruthenium, iridium, and nickel 
catalysts of alkene hydroacylation have emerged to improve upon or complement previous 
catalyst systems.  
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CHAPTER 2 
 
RHODIUM-CATALYZED ENANTIOSELECTIVE INTRAMOLECULAR 
HYDROACYLATION AS A ROUTE TO POLYCYCLIC NITROGEN 
HETEROCYCLES: CONSTRUCTION OF FIVE- AND SIX-MEMBERED RINGS IN 
THE ABSENCE OF CHELATION ASSISTANCE 
 
Modified from a paper published in Chemical Communications
1
 and a paper published in  
Organic Letters
2
 
 
Avipsa Ghosh, Xiang Wei Du, and Levi M. Stanley* 
2.1 Abstract 
We report catalytic, enantioselective intramolecular hydroacylation of N-vinylindole-
2-carboxaldehydes. These hydroacylation reactions occur in the presence of a readily 
accessible rhodium catalyst and form chiral, non-racemic 2,3-dihydro-1H-pyrrolo[1,2-
a]indol-1-ones in high yields with excellent enantioselectivities. The 
dihydropyrroloindolone products can be readily transformed to dihydropyrroloindoles that 
are core structures present in a variety of natural products and biologically relevant 
compounds. This methodology could be extended to hydroacylations of N-allylindole- and 
N-allylpyrrole-2-carboxaldehydes in construction of six-membered rings that generated 7,8-
dihydropyrido[1,2-a]indol-9(6H)ones and 6,7-dihydroindolizin-8(5H)-ones in moderate to 
high yields with excellent enantioselectivities. In contrast to many alkene hydroacylations 
that form six-membered rings, these endo-selective annulative processes occur in the 
absence of ancillary functionality to stabilize the acylrhodium(III) hydride intermediate. 
 
                                                 
1
 Ghosh, A.; Stanley, L. M. Chem. Commun. 2014, 6, 2765-2768. 
2
 Du, X. -W.; Ghosh, A.; Stanley, L. M. Org. Lett. 2014, 16, 4036-4039. 
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2.2 Introduction 
Chemical reactions that couple C-H bond activation with carbon-carbon bond 
formation and those that generate nitrogen heterocycles from simple starting materials are 
two of the most important classes of reactions in modern organic, medicinal, and 
materials chemistry. Intramolecular hydroacylation of alkenes in the presence of 
transition metal catalysts is a well-known process that couples C-H bond activation with 
carbon-carbon bond formation to form synthetically valuable ketone products.
1
 
Hydroacylations of substituted 4-pentenals and 2-vinylbenzaldehydes to form 
cyclopentanones are common
2 
and occur with high enantioselectivities in the presence of 
chiral, non-racemic catalysts.
3
 Recent reports have also shown that six-, seven- and eight-
membered carbocycles and heterocycles are accessible from intramolecular alkene 
hydroacylation reactions.
4
 However, alkene hydroacylations to generate nitrogen-
containing heterocycles are rare.
4e,5,6
  
 To date, there are only two reports of alkene hydroacylation to generate nitrogen-
containing heterocycles. Bendorf and co-workers reported amine-directed, intramolecular 
hydroacylation of 2-(homoallylamino)benzaldehydes (Scheme 2.1, eq 1).
5a 
These amine-
directed hydroacylation reactions occur in the presence of 10 mol % of Wilkinson’s catalyst, 
and the efficiency of the reactions is greatly influenced by the identity of the substituents on 
the nitrogen atom. Recently, Douglas reported hydroacylation of N-allylindole-2-
carboxaldehydes and N-allylpyrrole-2-carboxaldehydes (Scheme 2.1, eq 2).
5b
 These 
hydroacylation reactions involve in situ formation of imines to install chelating functionality 
to stabilize the resulting iminorhodium(III) hydride intermediate.
2j,7
  The heterocyclic ketone 
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products are formed in good yields, but the requirement for chelation assistance leads to 
poor atom economy and efforts to develop a highly enantioselective catalyst were 
unsuccessful. Although reports by Bendorf and Douglas provide an entry into practical 
alkene hydroacylation reactions to generate nitrogen containing heterocycles, the 
opportunity exists to form nitrogen heterocycles by alkene hydroacylations that occur 1) 
with high enantioselectivity and 2) without the need for strategies to stabilize the 
acylrhodium(III) hydride intermediate. 
Scheme 2.1 Synthesis of nitrogen heterocycles by intramolecular alkene hydroacylation 
Previous Studies:
H
O
N
R
Rh(PPh3)3Cl
(10 mol %)
CH2Cl2, rt
N
R
O
R = CH3: 11% yield; R = Bn: 10% yield; 
R = (CH2)2CH=CH2: 35% yield; R = CH2CH=CH2: 72% yield
(1)
N
O
H
Me
N
Me
H2N
N
(1 equiv)
[Rh(COE)2Cl]2 (2.5 mol %)
PPh3 (5 mol %)
BzOH (10 mol %)
PhNH2 (1.2 equiv)
PhCF3, 100 °C
N
O
Me
(2)
This Study:
N
O
H
R1
R2
R3
Chiral, non-racemic
rhodium catalyst
N
R2
O
R1
R3
(3)
High Yields
High Enantioselectivities
Rapid Access to Polycyclic Indole Derivatives  
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The potential for enantioselective intramolecular hydroacylation to create a rapid 
entry into dihydropyrroloindoles led us to study Rh-catalyzed hydroacylation of N-
vinylindole-2-carboxaldehydes (Scheme 2.1, eq 3). Dihydropyrroloindoles are core 
structures of a variety of indole alkaloids including yuremamine
8,9
 and antimalarial bis-
indoles from the Flindersia species, such as the isoborreverines (Figure 2.1).
10
  Thus, we 
report the synthesis of highly enantioenriched 2,3-dihydro-1H-pyrrolo[1,2-a]indolones by 
intramolecular hydroacylation of N-vinylindole-2-carboxaldehydes in the presence of a 
rhodium catalyst prepared in situ from commercially available precursors. 
N
OH
HO
HO
OH
OH
OH
NMe2
N
NMeR
H
H
HN
NMeR
Yuremamine
Isoborreverine: R = H
Dimethylisoborreverine: R = Me  
Figure 2.1 Dihydropyrroloindoles as Core Elements of Indole Alkaloids 
2.3 Results and Discussion 
 
2.3.1 Synthesis of 1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde 1a 
 
1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde 1a was synthesized from ethyl 
indole-2-carboxylate in 48% yield over three steps (Scheme 2.2). The ester functionality 
in ethyl indole-2-carboxylate was reduced in presence of LiAlH4 to form (1H-indol-2-
yl)methanol S2a in 95% yield. (1H-Indol-2-yl)methanol S2a was coupled with -
bromostyrene in presence of copper(I) iodide, ethylenediamine and potassium phosphate 
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in 1,4-dioxane at 110 °C to form (1-(1-phenylvinyl)-1H-indol-2-yl)methanol S3a in 60% 
yield. (1-(1-Phenylvinyl)-1H-indol-2-yl)methanol S3a was further oxidized in presence of 
activated MnO2 in acetonitrile to generate 1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde 
1a in 85% yield.
11
 
Scheme 2.2 Synthesis of 1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde 1a 
 
 
 
 
2.3.2 Identification of Reaction Conditions for Rh-Catalyzed Intramolecular 
Hydroacylation of 1a 
 
Initial studies to develop catalytic, enantioselective hydroacylations of N-
vinylindole-2-carboxaldehydes were guided by hydroacylations of 2-vinylbenzaldehydes 
catalyzed by a rhodium(I)-BINAP complex.  To test whether hydroacylation of N-
vinylindole-2-carboxaldehydes could occur with similar catalysts, we studied the reaction of 
1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde 1a catalyzed by complexes prepared in situ 
from [Rh(COD)Cl]2, (R)-BINAP 3, and a variety of silver salts having counteranions with 
varying degrees of coordinating strength (Table 2.1, entries 1-7).  We found that the 
hydroacylation of 1a did not occur in THF at 60 °C when the rhodium(I) catalysts contained  
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Table 2.1 Identification of catalysts for Rh-catalyzed hydroacylation of 1-(1-phenylvinyl)-
1H-indole-2-carboxaldehyde 1a
a 
PPh2
PPh2R
RPAr2
PAr2
N
O
H N
O
THF, 60 °C
[Rh(COD)Cl]2 (2.5 mol %)
Ligand 3-7 (5 mol %)
AgX (5 mol %)
3: Ar = Ph
4: Ar = 4-Me-C6H4
5: Ar = 3,5-Me2-C6H3
6: R = Me
7: R = OMe
1a 2a
 
Entry AgX Ligand Conversion (%)
b 
Yield (%)
c 
ee (%)
d
 
1 -- 3 0 -- -- 
2 AgNO3 3 0 -- -- 
3 AgOMs 3 0 -- -- 
4 AgClO4 3 96 10 ND 
5 AgBF4 3 75 54 94 
6 AgPF6 3 72 49 91 
7 AgSbF6 3 99 61 95 
8 AgBF4 4 95 75 96 
9 AgBF4 5 42 35 98 
10 AgBF4 6 80 63 97 
11 AgBF4 7 95 90 99 
a
 1a (0.100 mmol), [Rh(COD)Cl]2 (0.0025 mmol), ligand 3-7 (0.0050 mmol), AgBF4 (0.0050 
mmol) and THF (0.7 mL). 
b
 Determined by 
1
H NMR spectroscopy using 1,3,5-
trimethoxybenzene as the internal standard.  
c
 Isolated yield of 2a.  
d
 Determined by chiral HPLC 
analysis.    
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coordinating counteranions, such as chloride, nitrate, and mesylate (entries 1-3).  However, 
the hydroacylation of 1a formed dihydropyrroloindolone 2a in low to modest yield when the 
rhodium catalyst contained a weakly coordinating counteranion. The hydroacylation of 1a 
catalyzed by a rhodium catalyst with a perchlorate counteranion occurred to high 
conversion, but formed 2a in low yield (entry 4).  In contrast, the reaction of 1a generated 
dihydropyrroloindolone 2a in 49-61% yield in the presence of rhodium complexes with 
tetrafluoroborate, hexafluorophosphate, and hexafluoroantimonate counteranions (entries 5-
7). Although the catalyst containing a hexafluoroantimonate counterion led to the highest 
yield of 2a, this catalyst also promoted undesired side reactions.  We chose to continue our 
study with rhodium catalysts containing a tetrafluoroborate counterion since we observed 
less decomposition of 1a with this catalyst system. 
To improve the yield and selectivity of our model reaction, we studied the 
hydroacylation of 1a in the presence of catalysts prepared from [Rh(COD)Cl]2, AgBF4, 
and a selection of aromatic bisphosphine ligands 3-7 containing axial chiral backbones 
(Table 2.1, entries 5, 8-11).  The rhodium(I) complex of (R)-Tol-BINAP 4 catalyze the 
hydroacylation of 1a to form 2a in higher yield than the rhodium complex of the parent 
(R)-BINAP ligand, while the rhodium(I) complex of (R)-Xyl-BINAP catalyzes the 
formation of 2a in lower yield (compare entries 8 and 9 with entry 5).  Rhodium 
complexes of both (R)-Tol-BINAP and (R)-Xyl-BINAP catalyze the formation of 2a with 
higher enantioselectivity. The reaction of 1a occurred with the best combination of yield 
and enantioselectivity in the presence of rhodium complexes of (S)-Me-BIPHEP and (S)-  
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Scheme 2.3 Synthesis of (1-vinyl-1H-indol-2-yl)methanols S3a-S3p 
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MeO-BIPHEP (entries 10-11).  The hydroacylation of 1a catalyzed by rhodium(I) 
complex of (S)-MeO-BIPHEP formed dihydropyrroloindolone 2a in 90% yield with 99% 
ee (entry 11). 
2.3.3 Synthesis of N-Vinylindole-2-carboxaldehydes 1a-p 
A variety of N-vinylindole-2-carboxaldehydes were synthesized by coupling (1H-
indol-2-yl)methanols with  substitutions at 3-,4-,5- and 6- position in the indole ring with 
various 1,1-disubstituted, 1,2-disubstituted, 1,1,2-trisubstituted -bromoalkenes in 
presence of copper iodide, ethylene diamine and potassium phosphate in 1,4-dioxane 
(Scheme 2.3).
11
 These isolated (1-vinyl-1H-indol-2-yl)methanols were subjected to MnO2 
oxidation reaction conditions to obtain N-vinylindole-2-carboxaldehydes 1a-1p in 75-
90% yields (eq 2.1). Various -bromoalkenes were synthesized from the corresponding 
methyl ketone starting material in presence of triphenyl phosphite, triethylamine and 
bromine in 35-70% yield (Scheme 2.4).
12
 5-Methoxy-, 6-chloro-, (6-(trifluoromethyl)-1H-
indol-2-yl)methanols were synthesized from 3-methoxy-, 4-chloro-, 4-
trifluoromethylbenzaldehydes over 5 steps in 18-32% yields (Scheme 2.5).
13
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Scheme 2.4 Synthesis of -bromoalkenes 
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Scheme 2.5 Synthesis of 5- and 6-substituted-(1H-indol-2-yl)methanols 
 
2.3.4 Rh-Catalyzed Intramolecular Hydroacylation of N-Vinylindole-2-
carboxaldehydes: Substrate Scope  
 
The results of intramolecular hydroacylations of N-vinylindole-2-carboxaldehydes 
containing a range of substituted vinyl units are shown in Table 2.2. The hydroacylations 
of N-vinylindole-2-carboxaldehydes containing electron-neutral or electron-rich aryl 
groups at the 1-position of the N-vinyl moiety gave the corresponding 
dihydropyrroloindolones 2a (R
1
 = Ph) and 2b (R
1
 = 4-MeO-C6H4) in high yields (90-
99%) with 99% enantiomeric excess (entries 1 and 2).  The hydroacylation of N-
vinylindole-2-carboxaldehydes
 
substituted with electron-deficient aryl groups at the 1-
position of the vinyl group formed dihydropyrroloindolones 2c (R
1
 = 4-Cl-C6H4) and 2d 
(R
1
 = 4-F3C-C6H4) in lower yield (68% and 30%, entries 3 and 4).  However, these 
hydroacylations occurred with excellent enantioselectivity (98-99% ee), and the yield of  
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Table 2.2 Rhodium-catalyzed enantioselective hydroacylation of N-vinylindole-2-
carboxaldehydes 1a-h
a 
 
N
R1
O
H N
O
R1THF, 60 °C
[Rh(COD)Cl]2 (2.5 mol %)
7 (5 mol %)
AgBF4 (5 mol %)
1a-h 2a-h  
Entry R1 (1) 2 Yield (%)
b
 ee (%)
c
 
1 Ph (1a) 2a 90 99 
2 4-MeO-C6H4 (1b) 2b 99 99 
3 4-Cl-C6H4 (1c) 2c 68 98 
4 4-F3C-C6H4 (1d) 2d 30 99 
5
d
 4-F3C-C6H4 (1d) 2d 70 99 
6 3-MeO-C6H4 (1e) 2e 92 98 
7 3,4,5-(MeO)3-C6H2 (1f) 2f 82 99 
8 Me (1g) 2g 99 99 
9 Cyclohexyl (1h) 2h 20 97 
10
e
 Cyclohexyl (1h) 2h 45 95 
a
 1a-h (0.100 mmol), [Rh(COD)Cl]2 (0.0025 mmol), ligand 7 (0.0050 mmol), AgBF4 (0.0050 
mmol) and THF (0.7 mL). 
b
 Isolated yield of 2. 
c
 Determined by chiral HPLC analysis. 
d
 
Reaction run in the presence of 10 mol % catalyst. 
e
 Reaction run at 100 °C in 1,4-dioxane. 
 
2d improved to 70% when the reaction was run in the presence of 10 mol % rhodium 
catalyst (entry 5). 
N-Vinylindole-2-carboxaldehydes containing meta-substituted aryl groups at the 1-
position of the N-vinyl moiety are also excellent substrates for these intramolecular 
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hydroacylations. N-vinylindole-2-carboxaldehydes 1e (R
1
 = 3-MeO-C6H4) and 1f (R
1
 = 
3,4,5-(MeO)3-C6H2) reacted to form dihydropyrroloindolones 2e and 2f in 82-92% yield 
with 98-99% ee (entries 6 and 7).  We were unable to generate data on hydroacylations of 
N-vinylindole-2-carboxaldehydes containing ortho-substituted aryl groups at the 1-
position of the N-vinyl moiety because Ullmann-type coupling of appropriately 
substituted indoles and α-halogenated styrenes were unproductive in our hands.   
Reactions of N-vinylindole-2-carboxaldehydes containing alkyl groups at the 1-
position of the N-vinyl moiety also occurred with high enantioselectivity.  The reaction of 
1g (R
1
 = Me) formed 2g in nearly quantitative yield and nearly perfect enantioselectivity 
(entry 8). The reaction of N-vinylindole-2-carboxaldehyde 1h bearing a bulky cyclohexyl 
group formed the corresponding dihydropyrroloindole 2h with 97% enantiomeric excess 
(entry 9).  However, the yield of 2h was low when the reaction was run under our standard 
conditions.  The yield of 2h improved to 45% with a modest decrease in enantioselectivity 
when the reaction was performed in 1,4-dioxane at 100 °C (entry 10). 
Scheme 2.6 summarizes the results of hydroacylations with N-vinylindole-2-
carboxaldehydes containing substitution at the 3-, 4-, 5-, and 6-positions on the indole 
moiety.  A variety of N-vinylindole-2-carboxaldehydes containing electron-donating and 
electron-withdrawing substituents, as well as halogens, were excellent substrates for the 
intramolecular alkene hydroacylation.  Alkyl substitution at the 3-position of the indole ring 
was well tolerated, and the hydroacylation of 3-ethyl-1-(1-phenylvinyl)-1H-indole-2-
carboxaldehyde 1i (R
2
 = Et, R
3
 = H) formed product 2i in 89% yield with 98% ee.  
Hydroacylations of 4-MeO, 5-MeO, and 5-F substituted N-vinylindole-2-carboxaldehydes  
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Scheme 2.6 Rhodium-catalyzed enantioselective hydroacylation of N-vinylindole-2-
carboxaldehydes 1i-n  
 
N
H
O N
O
THF, 60 °C
(S)-MeO-BIPHEP (5.0 mol %)
[Rh(COD)Cl]2 (2.5 mol %)
AgBF4 (5.0 mol %)
R2 R2
R3 R3
1i-n 2i-n
1i  (R2 = Et, R3 = H), 1j (R2 = H, R3 = 4-MeO), 1k  (R2 = H, R3 = 5-MeO), 
1l  (R2 = H, R3 = 4-F), 1m  (R2 = H, R3 = 5-Cl), 1n  (R2 = H, R3 = 5-F3C),  
N
O
2i: 89%, 98% ee
N
O
OMe
2j: 90%, 99% ee
N
O
MeO
2k: 97%, 99% ee
N
O
F
2l: 92%, 98% ee
N
O
Cl
2m: 82%, 98% ee
N
O
F3C
2n: 81%, 99% ee
 
 
1j-l occurred with excellent enantioselectivity (98-99%), and dihydropyrroloindolones 2j-
l were isolated in 90-97% yield.  Intramolecular hydroacylations of 6-chloro- and 6-
trifluoromethyl-1-(1-phenylvinyl)-1H-indole-2-carboxaldehydes (1m and 1n) formed 
dihydropyrroloindolones 2m and 2n in slightly lower yield (81-82%), but the 
enantioselectivity remained high (98-99% ee). 
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Table 2.3 Impact of lower catalyst loading on the enantioselective hydroacylation of N-
vinylindole-2-carboxaldehyde 1a
a
 
 
 
 
Entry [Rh]  
(mol %) 
Solvent Conv  
(%) 
NMR yield  
(%)
b
 
ee 
(%)
c
 
1 5.00 THF 99 95 (92) 99 
2 2.50 THF 46 44 ND 
3 2.50 1,4-dioxane 99 99 (99) 95 
4 1.00 1,4-dioxane 99 99 (95) 96 
5 0.50 1,4-dioxane 95 85 (83) 98 
6 0.20 1,4-dioxane 94 78 (79) 98 
7 0.10 1,4-dioxane 56 40 ND 
a
 1a (0.100-2.00 mmol), [Rh(COD)Cl]2 (0.0020-0.025 mmol), ligand 7 (0.0040-0.050 mmol), 
AgBF4 (0.0040-0.050 mmol), and THF/1,4-dioxane (0.7-14 mL). 
b
 Determined by 
1
H NMR 
spectroscopy using 1,3,5-trimethoxybenzene as the internal standard, isolated yield of 2a is given 
in parenthesis.  
c
 Determined by chiral HPLC analysis.   
 
Although reactions of N-vinylindole-2-carboxaldehydes to establish the scope of 
these hydroacylations are conducted in the presence of 5 mol % of the rhodium catalyst, 
this relatively high catalyst loading is not a requirement to achieve high isolated yields 
and enantioselectivities (Table 2.3). The hydroacylation of 1-(1-phenylvinyl)-1H-indole-
2-carboxaldehyde 1a performed in the presence of 1 mol % of the rhodium catalyst at 100 
°C in 1,4-dioxane generates dihydropyrroloindolone 2a in 95% yield with 98% ee. 
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Decreasing the catalyst loading to 0.2 mol % led to a lower yield (79%) of 
dihydropyrroloindolone 2a, but this heterocyclic ketone was still formed with excellent 
enantioselectivity (98% ee). 
2.3.5 Absolute Stereochemistry of 2a  
The absolute configuration of dihydropyrroloindolone 2a was determined after 
bromination (Scheme 2.7).  Treatment of 2a with N-bromosuccinimide occurred to form 3 
in 88% yield. The absolute configuration of 9-bromo-3-phenyl-2,3-dihydro-1H-
pyrrolo[1,2-a]indol-1-one 3 was determined to be (3S) by X-ray crystallographic analysis.  
Thus, the catalyst generated from (S)-MeO-BIPHEP 7 leads to the formation of (S)-3. We 
thank Dr. Arkady Ellern and the Molecular Structure Laboratory (Iowa State University) 
for X-ray diffraction data collection and structure determination. 
Scheme 2.7 Absolute stereochemistry and structure of 3 based on X-ray diffraction data. 
N
O
Br
NBS
DMF, rt
2a
3
88% yield
 
2.3.6 Plausible Recation Mechanism 
 
Figure 2.2 illustrates the plausible reaction mechanism for Rh-catalyzed enantioselective 
hydroacylation of N-vinylindole-2-carboxaldehydes. Oxidative addition of Rh(I) to N-
vinylindole-2-carboxaldehyde 1 generates acylrhodium(III) hydride intermediate A. 
Coordination of alkene in A to rhodium center generates B which undergoes migratory insertion 
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to form six-membered rhodacycle C. Reductive elimination of rhodium in C finally leads to the 
formation of product 2, with regeneration of Rh(I) catalyst.  
 
Figure 2.2 Plausible reaction mechanism for Rh-catalyzed hydroacylation of N-vinylindole-2-
carboxaldehydes 
 
2.3.7 Rh-Catalyzed Intramolecular Hydroacylation of N-Allylindole-2-carboxaldehyde 
 
Hydroacylation reactions to form rings of greater than five atoms are often driven by 
strain release or rely on heteroatom functionality contained at specific sites within the substrate 
molecules to stabilize acylrhodium(III) hydride intermediates and prevent catalyst 
decomposition.
5
 Thus hydroacylations of N-allylindole-2-carboxaldehydes have proven more 
challenging because these processes involve the formation of a six-membered ring instead of a 
five-membered ring. During our studies, Douglas reported the first example of alkene 
hydroacylation involving N-allylindole-2-carboxaldehydes (eq 2.2).
5b
 These hydroacylation 
reactions are enabled by transient generation of a 2-aminopicoline-based aldimine that stabilizes 
the acylrhodium hydride intermediate. However, this approach to chelation assistance requires a 
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complex mixture of catalyst precursors and additives, and highly enantioselective 
hydroacylations involving 2-aminopicoline based aldimines have not been reported. 
 
Scheme 2.8 Synthesis of N-allylindole-2-carboxaldehyde 
 
We synthesized N-allylindole-2-carboxaldehyde from ethyl indole-2-carboxylate over 3 
steps in 68% yield (Scheme 2.8). Our attempt for intramolecular hydroacylation of N-allylindole-
2-carboxaldehyde in presence of catalyst generated in situ from [Rh(COD)Cl]2, MeO-BIPHEP 
and AgBF4 formed the dihydropyridoindolone 4 in 34% yield as the only product via endo-
selective pathway presumably through formation of seven-membered rhodacycle (Scheme 2.9a). 
This represents the first example of construction of six-membered ring via hydroacylation 
reaction in the absence chelation assistance. The chelation-free intramolecular hydroacylation 
reactions of N-allylindole-2-carboxaldehydes were further explored by Dr. Xiang Wei Du and 
the results are summarized in Scheme 2.9b.  
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Scheme 2.9 Construction of six-membered rings via Rh-catalyzed hydroacylation reaction in the 
absence of chelation assistance 
 
 
 
Even though Rh-catalyzed enantioselective, intramolecular hydroacylation reactions of 
N-vinylindole-, N-allylindole- and N-allylpyrrole-2-carboxaldehydes containing 1,1-disubstituted 
alkenes worked great for the construction of five- and six-membered rings, hydroacylations of 
indole and pyrrole based substrates containing 1,2-disubstituted and 1,1,2-trisubstituted alkenes 
were unproductive under our reaction conditions and did not form the desired hydroacylation 
products. 
2.4 Conclusion 
In conclusion, we have established a method for highly enantioselective 
intramolecular hydroacylation of N-vinylindole-2-carboxaldehydes in the presence of a 
rhodium catalyst prepared in situ from commercially available precursors.  These 
reactions encompass a broad range of N-vinylindole-2-carboxaldehydes bearing a variety 
of aryl and alkyl substituents on the olefin moiety and substitution throughout the indole 
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core. The enantioenriched dihydropyrroloindolone products are generated with 
consistently high enantioselectivity (95-99% ee) even at low catalyst loadings (0.2-5 
mol% Rh). This methodology could be extended to hydroacylations of N-allylindole- and 
N-allylpyrrole-2-carboxaldehydes in construction of six-membered rings that generated 
7,8-dihydropyrido[1,2-a]indol-9(6H)ones and 6,7-dihydroindolizin-8(5H)-ones in 
moderate to high yields with excellent enantioselectivities.  
2.5 Experimental Details 
2.5.1 General experimental details  
All air-sensitive procedures were conducted under inert atmosphere in a nitrogen-filled 
dry box or by standard Schlenk techniques. All reactions were performed under an atmosphere of 
nitrogen unless otherwise stated. All glassware for moisture sensitive reactions was dried at 140 
°C in an oven. THF and CH2Cl2 were degassed by purging with argon for 45 minutes and dried 
with a solvent purification system by passing through a one-meter column of activated alumina. 
Anhydrous acetonitrile, toluene, 1,2-dichloroethane and 1,4-dioxane were purchased from 
Aldrich. Flash column chromatography was performed on Fisher brand silica gel 60 (230-400 
mesh) using hexanes/EtOAc, hexanes/ether or hexanes/dichloromethane mixtures. Reaction 
products were visualized on TLC by UV light or by staining with KMnO4 or 2,4-dinitro-
phenylhydrazine. 
HRMS (EI) analysis was performed at the Iowa State University Chemical 
Instrumentation Facility on a Waters GCT GC-MS spectrometer. Optical rotations were 
measured on an Atago AP-300 automatic polarimeter.  HPLC analyses were carried out on a 
Water Alliance HPLC system with an e2695 Separations Module and a 2489 (UV/Vis) dual 
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wavelength detector.  NMR spectra were acquired on Varian MR-400 and Bruker Avance III 600 
spectrometers at the Iowa State University Chemical Instrumentation Facility. Chemical shifts 
are reported in ppm relative to a residual solvent peak (CDCl3 = 7.26 ppm for 
1
H and 77.36 ppm 
for 
13
C; C6D6 = 7.16 for 
1
H and 128.06 for 
13
C). 
19
F
 
NMR shifts are reported in ppm relative to 
trifluoroacetic acid as an external standard (F3CCO2H = -76.55 ppm). Coupling constants are 
reported in hertz.  
2.5.2 Materials 
(1-Bromovinyl)benzene S1a was purchased from Sigma-Aldrich and used without further 
purification.  1-(1-Bromovinyl)-4-methoxybenzene S1b, 1-(1-bromovinyl)-4-chlorobenzene S1c, 
1-(1-bromovinyl)-4-(trifluoromethyl)benzene S1d, 1-(1-bromovinyl)-3-methoxybenzene S1e, 5-
(1-bromovinyl)-1,2,3-trimethoxybenzene S1f, and (1-bromovinyl)cyclohexane were prepared 
according to a previously reported procedure. 2-Bromopropene was purchased from Alfa-Aesar 
and used without further purification.  Ethyl indole-2-carboxylate, ethyl 5-methoxyindole-2-
carboxylate, and ethyl 5-fluoroindole-2-carboxylate were purchased from AK Scientific and used 
without further purification. Ethyl 3-ethylindole-2-carboxylate, ethyl 4-methoxyindole-2-
carboxylate, ethyl 6-chloroindole-2-carboxylate, ethyl 6-trifluoromethylindole-2-carboxylate 
were synthesized according to a literature procedure.
13
 (1H-Indol-2-yl)methanols S2a-g by 
reduction of the corresponding ethyl indole-2-carboxylate with LiAlH4.
14
  Manganese dioxide, 
copper iodide, ethylenediamine and Martin Sulfurane were purchased from Sigma-Aldrich and 
used without further purification.  [Rh(COD)Cl]2, (R)-BINAP, rac-BINAP, (R)-tolyl-BINAP, 
(R)-xylyl-BINAP, (S)-Me-BIPHEP, (S)-MeO-BIPHEP, (R)-MeO-BIPHEP, silver nitrate, silver 
mesylate, silver triflate, silver perchlorate, silver tetrafluoroborate, silver hexafluorophosphate, 
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and silver hexafluoroantomonate were purchased from Strem Chemicals and used without 
further purification.    
2.5.3 General Procedure for Synthesis of (1-(1-Arylvinyl)-1H-indol-2-yl)methanols (S3a-f, 
S3i-n) and (1-(1-Alkylvinyl)-1H-indol-2-yl)methanols (S3g-h)  
 
 
(1-(1-Arylvinyl)-1H-indol-2-yl)methanols (S3a-f, S3i-n) and (1-(1-alkylvinyl)-1H-indol-
2-yl)methanols (S3g-h) were prepared according to a modified literature procedure from the 
appropriate vinyl bromides S1a-h and (1H-indol-2-yl)methanols S2a-g. In a nitrogen-filled 
glovebox, to a 20 mL scintillation vial or a 250 mL pressure vessel equipped with a vacuum 
valve were added CuI (0.200 equiv), the appropriate (1H-indol-2-yl)methanol S2a-g (1.20 
equiv), K3PO4 (2.00 equiv), the appropriate vinyl bromide S1a-h (1.00 equiv), ethylenediamine 
(0.400 equiv), and 1,4-dioxane (0.55 M final concentration of vinyl bromides S1a-h).  The 
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scintillation vial or pressure vessel was sealed with a teflon-lined septum cap or a PTFE stopper.  
The reaction vessel was removed from the glovebox, and the reaction mixture was stirred at 110 
°C for 24 h.  The reaction mixture was cooled to room temperature, diluted with EtOAc, and 
stirred for an addition 15 min.  Solids were removed by filtration and washed with EtOAc (3x).  
The organic layers were combined and concentrated under reduced pressure.  The crude product 
was purified by flash column silica gel chromatography (hexane:EtOAc) to give the appropriate 
(1-(1-arylvinyl)-1H-indol-2-yl)methanol (S3a-f, S3i-n) and (1-(1-alkylvinyl)-1H-indol-2-
yl)methanol (S3g-h). 
 
 (1-(1-Phenylvinyl)-1H-indol-2-yl)methanol (S3a): Prepared according to 
the general procedure from S1a (5.00 g, 27.3 mmol) and S2a (4.82 g, 32.8 
mmol). The mixture was purified by flash column chromatography (80:20 
hexane:EtOAc) to give S3a as a yellow oil in 65% yield (4.42 g, 17.7 mmol). 
1
H NMR (400 
MHz, CDCl3) δ 7.63 – 7.55 (m, 1H), 7.32 – 7.04 (m, 8H), 6.60 (s, 1H), 6.00 (s, 1H), 5.46 (s, 1H), 
4.54 (s, 2H), 1.62 (s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 142.9, 139.9, 138.6, 137.1, 129.5, 
129.1, 127.9, 126.0, 122.7, 121.0, 120.6, 114.1, 111.3, 103.1, 57.8. HRMS (EI): Calcd. for 
C17H15NO ([M]+): 249.1154, Found: 249.1149. 
 
 (1-(1-(4-Methoxyphenyl)vinyl)-1H-indol-2-yl)methanol (S3b): 
Prepared according to the general procedure from S1b (1.95 g, 9.15 mmol) 
and S2a (1.62 g, 11.0 mmol). The mixture was purified by flash column 
chromatography (80:20 hexane: EtOAc) to give S3b as a light yellow solid 
in 37% yield (0.950 g, 3.40 mmol). 
1
H NMR (400 MHz, CDCl3) δ 7.70 – 7.62 (m, 1H), 7.28 – 
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7.06 (m, 5H), 6.84 – 6.78 (m, 2H), 6.65 (s, 1H), 5.93 (s, 1H), 5.40 (s, 1H), 4.61 (s, 2H), 3.78 (s, 
3H), 1.77 (br s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 160.6, 142.5, 140.0, 138.6, 129.6, 127.8, 
127.4, 122.6, 120.9, 120.5, 114.4, 112.0, 111.4, 102.9, 57.8, 55.6. HRMS (EI): Calcd. for 
C18H17NO2 ([M]+): 279.1259, Found: 279.1259. 
 
 (1-(1-(4-Chlorophenyl)vinyl)-1H-indol-2-yl)methanol (S3c): Prepared 
according to the general procedure from S1c (1.50 g, 6.90 mmol) and S2a 
(1.22 g, 8.28 mmol). The mixture was purified by flash column 
chromatography (80:20 hexanes:EtOAc) to give S3c  as a light yellow oil in 
20% yield (0.400 g, 1.41 mmol). 
1
H NMR (400 MHz, CDCl3) δ 7.93 – 7.83 (m, 1H), 7.52 – 7.45 
(m, 2H), 7.42 – 7.26 (m, 5H), 6.88 (s, 1H), 6.27 (d, J = 1.4 Hz, 1H), 5.76 (d, J = 1.4 Hz, 1H), 
4.84 (s, 2H), 1.89 (br s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 142.0, 139.8, 138.5, 135.6, 135.4, 
129.3, 127.9, 127.4, 122.9, 121.1, 120.8, 114.6, 111.3, 103.4, 57.8. HRMS (EI): Calcd. for 
C17H14ClNO ([M]+): 283.0764, Found: 283.0760. 
 
 (1-(1-(4-(Trifluoromethyl)phenyl)vinyl)-1H-indol-2-yl)methanol (S3d): 
Prepared according to the general procedure from S1d (2.00 g, 7.97 mmol) 
and S2a (1.41 g, 9.56 mmol). The mixture was purified by flash column 
chromatography (80:20 hexane:EtOAc) to give S3d as a dark yellow oil in 
17% yield (0.425 g, 1.34 mmol). 
1
H NMR (400 MHz, C6D6) δ 7.68 (dq, J = 8.0, 1.2, 0.80 Hz, 
1H), 7.22 – 7.01 (m, 5H), 6.79 – 6.69 (m, 2H), 6.51 (q, J = 1.2, 0.40 Hz, 1H), 5.45 (s, 1H), 5.11 
(s, 1H), 4.21 (d, J = 5.6 Hz, 2H), 0.43 (s, 1H). 
13
C NMR (101 MHz, C6D6) δ 141.8, 140.5, 140.1, 
138.7, 130.9, 130.6, 126.4, 125.9, 125.8, 125.8, 125.8, 123.0, 121.3, 121.1, 115.8, 111.2, 103.3, 
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57.3.
 19
F NMR (CDCl3, 376 MHz): δ -63.0. HRMS (EI): Calcd. for C18H14F3NO ([M]+): 
317.1027, Found: 317.1030. 
 
 (1-(1-(3-Methoxyphenyl)vinyl)-1H-indol-2-yl)methanol (S3e): Prepared 
according to the general procedure from S1e (1.95 g, 9.15 mmol) and S2a 
(1.62 g, 11.0 mmol). The mixture was purified by flash column 
chromatography (80:20 hexane:EtOAc) to give S3e  as a light yellow solid in 
15% yield (0.260 g, 0.930 mmol). 
1
H NMR (400 MHz, CDCl3) δ 7.78 – 7.70 (m, 1H), 7.38 – 
6.20 (m, 4H), 6.98 (dd, J = 8.4, 1.6 Hz, 1H), 6.89 – 6.79 (m, 2H), 6.77 – 6.74 (m, 1H), 6.15 (s, 
1H), 5.63 (s, 1H), 4.71 (s, 2H), 3.84 (s, 3H), 1.79 (br s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 
160.2, 142.8, 139.9, 138.7, 130.2, 127.9, 122.7, 121.0, 120.6, 118.6, 114.7, 114.4, 111.9, 111.3, 
103.1, 57.8, 55.6. HRMS (EI): Calcd. for C18H17NO2 ([M]+): 279.1259, Found: 279.1249. 
 
 (1-(1-(3,4,5-Trimethoxyphenyl)vinyl)-1H-indol-2-yl)methanol (S3f): 
Prepared according to the general procedure from S1f (1.150 g, 4.210 
mmol) and S2a (0.744 g, 5.05 mmol). The mixture was purified by flash 
column chromatography (70:30 hexane:EtOAc) to give S3f  as a light 
yellow solid in 12% yield (0.170 g, 0.500 mmol). 
1
H NMR (400 MHz, CDCl3) δ 7.67 – 7.58 (m, 
1H), 7.25 – 7.06 (m, 3H), 6.64 (s, 1H), 6.38 (s, 2H), 5.96 (s, 1H), 5.47 (s, 1H), 4.62 (s, 2H), 3.84 
(s, 3H), 3.70 (s, 6H), 1.63 (br s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 153.7, 142.9, 140.0, 139.3, 
138.8, 132.9, 127.8, 122.7, 121.0, 120.6, 113.4, 111.3, 103.4, 103.2, 61.2, 57.8, 56.4. HRMS 
(EI): Calcd. for C20H21NO4 ([M]+): 339.1471, Found: 339.1484. 
 
57 
 
 
 (1-(Prop-1-en-2-yl)-1H-indol-2-yl)methanol (S3g): Prepared according to 
the general procedure from S1g (1.50 g, 12.4 mmol) and S2a (2.19 g, 14.9 
mmol). The mixture was purified by flash column chromatography (80:20 
hexane:ethylacetate) to give S3g  as a light yellow solid in 52% yield (1.22 g, 6.49 mmol). 
1
H 
NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 8.0, 0.8 Hz, 1H), 7.06 (dd, J = 8.0, 0.4 Hz, 1H), 6.90 
(dddd, J = 36.4, 15.2, 7.2, 1.2 Hz, 2H), 6.26 (s, 1H), 5.20 (q, J = 2.8, 1.2 Hz, 1H), 4.93 (s, 1H), 
4.48 (s, 2H), 1.91 (s, 3H), 1.56 (br s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 141.1, 138.8, 137.4, 
127.8, 122.5, 121.0, 120.3, 115.9, 110.8, 102.5, 57.7, 22.2. HRMS (EI): Calcd. for C12H13NO 
([M]+): 187.0997, Found: 187.1004. 
 
 (1-(1-Cyclohexylvinyl)-1H-indol-2-yl)methanol (S3h): Prepared according 
to the general procedure from S1h (1.70 g, 8.99 mmol) and S2a (1.59 g, 10.8 
mmol). The mixture was purified by flash column chromatography (80:20 
hexane:EtOAc) to give S3h as a light yellow oil in 9% yield (0.210 g, 0.822 mmol). 
1
H NMR 
(400 MHz, CDCl3) δ 7.75 – 7.67 (m, 1H), 7.45 – 7.35 (m, 1H), 7.27 (dddd, J = 30.0, 15.2, 8.4, 
7.2, 1.2 Hz, 2H), 6.69 (q, J = 1.6, 0.40 Hz, 1H), 5.57 (d, J = 1.6 Hz, 1H), 5.35 (d, J = 0.40 Hz, 
1H), 4.85 (s, 2H), 2.57 - 2.50 (m, 1H), 1.97 – 1.76 (m, 6H), 1.49 – 1.21 (m, 5H). 13C NMR (101 
MHz, CDCl3) δ 150.0, 139.7, 138.1, 127.7, 122.3, 120.9, 120.2, 113.4, 111.3, 102.2, 57.9, 43.6, 
31.9, 26.6, 26.4. HRMS (EI): Calcd. for C17H21NO ([M]+): 255.1623, Found: 255.1627. 
 
 (3-Ethyl-1-(1-phenylvinyl)-1H-indol-2-yl)methanol (S3i): Prepared 
according to the general procedure from S1a (0.800 g, 4.37 mmol) and S2b 
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(0.919 g, 5.24 mmol). The mixture was purified by flash column chromatography (80:20 
hexane:EtOAc) to give S3i  as a light yellow solid in 30% yield (0.370 g, 1.33 mmol). 
1
H NMR 
(400 MHz, CDCl3) δ 7.73 – 7.53 (m, 1H), 7.44 – 7.23 (m, 3H), 7.25 – 7.08 (m, 5H), 6.06 (s, 1H), 
5.54 (s, 1H), 4.61 (s, 2H), 2.89 (q, J = 15.2, 7.6 Hz, 2H), 1.36 – 1.32 (t, J = 7.6 Hz,  3H). 13C 
NMR (101 MHz, CDCl3) δ 143.2, 137.9, 137.6, 134.8, 129.5, 129.2, 127.6, 126.1, 123.0, 120.0, 
119.5, 118.7, 114.2, 111.3, 54.9, 18.0, 16.7. HRMS (EI): Calcd. for C19H19NO ([M]+): 
277.1467, Found: 277.1469. 
 
 (4-Methoxy-1-(1-phenylvinyl)-1H-indol-2-yl)methanol (S3j): Prepared 
according to the general procedure from S1a (0.900 g, 4.92 mmol) and S2c 
(1.05 g, 5.90 mmol). The mixture was purified by flash column 
chromatography (80:20 hexane:EtOAc) to give S3j  as a light yellow solid in 
51% yield (0.700 g, 2.51 mmol). 
1
H NMR (400 MHz, CDCl3) δ 7.24 – 7.04 (m, 3H), 6.90 (dt, J 
= 8.4, 2.0 Hz, 3H), 6.67 – 6.57 (m, 2H), 6.39 (dd, J = 7.6, 0.80 Hz, 1H), 5.87 (d, J = 1.6 Hz, 1H), 
5.35 (d, J = 1.6 Hz, 1H), 4.40 (s, 2H), 3.81 (d, J = 1.2 Hz, 3H), 1.67 (br s, 1H). 
13
C NMR (101 
MHz, CDCl3) δ 153.2, 142.7, 139.7, 138.3, 137.1, 136.8, 136.0, 129.2, 128.8, 128.5, 127.4, 
126.1, 125.7, 124.1, 124.0, 123.2, 121.6, 118.1, 113.9, 104.9, 104.5, 101.9, 101.0, 100.2, 57.4, 
55.4. HRMS (EI): Calcd. for C18H17NO2 ([M]+): 279.1259, Found: 
279.1272. 
 (5-Methoxy-1-(1-phenylvinyl)-1H-indol-2-yl)methanol (S3k): 
Prepared according to the general procedure from S1a (1.30 g, 7.10 
mmol) and S2d (1.51 g, 8.52 mmol). The mixture was purified by flash column chromatography 
(80:20 hexane:EtOAc) to give S3k  as a light yellow solid in 29% yield (0.568 g, 2.03 mmol). 
1
H 
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NMR (400 MHz, CDCl3) δ 7.26 – 7.09 (m, 3H), 7.05 – 6.86 (m, 4H), 6.65 (dd, J = 8.8, 2.0 Hz, 
1H), 6.43 (s, 1H), 5.86 (s, 1H), 5.35 (s, 1H), 4.43 (s, 2H), 3.71 (s, 3H), 1.66 (br s, 1H). 
13
C NMR 
(101 MHz, CDCl3) δ 154.8, 143.0, 140.5, 137.2, 133.8, 129.5, 129.1, 128.2, 126.1, 113.8, 112.8, 
112.1, 102.8, 102.6, 57.8, 56.1. HRMS (EI): Calcd. for C18H17NO2 ([M]+): 279.1259, Found: 
279.1267. 
 
5-Fluoro-1-(1-phenylvinyl)-1H-indol-2-yl)methanol (S3l): Prepared 
according to the general procedure from S1a (0.688 g, 3.76 mmol) and 
S2e (0.745 g, 4.51 mmol). The mixture was purified by flash column 
chromatography (80:20 hexane:EtOAc) to give S3l  as a light yellow solid 
in 55% yield (0.551 g, 2.06 mmol). 
1
H NMR (400 MHz, CDCl3) δ 7.25 – 7.06 (m, 4H), 6.96 - 
6.90 (m, 2H), 6.86 (dd, J = 9.2, 4.4 Hz, 1H), 6.67 (tdd, J = 9.2, 2.4, 0.80 Hz, 1H), 6.40 (s, 1H), 
5.84 (s, 1H), 5.30 (s, 1H), 4.38 (s, 2H), 1.69 (br s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 159.7, 
157.3, 142.8, 141.5, 136.8, 135.1, 129.6, 129.2, 128.2, 128.1, 126.0, 114.2, 112.1, 112.0, 111.2, 
110.9, 105.9, 105.6, 102.9, 102.9, 57.8.
 19
F NMR (CDCl3, 376 MHz): δ -124.5. HRMS (EI): 
Calcd. for C17H14FNO ([M]+): 267.1059, Found: 267.1068. 
 
 
 (6-Chloro-1-(1-phenylvinyl)-1H-indol-2-yl)methanol (S3m): Prepared 
according to the general procedure from S1a (1.95 g, 10.6 mmol) and S2f 
(2.32 g, 12.8 mmol). The mixture was purified by flash column 
chromatography (80:20 hexane:EtOAc) to give S3m  as a light yellow oil in 53% yield (1.60 g, 
5.64 mmol). 
1
H NMR (400 MHz, C6D6) δ 7.40 – 7.35 (m, 2H), 7.18 - 7.16 (m, 3H), 6.98 – 6.82 
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(m, 3H), 6.43 (s, 1H), 5.44 (s, 1H), 4.95 (s, 1H), 4.20 (s, 2H), 1.65 (s, 1H). 
13
C NMR (101 MHz, 
C6D6) δ 142.4, 141.3, 139.3, 136.8, 129.3, 129.0, 125.9, 122.0, 121.6, 114.1, 111.3, 102.7, 57.5. 
HRMS (EI): Calcd. for C17H14ClNO ([M]+): 283.0764, Found: 283.0762. 
 
 (1-(1-Phenylvinyl)-6-(trifluoromethyl)-1H-indol-2-yl)methanol 
(S3n): Prepared according to the general procedure from S1a (1.20 g, 
6.56 mmol) and S2g (1.69 g, 7.87 mmol). The mixture was purified by 
flash column chromatography (80:20 hexane:EtOAc) to give S3n  as a light yellow oil in 30% 
yield (0.620 g, 1.95 mmol). 
1
H NMR (400 MHz, C6D6) δ 7.69 (s, 1H), 7.53 – 7.39 (m, 2H), 6.97 
– 6.76 (m, 5H), 6.49 (s, 1H), 5.43 (s, 1H), 4.92 (s, 1H), 4.19 (s, 2H), 1.44 (br s, 1H). 13C NMR 
(101 MHz, C6D6) δ 143.3, 142.2, 137.8, 136.5, 130.7, 129.4, 129.0, 127.4, 125.8, 125.2, 124.9, 
124.7, 124.6, 124.3, 121.5, 117.4, 114.3, 108.6, 102.5, 57.5. 
19
F NMR (CDCl3, 376 MHz): δ -
60.7. HRMS (EI): Calcd. for C18H14F3NO ([M]+): 317.1027, Found: 317.1023. 
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2.5.4 General Procedure for Synthesis of 1-(1-Arylvinyl)-1H-indole-2-carbaldehydes (1a-f, 
1i-n) and 1-(1-Alkylvinyl)-1H-indole-2-carboxaldehydes (1g-h) 
 
 
To an acetonitrile solution (0.40 M) of the appropriate (1-(1-arylvinyl)-1H-indol-2-
yl)methanol (S3a-f, S3i-n) or (1-(1-alkylvinyl)-1H-indol-2-yl)methanol (S3g-h) (1.00 equiv) in a 
round-bottom flask was manganese dioxide (8.00 equiv) added. The reaction mixture was stirred 
at room temperature under N2 atmosphere for 24 hours. The reaction mixture was filtered 
through celite, washed with mixture of hexane:EtOAc (60:40), and the filtrate was concentrated 
under reduced pressure. The crude product was purified by flash column silica gel 
chromatography (hexane:EtOAc) to give the appropriate 1-(1-arylvinyl)-1H-indole-2-
carboxaldehydes (1a-f, 1i-n) or 1-(1-alkylvinyl)-1H-indole-2-carboxaldehydes (1g-h). 
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1-(1-Phenylvinyl)-1H-indole-2-carboxaldehyde (1a): Prepared according to 
the general procedure from S3a (5.00 g, 20.1 mmol). The mixture was purified 
by flash column chromatography (90:10 hexane:EtOAc) to give 1a as a light 
yellow solid in 85% yield (4.20 g, 17.0 mmol). 
1
H NMR (400 MHz, CDCl3) δ 
9.72 (d, J = 1.2 Hz, 1H), 7.72 (dq, J = 8.4, 1.6, 0.80 Hz, 1H), 7.35 (q, J = 1.2, 0.8 Hz, 1H), 7.33 – 
7.25 (m, 2H), 7.24 – 7.12 (m, 3H), 7.06 – 7.00 (m, 2H), 6.02 (d, J = 0.4 Hz, 1H), 5.41 (d, J = 0.4 
Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 181.7, 143.1, 141.0, 137.3, 136.7, 129.4, 129.0, 127.5, 
126.8, 125.7, 123.6, 122.1, 115.7, 113.9, 112.1. HRMS (EI): Calcd. for C17H13NO ([M]+): 
247.0997, Found: 247.1006. 
 
1-(1-(4-Methoxyphenyl)vinyl)-1H-indole-2-carboxaldehyde (1b): 
Prepared according to the general procedure from S3b (0.958 g, 3.43 mmol). 
The mixture was purified by flash column chromatography (90:10 
hexane:EtOAc) to give 1b as a light yellow solid in 80% yield (0.760 g, 
2.740 mmol). 
1
H NMR (400 MHz, CDCl3) δ 9.87 (s, 1H), 7.84 (dt, J = 8.0, 0.80 Hz, 1H), 7.47 
(d, J = 0.80, 1H), 7.45 – 7.37 (m, 2H), 7.32 – 7.23 (m, 1H), 7.16 – 7.07 (m, 2H), 6.88 – 6.80 (m, 
2H), 6.03 (s, 1H), 5.42 (s, 1H), 3.79 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 181.6, 160.4, 142.4, 
140.8, 136.6, 129.7, 127.3, 126.9, 126.6, 123.4, 121.9, 115.1, 114.2, 112.0, 111.8, 55.4. HRMS 
(EI): Calcd. for C18H15NO2 ([M]+): 277.1103, Found: 277.1112. 
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1-(1-(4-Chlorophenyl)vinyl)-1H-indole-2-carboxaldehyde (1c): Prepared 
according to the general procedure from S3c (0.373 g, 1.31 mmol). The 
mixture was purified by flash column chromatography (90:10 hexane:EtOAc) 
to give 1c as a light yellow solid in 80% yield (0.295g, 1.05 mmol). 
1
H NMR 
(400 MHz, CDCl3) δ 9.67 (s, 1H), 7.69 (dt, J = 8.0, 1.2 Hz, 1H), 7.36 – 7.22 (m, 3H), 7.22 – 7.07 
(m, 3H), 6.97 – 6.88 (m, 2H), 5.95 (s, 1H), 5.38 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 181.4, 
142.2, 141.0, 136.5, 135.9, 135.2, 129.3, 127.7, 127.0, 126.8, 123.7, 122.2, 116.7, 114.2, 111.9. 
HRMS (EI): Calcd. for C17H12ClNO ([M]+): 281.0607, Found: 281.0600. 
 
1-(1-(4-(Trifluoromethyl)phenyl)vinyl)-1H-indole-2-carboxaldehyde 
(1d): Prepared according to the general procedure from S3d (0.425 g, 1.34 
mmol). The mixture was purified by flash column chromatography (90:10 
hexane:EtOAc) to give 1d as a light yellow solid in 80% yield (0.339 g, 1.08 
mmol). 
1
H NMR (400 MHz, CDCl3) δ 9.70 (s, 1H), 7.74 (dt, J = 8.0, 0.80 Hz, 1H), 7.45 (d, J = 
8.4 Hz, 2H), 7.40 – 7.26 (m, 3H), 7.18 – 7.13 (m, 1H), 7.10 (d, J = 8.4 Hz, 2H), 6.09 (s, 1H), 
5.52 (s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 181.3, 142.2, 141.1, 140.8, 136.4, 131.5, 131.2, 
130.8, 130.5, 127.9, 126.8, 125.9, 125.6, 123.8, 122.8, 122.3, 117.4, 115.8, 111.7. 
19
F NMR 
(CDCl3, 376 MHz): δ -63.1. HRMS (EI): Calcd. for C18H12F3NO ([M]+): 315.0871, Found: 
315.0881. 
 
1-(1-(3-Methoxyphenyl)vinyl)-1H-indole-2-carboxaldehyde (1e): Prepared 
according to the general procedure from S3e (0.147 g, 0.526 mmol). The 
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mixture was purified by flash column chromatography (90:10 hexane:EtOAc) to give 1e as a 
light yellow solid in 74% yield (0.108 g, 0.389 mmol). 
1
H NMR (400 MHz, CDCl3) δ 9.68 (s, 
1H), 7.67 (d, J = 8.0 Hz, 1H), 7.33 – 7.19 (m, 3H), 7.17 – 7.01 (m, 2H), 6.76 – 6.68 (m, 1H), 
6.62 – 6.54 (m, 2H), 5.98 (s, 1H), 5.37 (s, 1H), 3.60 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
181.6, 160.1, 142.8, 141.0, 138.7, 136.6, 130.0, 127.4, 126.6, 123.5, 122.0, 118.1, 115.6, 114.4, 
114.1, 111.9, 111.6, 55.4. HRMS (EI): Calcd. for C18H15NO2 ([M]+): 277.1103, Found: 
277.1111. 
 
1-(1-(3,4,5-Trimethoxyphenyl)vinyl)-1H-indole-2-carboxaldehyde (1f): 
Prepared according to the general procedure from S3f (0.170 g, 0.501 
mmol). The mixture was purified by flash column chromatography (80:20 
hexane:EtOAc) to give 1f as a light yellow solid in 83% yield (0.140 g, 
0.415 mmol). 
1
H NMR (400 MHz, CDCl3) δ 9.53 (d, J = 1.6 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 
7.17 – 7.13 (m, 1H), 7.12 – 7.05 (m, 2H), 6.99 – 6.90 (m, 1H), 6.05 (d, J = 1.2 Hz, 2H), 5.74 (s, 
1H), 5.16 (s, 1H), 3.54 (d, J = 1.2 Hz, 3H), 3.41 (d, J = 1.2 Hz, 6H). 
13
C NMR (101 MHz, 
CDCl3) δ 181.7, 153.7, 142.8, 141.1, 139.3, 136.8, 133.0, 127.5, 126.7, 123.6, 122.1, 115.5, 
113.3, 112.1, 103.2, 61.2, 56.4. HRMS (EI): Calcd. for C20H19NO4 ([M]+): 337.1314, Found: 
337.1303. 
 
1-(Prop-1-en-2-yl)-1H-indole-2-carboxaldehyde (1g): Prepared according to 
the general procedure from S3g (1.10 g, 5.87 mmol). The mixture was purified 
by flash column chromatography (90:10 hexane:EtOAc) to give 1g as a light 
yellow solid in 84% yield (0.914g, 4.94 mmol). 
1
H NMR (400 MHz, CDCl3) δ 9.68 (bs, 1H), 
65 
 
 
7.53 (dq, J = 8.0, 2.0, 1.2 Hz, 1H), 7.31 – 7.15 (m, 2H), 7.11 (bs, 1H), 7.00 (ddt, J = 7.6, 1.6, 1.2 
Hz, 1H), 5.28 (q, J = 2.8, 1.2 Hz, 1H), 4.96 (bs, 1H), 1.96 (bs, 3H). 
13
C NMR (101 MHz, 
CDCl3) δ 181.5, 141.1, 139.9, 135.7, 127.3, 126.5, 123.3, 121.5, 117.2, 114.6, 111.6, 22.4. 
HRMS (EI): Calcd. for C12H11NO ([M]+): 185.0841, Found: 185.0837. 
 
1-(1-Cyclohexylvinyl)-1H-indole-2-carboxaldehyde (1h): Prepared 
according to the general procedure from S3h (0.253 g, 0.992 mmol). The 
mixture was purified by flash column chromatography (90:10 hexane:EtOAc) 
to give 1h as a light yellow solid in 77% yield (0.193g, 0.763 mmol). 
1
H NMR (400 MHz, 
CDCl3) δ 9.81 (bs, 1H), 7.64 (dt, J = 8.4, 0.80 Hz, 1H), 7.36 – 7.24 (m, 3H), 7.09 (ddd, J = 7.6, 
6.4, 1.2 Hz, 1H), 5.37 (d, J = 1.6 Hz, 1H), 5.11 (bs, 1H), 2.29 – 2.18 (m, 1H), 2.13 – 0.73 (m, 
10H). 
13
C NMR (101 MHz, CDCl3) δ 181.8, 150.0, 141.0, 136.1, 127.1, 126.3, 123.3, 121.5, 
116.6, 112.2, 111.9, 44.3, 26.4. HRMS (EI): Calcd. for C17H19NO ([M]+): 253.1467, Found: 
253.1475. 
 
3-Ethyl-1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde (1i): Prepared 
according to the general procedure from S3i (0.260 g, 0.937 mmol). The 
mixture was purified by flash column chromatography (90:10 hexane:EtOAc) 
to give 1i as a light yellow solid in 74% yield (0.192 mg, 0.697 mmol). 
1
H 
NMR (400 MHz, CDCl3) δ 9.88 (s, 1H), 7.70 (dt, J = 8.4, 0.80 Hz, 1H), 7.29 – 7.09 (m, 6H), 
7.05 – 6.99 (m, 2H), 5.98 (s, 1H), 5.38 (s, 1H), 3.10 (q, J = 7.6 Hz, 2H), 1.30 (t, J = 7.6 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 181.5, 143.2, 140.1, 137.5, 132.4, 131.5, 129.3, 129.0, 127.6, 
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126.8, 125.7, 121.6, 121.3, 113.8, 111.9, 17.9, 16.6. HRMS (EI): Calcd. for C19H17NO ([M]+): 
275.1310, Found: 275.1323. 
 
4-Methoxy-1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde (1j): Prepared 
according to the general procedure from S3j (0.490 g, 1.75 mmol). The mixture 
was purified by flash column chromatography (90:10 hexane:EtOAc) to give 1j 
as a light yellow solid in 80% yield (0.390 g, 1.41 mmol). 
1
H NMR (400 MHz, 
CDCl3) δ 9.71 (s, 1H), 7.45 – 7.42 (m, 1H), 7.20 – 7.12 (m, 4H), 7.03 – 6.98 (m, 2H), 6.86 (dt, J 
= 8.4, 0.80 Hz, 1H), 6.46 (d, J = 7.6, 1H), 5.96 (d, J = 0.4 Hz, 1H), 5.37 (d, J = 0.4 Hz, 1H), 3.89 
(s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 181.1, 155.3, 143.2, 142.5, 137.2, 135.7, 129.2, 128.9, 
128.7, 125.6, 118.4, 114.0, 113.8, 104.6, 100.8, 55.8. HRMS (EI): Calcd. for C18H15NO2 ([M]+): 
277.1103, Found: 277.1091. 
 
5-Methoxy-1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde (1k): 
Prepared according to the general procedure from S3k (0.500 g, 1.79 
mmol). The mixture was purified by flash column chromatography 
(90:10 hexane:EtOAc) to give 1k as a light yellow solid in 80% yield (0.400 g, 1.44 mmol). 
1
H 
NMR (400 MHz, CDCl3) δ 9.76 (s, 1H), 7.34 (d, J = 0.8 Hz, 1H), 7.31 – 7.24 (m, 4H), 7.16 – 
7.09 (m, 3H), 7.03 (dd, J = 9.2, 2.4 Hz, 1H), 6.08 (d, J = 0.4 Hz, 1H), 5.48 (d, J = 0.4 Hz, 1H), 
3.88 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 181.6, 155.7, 143.1, 137.3, 136.9, 136.5, 129.4, 
129.0, 127.1, 125.7, 119.4, 114.6, 113.9, 113.1, 102.9, 56.0. HRMS (EI): Calcd. for C18H15NO2 
([M]+): 277.1103, Found: 277.1111. 
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5-Fluoro-1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde (1l): Prepared 
according to the general procedure from S3l (0.515 g, 1.93 mmol). The 
mixture was purified by flash column chromatography (90:10 
hexane:EtOAc) to give 1l as a light yellow solid in 72% yield (0.367 g, 1.38 mmol). 
1
H NMR 
(400 MHz, CDCl3) δ 9.79 (s, 1H), 7.42 (dd, J = 8.8, 2.4, 0.4 Hz, 1H), 7.38 (d, J = 0.8 Hz, 1H), 
7.34 – 7.24 (m, 4H), 7.16 – 7.07 (m, 3H), 6.11 (d, J = 0.8 Hz, 1H), 5.49 (d, J = 0.8 Hz, 1H). 13C 
NMR (101 MHz, CDCl3) δ 181.7, 160.1, 157.7, 143.0, 137.7, 137.1, 129.6, 129.1, 126.8, 125.6, 
116.8, 116.6, 114.8, 114.2, 113.3, 107.7, 107.5. 
19
F NMR (CDCl3, 376 MHz): δ -121.8. HRMS 
(EI): Calcd. for C17H12FNO ([M]+): 265.0903, Found: 265.0896. 
 
6-Chloro-1-(1-phenylvinyl)-1H-indole-2-carboxaldehyde (1m): 
Prepared according to the general procedure from S3m (1.30 g, 4.58 
mmol). The mixture was purified by flash column chromatography (90:10 
hexane:EtOAc) to give 1m as a light yellow solid in 77% yield (1.00 g, 3.55 mmol). 
1
H NMR 
(400 MHz, CDCl3) δ 9.64 (bs, 1H), 7.58 (dd, J = 8.4, 0.4 Hz, 1H), 7.28 – 7.24 (m, 2H), 7.21 – 
7.12 (m, 3H), 7.07 (dd, J = 8.8, 1.6 Hz, 1H), 6.99 – 6.94 (m, 2H), 5.98 (d, J = 0.8 Hz, 1H), 5.36 
(d, J = 0.8 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 181.4, 142.8, 141.3, 137.2, 136.9, 133.6, 
129.6, 129.1, 125.6, 125.2, 124.6, 123.3, 115.4, 114.2, 111.9. HRMS (EI): Calcd. for 
C17H12ClNO ([M]+): 281.0607, Found: 281.0598. 
 
1-(1-Phenylvinyl)-6-(trifluoromethyl)-1H-indole-2-carboxaldehyde 
(1n): Prepared according to the general procedure from S3n (0.584 g, 
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1.84 mmol). The mixture was purified by flash column chromatography (90:10 hexane:EtOAc) 
to give 1n as a light yellow solid in 72% yield (0.420 g, 1.33 mmol). 
1
H NMR (400 MHz, 
CDCl3) δ 9.71 (bs, 1H), 7.78 (d, J = 8.4, 1H), 7.63 – 7.57 (m, 1H), 7.38 – 7.30 (m, 2H), 7.23 – 
7.11 (m, 3H), 7.02 – 6.94 (m, 2H), 6.04 (bs, 1H), 5.41 (bs, 1H). 13C NMR (101 MHz, CDCl3) δ 
181.6, 142.6, 139.7, 138.4, 136.8, 129.7, 129.2, 125.5, 124.4, 118.5, 114.5, 109.7. 
19
F NMR 
(CDCl3, 376 MHz): δ -61.9. HRMS (EI): Calcd. for C18H12F3NO ([M]+): 315.0871, Found: 
315.0862. 
2.5.5 General Procedure for Synthesis of 3-Aryl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-ones 
(2a-f, 2i-n) and 3-Alkyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-ones (2g-h) 
 
              
In a nitrogen-filled glovebox, the appropriate 1-(1-arylvinyl)-1H-indole-2-
carboxaldehyde (1a-f, 1i-n) or 1-(1-alkylvinyl)-1H-indole-2-carboxaldehyde (1g-h) (0.10 mmol, 
1.0 equiv), [Rh(COD)Cl]2 (1.2 mg, 0.0025 mmol, 0.025 equiv), (S)-MeO-BIPHEP (2.9 mg, 
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0.0050 mmol, 0.050 equiv), AgBF4 (1.0 mg, 0.0050 mmol, 0.050 equiv) and THF (0.7 mL) were 
added to a 1-dram vial.  The vial was sealed with a PTFE/silicone-lined septum cap and removed 
from the glovebox.  The reaction mixture was stirred at 60 °C in an oil bath for 16 h.  The vial 
was removed from the oil bath and allowed to cool to room temperature.  The reaction mixture 
was filtered through short plug of silica gel (eluting with 20 ml of 3:2 hexanes:EtOAc).  The 
crude reaction mixture was concentrated under reduced pressure.  The crude reaction mixture 
was purified by flash column silica gel chromatography (hexanes:EtOAc) to give the appropriate 
3-aryl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-ones (2a-f, 2i-n) or 3-alkyl-2,3-dihydro-1H-
pyrrolo[1,2-a]indol-1-ones (2g-h).  
 
 (S)-3-Phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2a) (Table 2, 
entry 1): Prepared according to the general procedure from 1a (25.0 mg, 
0.101 mmol). The mixture was purified by flash column chromatography 
(90:10 hexane:EtOAc) to give 2a as a light yellow solid in 92% yield (23.0 
mg, 0.0930 mmol). The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) 
tR 15.6 min (major); tR 12.9 min (minor) [Chiracel AD-H (0.46 cm x 25 cm)(from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 99% ee. [α]D
24
 = -209.0° (c 0.31, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.85 – 7.73 (m, 1H), 7.39 – 7.31 (m, 3H), 7.22 – 7.09 
(m, 5H), 6.97 – 6.91 (m, 1H), 5.74 (dd, J = 8.0, 4.0 Hz, 1H), 3.68 (dd, J = 18.4, 8.0 Hz, 1H), 3.07 
(dd, J = 18.4, 4.0 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 192.4, 140.2, 136.5, 135.2, 132.8, 
129.6, 128.8, 126.3, 125.6, 124.5, 121.9, 112.0, 99.5, 57.5, 50.6. HRMS (EI): Calcd. for 
C17H13NO ([M]+): 247.0997, Found: 247.0989. 
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 (S)-3-(4-Methoxyphenyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2b) 
(Table 2, entry 2): Prepared according to the general procedure from 1b (28.0 
mg, 0.101 mmol). The mixture was purified by flash column chromatography 
(90:10 hexane:EtOAc) to give 2b as a light yellow solid in 99% yield (27.9 
mg, 0.101 mmol). The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) 
tR 16.9 min (major); tR 7.37 min (minor) [Chiracel OD-H (0.46 cm x 25 cm)(from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 99% ee. [α]D
24
 = -226.0° (c 0.88, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.81 – 7.72 (m, 1H), 7.16 (ddd, J = 9.3, 7.8, 1.2 Hz, 2H), 
7.11 – 7.04 (m, 3H), 6.97 – 6.92 (m, 1H), 6.91 – 6.84 (m, 2H), 5.69 (dd, J = 8.0, 4.0 Hz, 1H), 
3.80 (s, 3H), 3.65 (dd, J = 18.4, 8.0 Hz, 1H), 3.05 (dd, J = 18.4, 4.0 Hz, 1H). 
13
C NMR (101 
MHz, CDCl3) δ 192.6, 159.9, 136.5, 135.2, 132.8, 132.2, 127.6, 125.5, 124.4, 121.8, 114.9, 
112.1, 99.3, 57.1, 55.6, 50.7. HRMS (EI): Calcd. for C18H15NO2 ([M]+): 277.1103, Found: 
277.1109. 
 
 (S)-3-(4-Chlorophenyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2c) 
(Table 2, entry 3): Prepared according to the general procedure from 1c (29.0 
mg, 0.103 mmol). The mixture was purified by flash column chromatography 
(90:10 hexane:EtOAc) to give 2c as a light yellow solid in 68% yield (19.7 
mg, 0.070 mmol). The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) 
tR 28.9 min (major); tR 33.5 min (minor) [Chiracel AD-H (0.46 cm x 25 cm)(from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 98% ee. [α]D
24
 = +150.2° (c 0.35, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.81 – 7.76 (m, 1H), 7.37 – 7.30 (m, 2H), 7.24 – 7.13 
(m, 2H), 7.11 (d, J = 0.4 Hz, 1H), 7.10 – 7.03 (m, 2H), 6.92 (dq, J = 8.4, 2.0, 1.2 Hz, 1H), 5.74 
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(dd, J = 8.0, 3.6 Hz, 1H), 3.69 (dd, J = 18.4, 8.0 Hz, 1H), 3.02 (dd, J = 18.4, 3.6 Hz, 1H). 
13
C 
NMR (101 MHz, CDCl3) δ 191.9, 138.8, 136.4, 135.1, 134.8, 132.9, 129.9, 127.7, 125.8, 124.7, 
122.1, 111.9, 99.9, 56.8, 50.5. HRMS (EI): Calcd. for C17H12ClNO ([M]+): 281.0607, Found: 
281.0602. 
 
 (S)-3-(4-(Trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-
one (2d) (Table 2, entry 4): Prepared according to a modified version of the 
general procedure from 1d (32.0 mg, 0.101 mmol).  In a nitrogen-filled 
glovebox, 1d (32.0 mg, 0.101 mmol), [Rh(COD)Cl]2 (2.5 mg, 0.00505 mmol, 
0.0500 equiv), (S)-MeO-BIPHEP (5.9 mg, 0.0101 mmol, 0.100 equiv), AgBF4 (2.0 mg, 0.0101 
mmol, 0.100 equiv) and THF (0.7 mL) were added to a 1-dram vial.  The vial was sealed with a 
PTFE/silicone-lined septum cap and removed from the glovebox.  The reaction mixture was 
stirred at 60 °C in an oil bath for 16 h.  The vial was removed from the oil bath and allowed to 
cool to room temperature.  The reaction mixture was filtered through short plug of silica gel 
(eluting with 20 mol of 3:2 hexanes:EtOAc).  The crude reaction mixture was concentrated under 
reduced pressure.  The crude reaction mixture was purified by flash column silica gel 
chromatography (90:10 hexanes:EtOAc) to give 2d as a light yellow solid in 70% yield (22.5 
mg, 0.0713 mmol). The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) 
tR 34.6 min (major); tR 47.9 min (minor) [Chiracel AD-H (0.46 cm x 25 cm)(from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 99:1, 1.0 mL/min] to be 99% ee. [α]D
24
 = -253.0° (c 0.24, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.87 – 7.74 (m, 1H), 7.69 – 7.57 (m, 2H), 7.27 – 7.15 
(m, 4H), 7.14 (d, J = 0.8 Hz, 1H), 6.91 (dq, J = 8.4, 2.4,1.2 Hz, 1H), 5.83 (dd, J = 8.0, 3.6 Hz, 
1H), 3.73 (dd, J = 18.4, 8.0 Hz, 1H), 3.03 (dd, J = 18.4, 3.6 Hz, 1H). 
13
C NMR (101 MHz, 
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CDCl3) δ 191.5, 144.3, 136.4, 135.1, 132.9, 131.4, 131.0, 126.8, 126.8, 126.7, 126.7, 126.0, 
125.5, 124.7, 122.8, 122.2, 111.8, 100.1, 56.9, 50.3. 
19
F NMR (CDCl3, 376 MHz): δ -63.1.  
HRMS (EI): Calcd. for C18H12F3NO ([M]+): 315.0871, Found: 315.0886. 
  
 (S)-3-(3-Methoxyphenyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2e) 
(Table 2, entry 5): Prepared according to the general procedure from 1e (28.0 
mg, 0.101 mmol). The mixture was purified by flash column chromatography 
(90:10 hexane:EtOAc) to give 2e as a light yellow solid in 92% yield (25.8 
mg, 0.0930 mmol). The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) 
tR 14.5 min (major); tR 10.5 min (minor) [Chiracel AD-H (0.46 cm x 25 cm)(from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 98% ee. [α]D
23
 = -206.6° (c 0.54, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.79 – 7.75 (m, 1H), 7.21 – 7.11 (m, 2H), 7.11 – 7.05 
(m, 3H), 6.95 (dq, J = 8.4, 2.4, 1.2 Hz, 1H), 6.91 – 6.84 (m, 2H), 5.69 (dd, J = 8.0, 4.0 Hz, 1H), 
3.80 (s, 3H), 3.65 (dd, J = 18.4, 8.0 Hz, 1H), 3.05 (dd, J = 18.4, 4.0 Hz, 1H). 
13
C NMR (101 
MHz, CDCl3) δ 192.4, 160.6, 141.9, 136.5, 135.3, 132.8, 130.8, 125.6, 124.5, 121.9, 118.5, 
113.9, 112.2, 99.5, 57.4, 55.6, 50.5. HRMS (EI): Calcd. for C18H15NO2 ([M]+): 277.1103, 
Found: 277.1102. 
 
 (S)-3-(3,4,5-Trimethoxyphenyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-
one (2f) (Table 2, entry 6): Prepared according to the general procedure 
from 1f (34.0 mg, 0.100 mmol). The mixture was purified by flash column 
chromatography (80:20 hexane:EtOAc) to give 2f as a light yellow solid in 
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82% yield (27.8 mg, 0.0820 mmol). The enantiomeric excess was determined by HPLC analysis 
(220 nm, 25 °C) tR 21.8 min (major); tR 18.8 min (minor) [Chiracel AD-H (0.46 cm x 25 
cm)(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 99% ee. [α]D
24
 = 
-229.1° (c 0.48, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.80 – 7.76 (m, 1H), 7.20 (dddd, J = 
24.4, 14.8, 6.8, 0.8 Hz, 2H), 7.10 (d, J = 0.4 Hz, 1H), 7.01 (dq, J = 8.4, 2.0, 1.2 Hz, 1H), 6.32 (s, 
2H), 5.66 (dd, J = 8.0, 3.6 Hz, 1H), 3.84 (s, 3H), 3.74 (s, 6H), 3.66 (dd, J = 18.4, 8.0 Hz, 1H), 
3.08 (dd, J = 18.4, 3.6 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 192.4, 154.3, 138.3, 136.6, 
135.9, 135.4, 132.8, 125.7, 124.5, 122.0, 112.2, 103.2, 99.7, 61.2, 57.8, 56.5, 50.6. HRMS (EI): 
Calcd. for C20H19NO4 ([M]+): 337.1314, Found: 337.1306. 
 
 (R)-3-Methyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2g) (Table 2, 
entry 7): Prepared according to the general procedure from 1g (19.0 mg, 
0.102 mmol). The mixture was purified by flash column chromatography 
(80:20 hexane:EtOAc) to give 2g as a light yellow solid in 99% yield (18.9 mg, 0.102 mmol). 
The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 27.2 min 
(major); tR 23.9 min (minor) [Chiracel AD-H (0.46 cm x 25 cm)(from Daicel Chemical Ind., 
Ltd.) hexane/i-PrOH, 99:1, 1.0 mL/min] to be 99% ee. [α]D
24
 = -127.6° (c 0.75, CHCl3). 
1
H 
NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.4, 1H), 7.53 – 7.43 (m, 1H), 7.37 (t, J = 7.6 Hz, 1H), 
7.19 (t, J = 7.6 Hz, 1H), 6.99 (bs, 1H), 4.99 – 4.83 (m, 1H), 3.43 (dd, J = 18.4, 7.6 Hz, 1H), 2.80 
(dd, J = 18.4, 3.2 Hz, 1H), 1.69 (d, J = 6.4 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 193.1, 
135.9, 134.9, 132.7, 125.4, 124.7, 121.6, 111.5, 110.3, 99.1, 49.6, 48.7, 22.0. HRMS (EI): Calcd. 
for C12H11NO ([M]+): 185.0841, Found: 185.0842. 
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 (S)-3-Cyclohexyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2h) (Table 2, 
entry 8): Prepared according to a modified version of the general procedure 
from 1h (26.0 mg, 0.102 mmol).  In a nitrogen-filled glovebox, 1h (26.0 mg, 
0.102 mmol), [Rh(COD)Cl]2 (1.3 mg, 0.00255 mmol, 0.0250 equiv), (S)-
MeO-BIPHEP (3.0 mg, 0.00513 mmol, 0.0500 equiv), AgBF4 (1.0 mg, 0.00513 mmol, 0.0500 
equiv) and 1,4-dioxane (0.7 mL) were added to a 1-dram vial.  The vial was sealed with a 
PTFE/silicone-lined septum cap and removed from the glovebox.  The reaction mixture was 
stirred at 101 °C in an oil bath for 16 h.  The vial was removed from the oil bath and allowed to 
cool to room temperature.  The reaction mixture was filtered through short plug of silica gel 
(eluting with 20 mol of 3:2 hexanes:EtOAc).  The crude reaction mixture was concentrated under 
reduced pressure.  The crude reaction mixture was purified by flash column silica gel 
chromatography (90:10 hexanes:EtOAc) to give 2h as a light yellow solid in 45% yield (11.7 
mg, 0.0462 mmol). The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) 
tR 12.3 min (major); tR 8.66 min (minor) [Chiracel AD-H (0.46 cm x 25 cm)(from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 95% ee. [α]D
24
 = +253.9° (c 0.16, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.0 Hz, 1H), 7.54 – 7.45 (m, 1H), 7.35 (t, J = 
7.6 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 6.97 (bs, 1H), 4.86 – 4.77 (m, 1H), 3.14 (dd, J = 18.4, 8.0 
Hz, 1H), 2.96 (dd, J = 18.4, 2.4 Hz, 1H), 2.37 – 2.25 (m, 1H), 1.89 – 1.76 (m, 2H), 1.74 – 1.55 
(m, 2H), 1.41 – 1.19 (m, 2H), 1.19 – 0.78 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 193.5, 136.5, 
135.2, 132.7, 125.3, 124.7, 121.6, 111.9, 98.7, 58.4, 42.5, 41.4, 30.0, 26.5, 25.8, 25.0. HRMS 
(EI): Calcd. for C17H19NO ([M]+): 253.1467, Found: 253.1468. 
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 (S)-9-Ethyl-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2i) 
(Table 3, entry 1): Prepared according to the general procedure from 1i (28.0 
mg, 0.101 mmol). The mixture was purified by flash column chromatography 
(90:10 hexane:EtOAc) to give 2i as a light yellow solid in 89% yield (25.0 mg, 
0.0900 mmol). The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 
8.57 min (major); tR 12.6  min (minor) [Chiracel OD-H (0.46 cm x 25 cm)(from Daicel Chemical 
Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 98% ee. [α]D
24
 = -160.9° (c 0.65, CHCl3). 
1
H 
NMR (400 MHz, CDCl3) δ 7.78 (dq, J = 8.0, 1.2, 0.4 Hz, 1H), 7.40 – 7.29 (m, 3H), 7.21 – 7.08 
(m, 4H), 6.88 (dt, J = 8.4, 0.8 Hz, 1H), 5.68 (dd, J = 8.0, 4.0 Hz, 1H), 3.65 (dd, J = 18.4, 8.0 Hz, 
1H), 3.12 (qd, J = 15.2, 7.6, 1.6 Hz, 2H), 3.04 (dd, J = 18.4, 4.0 Hz, 1H), 1.40 (t, J = 7.2 Hz, 
3H). 
13
C NMR (101 MHz, CDCl3) δ 192.6, 140.7, 135.0, 132.8, 132.1, 129.6, 128.7, 126.4, 
125.6, 122.7, 120.9, 119.9, 112.0, 57.1, 51.1, 17.9, 15.9. HRMS (EI): Calcd. for C19H17NO 
([M]+): 275.1310, Found: 275.1315. 
 
 (S)-8-Methoxy-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2j) 
(Table 3, entry 2): Prepared according to the general procedure from 1j (28.0 
mg, 0.100 mmol). The mixture was purified by flash column chromatography 
(90:10 hexane:EtOAc) to give 2j as a light yellow solid in 90% yield (25.2 
mg, 0.0900 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) 
tR 20.4 min (major); tR 27.8 min (minor) [Chiracel AD-H (0.46 cm x 25 cm)(from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 99% ee. [α]D
24
 = -185.3° (c 0.71, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.38 – 7.31 (m, 2H), 7.22 (d, J = 0.4 Hz, 1H), 7.14 – 
7.09 (m, 3H), 6.50 (dd, J = 11.6, 8.4 Hz, 2H), 5.71 (dd, J = 8.0, 4.0 Hz, 1H), 3.96 (s, 3H), 3.67 
76 
 
 
(dd, J = 18.4, 8.0 Hz, 1H), 3.05 (dd, J = 18.4, 4.0 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 
191.9, 155.9, 140.3, 136.5, 135.4, 129.6, 128.8, 126.7, 126.3, 124.5, 104.8, 100.4, 97.4, 57.5, 
55.7, 50.7. HRMS (EI): Calcd. for C18H15NO2 ([M]+): 277.1103, Found: 277.1107. 
 
(S)-7-Methoxy-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one 
(2k) (Table 3, entry 3): Prepared according to the general procedure 
from 1k (28.0 mg, 0.101 mmol). The mixture was purified by flash 
column chromatography (90:10 hexane:EtOAc) to give 2k as a light 
yellow solid in 97% yield (27.2 mg, 0.0980 mmol). The enantiomeric excess was determined by 
HPLC analysis (220 nm, 25 °C) tR 23.7 min (major); tR 17.8 min (minor) [Chiracel AD-H (0.46 
cm x 25 cm)(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 98% ee. 
[α]D
24
 = -226.2° (c 0.88, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.39 – 7.30 (m, 3H), 7.15 – 7.09 
(m, 3H), 7.01 (d, J = 0.4 Hz, 1H), 6.89 – 6.79 (m, 2H), 5.72 (dd, J = 8.0, 4.0 Hz, 1H), 3.83 (s, 
3H), 3.67 (dd, J = 18.8, 8.0 Hz, 1H), 3.05 (dd, J = 18.8, 4.0 Hz, 1H). 
13
C NMR (101 MHz, 
CDCl3) δ 191.9, 155.5, 140.3, 137.0, 133.3, 130.9, 129.6, 128.8, 126.3, 118.2, 113.0, 103.3, 98.9, 
57.5, 55.8, 50.5. HRMS (EI): Calcd. for C18H15NO2 ([M]+): 277.1103, Found: 277.1105. 
 
 (S)-7-Fluoro-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2l) 
(Table 3, entry 4): Prepared according to the general procedure from 1l 
(27.0 mg, 0.102 mmol). The mixture was purified by flash column 
chromatography (90:10 hexane:EtOAc) to give 2l as a light yellow solid in 
92% yield (24.9 mg, 0.0940 mmol). The enantiomeric excess was determined by HPLC analysis 
(220 nm, 25 °C) tR 16.9 min (major); tR 12.4 min (minor) [Chiracel AD-H (0.46 cm x 25 
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cm)(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 98% ee. [α]D
24
 = -
145.6° (c 0.73, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.31 (m, 4H), 7.17 – 7.08 (m, 2H), 
7.04 (d, J = 0.4 Hz, 1H), 6.95 (td, J = 9.2, 2.4 Hz, 1H), 6.86 (dd, J = 9.2, 4.4 Hz, 1H), 5.73 (dd, J 
= 8.0, 4.0 Hz, 1H), 3.68 (dd, J = 18.8, 8.0 Hz, 1H), 3.06 (dd, J = 18.8, 4.0 Hz, 1H). 
13
C NMR 
(101 MHz, CDCl3) δ 192.0, 159.9, 157.5, 139.9, 137.9, 133.0, 132.9, 131.9, 129.7, 129.0, 126.3, 
115.4, 115.1, 113.1, 113.0, 108.4, 108.2, 99.2, 57.7, 50.5. 
19
F NMR (CDCl3, 376 MHz): δ -
121.3. HRMS (EI): Calcd. for C17H12FNO ([M]+): 265.0903, Found: 265.0899. 
 
 (S)-6-Chloro-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one 
(2m) (Table 3, entry 5): Prepared according to the general procedure 
from 1m (28.5 mg, 0.101 mmol). The mixture was purified by flash 
column chromatography (90:10 hexane:EtOAc) to give 2m as a light 
yellow solid in 82% yield (23.4 mg, 0.0830 mmol). The enantiomeric excess was determined by 
HPLC analysis (220 nm, 25 °C) tR 34.5 min (major); tR 58.3 min (minor) [Chiracel AD-H (0.46 
cm x 25 cm)(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 99:1, 1.0 mL/min] to be 98% ee. 
[α]D
24
 = -270.6° (c 0.70, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 8.8, 1H), 7.44 – 
7.30 (m, 3H), 7.15 – 7.08 (m, 3H), 7.06 (d, J = 0.8 Hz, 1H), 6.93 (bs, 1H), 5.71 (dd, J = 8.0, 4.0 
Hz, 1H), 3.68 (dd, J = 18.8, 8.0 Hz, 1H), 3.06 (dd, J = 18.8, 4.0 Hz, 1H). 
13
C NMR (101 MHz, 
CDCl3) δ 191.6, 139.4, 136.9, 134.9, 131.3, 130.9, 129.5, 128.8, 125.9, 125.1, 122.7, 111.3, 99.4, 
57.3, 50.2. HRMS (EI): Calcd. for C17H12ClNO ([M+H]+): 281.0607, Found: 281.0594. 
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(S)-3-Phenyl-6-(trifluoromethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-
1-one (2n) (Table 3, entry 6): Prepared according to the general 
procedure from 1n (32.0 mg, 0.101 mmol). The mixture was purified by 
flash column chromatography (90:10 hexane:EtOAc) to give 2n as a light yellow solid in 81% 
yield (26.0 mg, 0.0820 mmol). The enantiomeric excess was determined by HPLC analysis (220 
nm, 25 °C) tR 29.9 min (major); tR 45.6 min (minor) [Chiracel AD-H (0.46 cm x 25 cm)(from 
Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 99:1, 1.0 mL/min] to be 99% ee. [α]D
24
 = -234.1° (c 
0.73, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 8.4 Hz, 1H), 7.43 – 7.33 (m, 4H), 7.24 
– 7.20 (m, 1H), 7.17 – 7.10 (m, 3H), 5.81 (dd, J = 8.0, 4.0 Hz, 1H), 3.72 (dd, J = 18.8, 8.0 Hz, 
1H), 3.11 (dd, J = 18.8, 4.0 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 192.2, 139.5, 138.8, 134.6, 
133.7, 129.9, 129.3, 127.4, 127.1, 126.2, 126.1, 125.2, 123.4, 118.2, 109.6, 99.3, 57.8, 50.5. 
19
F 
NMR (CDCl3, 376 MHz): δ -61.9. HRMS (EI): Calcd. for C18H12F3NO ([M]+): 315.0871, 
Found: 315.0878. 
2.5.6 Procedures for Synthesis of 2a at 0.2 and 1 mol % Catalyst Loading 
N
O
H N
O
1,4-dioxane, 100 °C
[Rh(COD)Cl]2 (5 mol %)
(S)-7 (0.2-1 mol %)
AgBF4 (0.2-1 mol %)
1a 2a
1 mol % Rh
99% conversion
95% yield
98% ee
0.2 mol % Rh
94% conversion
79% yield
98% ee  
1 mol % Catalyst Loading: In a nitrogen-filled glovebox, 1-(1-phenylvinyl)-1H-indole-2-
carboxaldehyde (1a) (100 mg, 0.400 mmol, 1.00 equiv), [Rh(COD)Cl]2 (1.0 mg, 0.0020 mmol, 
0.0050 equiv), (S)-MeO-BIPHEP (7) (2.3 mg, 0.0040 mmol, 0.010 equiv), AgBF4 (0.8 mg, 0.004 
mmol, 0.01 equiv) and 1,4-dioxane (2.8 mL) were added to a 1-dram vial. The vial was sealed 
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with a PTFE/silicone-lined septum cap and removed from the glovebox.  The reaction mixture 
was stirred at 101 °C in an oil bath for 16 h.  The vial was removed from the oil bath and allowed 
to cool to room temperature.  The reaction mixture was filtered through short plug of silica gel 
(eluting with 50 ml of 3:2 hexanes:EtOAc).  The crude reaction mixture was concentrated under 
reduced pressure.  The crude reaction mixture was purified by flash column silica gel 
chromatography (90:10 hexanes:EtOAc) to give (S)-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-
a]indol-1-one (2a) as a light yellow solid in 95% yield (95 mg, 0.38 mmol). The enantiomeric 
excess was determined by HPLC analysis (220 nm, 25 °C) tR 15.6 min (major); tR 12.9 min 
(minor) [Chiracel AD-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 
95:5, 1.0 mL/min] to be 98% ee. 
0.2 mol % Catalyst Loading: In a nitrogen-filled glovebox, 1-(1-phenylvinyl)-1H-indole-2-
carboxaldehyde (1a) (500 mg, 2.0 mmol, 1.0 equiv), [Rh(COD)Cl]2 (1.0 mg, 0.0020 mmol, 
0.0010 equiv), (S)-MeO-BIPHEP (7) (2.3 mg, 0.0040 mmol, 0.0020 equiv), AgBF4 (0.8 mg, 
0.0040 mmol, 0.0020 equiv) and 1,4-dioxane (14 mL) were added to a 20 mL scintillation vial. 
The vial was sealed with a PTFE/silicone-lined septum cap and removed from the glovebox.  
The reaction mixture was stirred at 101 °C in an oil bath for 16 h.  The vial was removed from 
the oil bath and allowed to cool to room temperature.  The reaction mixture was filtered through 
short plug of silica gel (eluting with 150 ml of 3:2 hexanes:EtOAc).  The crude reaction mixture 
was concentrated under reduced pressure.  The crude reaction mixture was purified by flash 
column silica gel chromatography (90:10 hexanes:EtOAc) to give (S)-3-phenyl-2,3-dihydro-1H-
pyrrolo[1,2-a]indol-1-one (2a) as a light yellow solid in 79% yield (395 mg, 1.60 mmol). The 
enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 15.6 min (major); tR 
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12.9 min (minor) [Chiracel AD-H (0.46 cm x 25 cm)(from Daicel Chemical Ind., Ltd.) hexane/i-
PrOH, 95:5, 1.0 mL/min] to be 98% ee. 
2.5.7 Synthesis of (S)-9-Bromo-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (3) 
                                           
To a solution of (S)-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2a) (150.0 mg, 
0.606 mmol) in DMF (10 ml) was added N-bromosuccinimide (113.0 mg, 0.637 mmol). The 
reaction mixture was stirred for 2 hours at 23 °C under a nitrogen atmosphere. The reaction 
mixture was diluted with ethyl acetate and washed with brine. The organic layer was dried over 
magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was 
purified by flash column silica gel chromatography (90:10 hexane:EtOAc) to give (S)-9-bromo-
3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (3) as an off-white solid in 88% yield (175 
mg, 0.535 mmol). The resulting product was recrystallized from methanol to obtain colorless 
single crystals for single crystal XRD analysis. m.p. = 134-136 °C (decomposition) [α]D
24
 = -
151.2° (c 0.65, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.77 – 7.68 (m, 1H), 7.46 – 7.30 (m, 3H), 
7.25 – 7.19 (m, 2H), 7.18 – 7.12 (m, 2H), 6.96 – 6.86 (m, 1H), 5.71 (dd, J = 8.0, 4.0 Hz, 1H), 
3.70 (dd, J = 18.8, 8.0 Hz, 1H), 3.10 (dd, J = 18.4, 4.0 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 
190.6, 139.7, 134.9, 132.9, 132.2, 129.7, 129.1, 126.7, 126.4, 122.6, 112.2, 88.8, 57.6, 50.9. 
HRMS (EI): Calcd. for C17H12BrNO ([M]+): 325.0102, Found: 325.0108. 
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CHAPTER 3 
 
AN ENANTIOSELECTIVE MODEL SYNTHESIS AND PROGRESS TOWARD THE 
PUTATIVE STRUCTURE OF YUREMAMINE 
 
Modified from a paper published in The Journal of Organic Chemistry
1
 
 
Avipsa Ghosh, David T. Bainbridge, and Levi M. Stanley* 
3.1 Abstract 
An enantioselective model synthesis of 2,3-Dihydro-1H-pyrrolo[1,2-a]-indole core 
of putative structure of yuremamine is reported in 39% overall yield and 96% ee over 5 
steps. The model synthesis leverages enantioselective, rhodium-catalyzed hydroacylation of 
an N-vinylindole-2-carboxaldehyde as the key step in the installation of the stereochemical 
triad. An enantioselective synthesis of a densely functionalized dihydropyrroloindolone that 
maps onto the putative structure of yuremamine is demonstrated in 26% yield and 97% ee 
over 8 steps. 
 
 
 
                                                 
1
 Ghosh, A.; Bainbridge, D. T.; Stanley, L. M. J. Org. Chem. 2016, 10.1021/acs.joc.6b01730 
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3.2 Introduction 
2,3-Dihydro-1H-pyrrolo[1,2-a]-indole and oxidized derivatives are recurring motifs in 
natural products and drug candidates including the antimalarial flinderoles
1
 and isoborreverines,
2
 
the antitumor antibiotic mitomycin C,
3
 the PKC inhibitor JTT-010
4
 and isatisine A
5
 which 
exhibits antiviral activity. Yuremamine, a phytoindole alkaloid with hallucinogenic and 
psychoactive properties was isolated from the stem bark of Mimosa hostilis in 2005 by Callaway 
and co-workers.
6
 The structure of yuremamine, originally proposed to be the densely 
functionalized dihydropyrroloindole 1 with three contiguous stereogenic centers, was recently 
revised to the flavonoidal indole 2 by Sperry and co-workers (Figure 3.1).
7
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Figure 3.1 Originally proposed structure and revised structure of yuremamine 
The intriguing molecular architecture of 1 prompted numerous synthetic studies towards 
the putative structure since the isolation of yuremamine. While several synthetic strategies 
towards the dihydropyrroloindole core of 1 have been developed by the Kerr, Shi, Dethe, Chen, 
France, You, Sperry and Zu groups,
8
 the first racemic total synthesis was reported by the 
Iwasawa group in 2015.
9
 Despite these synthetic efforts during the past decade, enantioselective 
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total synthesis of 1 or synthetic approaches to generate the chiral dihydropyrroloindole core with 
control of the absolute configuration of the stereochemical triad have not been reported.  
Scheme 3.1 Enantioselective Hydroacylation of N-Vinylindole-2-carboxadehydes to Access 
Chiral Dihydropyrroloindolones 
N
O
R3
R1
R2
N
R3
H
O
chiral, non-racemic
 Rh catalystR
1
R2
up to 99% yield
up to 99% ee
 
Compound 1 is a fundamentally challenging target due to the lack of well-established 
enantioselective methods to generate chiral 2,3-dihydro-1H-pyrrolo[1,2-a]-indoles.
10
 The 
dihydropyrroloindole core of 1 contains three contiguous stereogenic centers that must be formed 
in a stereocontrolled fashion. Recently, we reported catalytic, intramolecular hydroacylations of 
N-vinylindole-2-carboxaldehydes to form β-substituted dihydropyrroloindolones with high 
enantioselectivities that offer the potential to address these challenges (Scheme 3.1).
11
 The 
enantioselective hydroacylation would enable control of the absolute configuration of one of the 
requisite stereogenic centers present in the dihydropyrroloindole core. In addition, the ketone 
functionality present in the dihydropyrroloindolone product of hydroacylation can serve as a 
synthetic handle to install the additional stereogenic centers with precise control of the absolute 
and relative configuration of the stereochemical triad. 
Herein, we report an enantioselective model synthesis of the 2,3-dihydro-1H-pyrrolo[1,2-
a]indole core of 1 utilizing enantioselective rhodium-catalyzed hydroacylation of an N-
vinylindole-2-carboxaldehyde as the key step for installation of the three contiguous stereogenic 
centers. We also report an enantioselective synthesis of a functionalized chiral 
dihydropyrroloindolone that maps onto the structure of 1. 
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3.3 Retrosynthetic Analysis and Synthesis Plan 
Scheme 3.2 Retrosynthetic Analysis for the Enantioselective Synthesis of Compound 1 
 
Scheme 3.2 illustrates the strategy we originally envisioned to complete an 
enantioselective synthesis of 1. Installation of the stereochemical triad in 1 would be achieved by 
a sequence of hydroboration and oxidation occurring on the face of the olefin opposite to the aryl 
group attached to the stereogenic center in 3.
12
 Compound 3 would be synthesized by a sequence 
of Grignard addition to the chiral dihydropyrroloindolone 4 followed by dehydration of the 
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resulting tertiary alcohol to form the required alkene. Based on our previous studies, we planned 
the synthesis of 4 from N-vinylindole-2-carboxaldehyde 5 by an enantioselective, intramolecular 
rhodium-catalyzed hydroacylation reaction.
11
 Compound 5 would be generated by a palladium-
catalyzed cross-coupling reaction of indole 7 and hydrazone 6.
13
 Indole 7 could be derived from 
8 by direct installation of the ester functionality at the 2-position of the indole followed by 
removal of the protecting group from the indole nitrogen. 
3.4 Results and Discussion 
3.4.1 Enantioselective model synthesis of dihydropyrroloindole core of putative 
yuremamine  
 
We were aware that intermediate 3 may be susceptible to olefin isomerization that could 
racemize the stereogenic center set by enantioselective hydroacylation. To test our strategy to 
install the three contiguous stereogenic centers in an enantioselective and diastereoselective 
fashion, we conducted a model study starting from N-vinylindole-2-carboxaldehyde 9 (Scheme 
3.3).  Enantioselective hydroacylation of 9 in the presence of 0.5 mol% of a Rh catalyst prepared 
in situ from [Rh(COD)Cl]2, (R)-MeO-BIPHEP, and AgBF4 formed dihyropyrroloindolone 10 in 
83% yield with 97% ee.  Addition of phenylmagnesium bromide to 10 generated the tertiary 
alcohol 11 in 90% yield as a 6:1 mixture of diastereomers with complete retention of 
enantiomeric excess (97% ee). Subsequent dehydration of the resulting tertiary alcohol with 
Martin sulfurane generated (R)-1,3-diphenyl-3H-pyrrolo[1,2-a]indole 12.
14
  The carbon skeleton 
present in the dihydropyrroloindole core of 1 was established by immediate hydroboration of 12 
followed by oxidation of the resulting alkylborane with basic hydrogen peroxide. 
Dihydropyrroloindole 13 was isolated as a 9:1 mixture of diastereomers in 52% yield over three 
steps without significant loss of enantioselectivity (96% ee). Consistent with hydroboration and 
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oxidations of 1,3-diarylcyclopent-1-enes, the hydroboration and oxidation of 12 preferentially 
occurs on the face of the olefin opposite to the phenyl group attached to the stereogenic center.
12
 
This sequence occurs to set a stereochemical triad with both aryl groups trans to the hydroxyl 
group.  The relative stereochemistry of the dihydropyrroloindole core 13 was established by 
geminal carbon-proton spin coupling-constant (
2
JC,H) values (J-based configuration analysis) and 
the dependence of these values on dihedral angles.
15
  
Scheme 3.3 Enantioselective Model Synthesis of the 2,3-Dihydro-1H-pyrrolo[1,2-a]indole Core 
of 1 
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Figure 3.2 Possible products of hydroboration-oxidation reaction of 12 
 
3.4.2 Stereochemical Analysis of 13  
 
The relative stereochemistry of 13 was established based on the geminal carbon-proton 
spin coupling-constant (
2
JC,H) values (J-based configuration analysis) and the dependence of 
these values on dihedral angles (Figure 3.2 and Figure 3.3b). The magnitude of coupling between 
13
C and 
1
H across two bonds, the 
2
JC,H value including (+/-) sign, depends on the relative spatial 
arrangement of the proton and the electronegative substituent on the particular carbon. If an 
oxygen atom on a carbon atom is gauche to its geminal proton, the 
2
JC,H values are large; and the 
values become small when the oxygen atom is anti to its germinal proton. 
2
JC2,H1 and 
2
JC2,H3 
values in compound 13 were determined to be -5.0 Hz and -6.2 Hz respectively, consistent with 
the gauche orientation of the hydroxyl group with both H1 and H3 methine protons (Figure 3.2 
and Figure 3.3). These carbon-proton spin coupling-constant values were determined by a hetero 
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half-filtered TOCSY experiment, often called HETLOC (HETeronuclear LOng-range Coupling). 
The (+/-) sign of 
2
JCx,Ha was determined from the slope of the linked line between the split peaks 
against the slope of the diagonal peaks (Figure 3.3c); the 
2
JCx,Ha value is positive if the 
coefficients for the slope of both lines take the same (+/-) signs, whereas the value is negative if 
they have different signs for the coefficients. The magnitude of 
2
JCx,Ha values were evaluated 
from a chemical shift difference of the two Hx(F1)-Ha(F2) peaks split in the F2 dimension 
(Figure 3.3d). 
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Figure 3.3 (a) Structure of 13; (b) Dihedral angle dependence of geminal 
13
C-
1
H coupling 
constants, 
2
JC,H; (c) Determination of sign (+/-) for 
2
JC,H coupling constant values in partial 
HETLOC spectrum of 13, and (d) Determination of 
2
JC,H coupling constant values in partial 
HETLOC spectrum of 13. 
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3.4.3 Progress toward enantioselective synthesis of putative structure of yuremamine 
Encouraged by the results of our model synthesis, we initiated studies toward an 
enantioselective synthesis of 1. We conducted our studies starting from the TBS ether of 
tryptophol 17. Scheme 3.4 illustrates synthesis of tryptophol 17 starting from indole 14 over 4 
steps in 81% yield.
16
 Reaction of 14 with oxalyl chloride formed 3-indolylglyoxylyl chloride 
which on refluxing in ethanol in presence of triethylamine generated ethyl 3-indolylglyoxylate 
15. LiAlH4 reduction of 15 generated tryptophol 16. The alcohol in 16 was protected in presence 
of imidazole and TBSCl to generate TBS protected tryptophol 17. Attempts for one-step 
synthesis of tryptophol 16 proved challenging especially when the reactions were carried out in 
multigram scale (Scheme 3.5).
17
  
Scheme 3.6 illustrates the synthesis of indole 20 from the TBS ether of tryptophol 17.
16c
 
The indole nitrogen in 17 was protected using benzenesulfonyl chloride in the presence of 
tetrabutylammonium hydrogensulfate (TBAHS) to furnish 18 in 99% yield.
18
 We envisioned 
direct installation of an ester at the 2-position of indole via lithiation followed by quenching with 
an appropriate electrophile. Interestingly, common lithiating agents such as n-BuLi, sec-BuLi, 
and tert-BuLi led to the formation of complex mixtures of multiple products even with less than 
one equivalent of base (Equation 3.1).
19
 However, lithiation in the presence of freshly prepared 
lithium diisopropylamide (LDA) at -78 °C followed by reaction with diethyl carbonate or ethyl 
chloroformate formed the desired ethyl indole-2-carboxylate 19 as the only product in 30-75% 
yield (Table 3.1, entries 1 and 3). The use of ethyl chloroformate as the electrophile and 
increasing the reaction temperature improved the yield of the desired product to 90% (Table 3.1, 
entry 4). 
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Scheme 3.4 Synthesis of TBS protected Tryptophol 17 
 
 
Scheme 3.5 One-Step Synthesis of Tryptophol 16 
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Scheme 3.6 Synthesis of Indole 20 
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Table 3.1 Identification of Reaction Conditions for Synthesis of Ester 19
a
 
 
entry temp (°C) electrophile Yield (%)
b
 
1 -78 diethyl carbonate 30 
2 -78→0 diethyl carbonate 60 
3 -78 ethyl chloroformate 75 
4 -78→0 ethyl chloroformate 90 
a
Reaction conditions: 18 (1.20 mmol, 1.00 equiv), LDA (1.20 mmol, 1.00 equiv), Electrophile 
(1.44 mmol, 1.20 equiv) and THF (7.0 mL). 
b
Isolated yield of 19 after column chromatography.  
 
With a suitable method to install the ester functionality, we attempted to remove the 
benzenesulfonyl protecting group in 19. Although many methods are established to accomplish 
similar transformations, the deprotection of 19 proved challenging.
20
 Deprotection in the 
presence of Na-Hg/Na2HPO4 led to incomplete conversion (60%) of 19 to indole 20.
20a
 The 
reaction of 19 in presence of sodium tert-butoxide in 1,4-dioxane was plagued by undesired 
transesterification and hydrolysis of the ester (Equation 3.2).
20b
  
 
Deprotection of 19 in the presence of Cs2CO3 in a 2:1 mixture of THF:ethanol at room 
temperature led to 99% conversion of 19 to 20 along with the formation of ethyl 
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benzenesulfonate (Equation 3.3).
21
 However, the similar polarities of 20 and ethyl 
benzenesulfonate rendered isolation of pure 20 challenging by standard chromatographic 
techniques. Conducting the reaction at reflux for 16 h led to the formation of 20 in 95% yield 
along with benzenesulfonic acid, which were easily separable by flash column chromatography 
(Equation 3.4). All the synthetic transformations shown in Scheme 3.4 and Scheme 3.6 are robust 
and were conducted in multi-millimolar scale (up to 20 mmole). 
 
            Scheme 3.7 describes the synthesis of N-tosylhydrazone 6 from 3,4,5-trimethoxybenzoic 
acid 24 over three steps in 38% yield.
13, 22
 Reaction of 24 with thionyl chloride under reflux 
conditions formed acid chloride 26. Reaction of 26 with methyl magnesium bromide in presence 
of Fe(acac)3 generated 1-(3,4,5-trimethoxyphenyl)ethanone 27 in 63% yield which in the 
presence of tosylhydrazide in methanol at 60 °C formed N-tosylhydrazone 6 in 61% yield. 
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Scheme 3.7 Synthesis of N-tosylhydrazone 6 
 
Scheme 3.8 illustrates the enantioselective synthesis of the functionalized chiral 
dihydropyrroloindolone 29. Palladium-catalyzed cross-coupling of 20 with hydrazone 6 
generated ethyl N-vinylindole-2-carboxylate 27 in 40% isolated yield. A sequence of DIBAL-H 
mediated reduction of 27 followed by oxidation of the resulting crude alcohol with MnO2 
furnished N-vinylindole-2-carboxaldehyde 28 in 84% yield over two steps. Enantioselective, 
intramolecular hydroacylation of 28 in the presence of a catalyst generated in situ from 
[Rh(COD)Cl]2, (R)-MeO-BIPHEP, and AgBF4 formed dihyropyrroloindolone 29 in 90% yield 
with 97% ee. 
Chiral dihydropyrroloindolone 29 is suitably functionalized to complete an 
enantioselective synthesis of 1 based on the model synthesis illustrated in Scheme 3.3. However, 
we elected to terminate our efforts toward 1 following the structural reassignment of yuremamine 
from a dihydropyrroloindole to a flavonoidal indole.  
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Scheme 3.8 Synthesis of Dihydropyrroloindolone 29 
 
As an alternate synthetic route, we explored synthesis of chiral dihydropyrroloindolone 
36 from tryptamine 30 as the starting material (Scheme 3.9). Reductive methylation of 
tryptamine followed by phenyl sulfonyl protection of indole nitrogen in 31 formed 8. Direct 
installation of ester group at the 2-position of indole in presence of LDA and ethyl chloroformate 
followed by deprotection of phenyl sulfonyl group in 32 generated 7. Palladium(0)-catalyzed 
coupling of 7 with 6 formed 33 in 45% yield. DIBAL-H reduction of 33 followed by oxidation of 
34 in presence of activated manganese dioxide generated 35. The key hydroacylation step with 
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N,N-dimethyltryptamine derivative 35 was not encouraging, presumably due to coordination of 
the basic nitrogen in 35 to the rhodium center (Scheme 3.9).  
Scheme 3.9 Attempt towards synthesis of dihydropyrroloindolone 36 
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3.5 Conclusion 
In conclusion, we have developed an enantioselective model synthesis of the 2,3-dihydro-
1H-pyrrolo[1,2-a]indole core present in the putative structure of yuremamine. The 2,3-dihydro-
1H-pyrrolo[1,2-a]indole core containing three contiguous stereogenic centers was synthesized in 
39% overall yield and 96% ee in 5 steps. The catalytic protocol for enantioselective rhodium-
catalyzed hydroacylation of N-vinylindole-2-carboxaldehyde reported by our group was utilized 
in multi-milllimolar scale as the key step for installation of the stereochemical triad. The ketone 
functionality present in the hydroacylation product served as a synthetic handle for the 
installation of additional stereocenters with precise control of absolute and relative 
stereochemistry. Progress toward enantioselective synthesis of the putative structure of 
yuremamine is reported, and the enantioselective synthesis of a densely functionalized 
dihydropyrroloindolone core that maps onto this structure has been demonstrated in 26% yield 
and 97% ee over 8 steps. The synthetic strategy is likely to be amenable to synthesis of other 
natural products containing a 2,3-dihydro-1H-pyrrolo[1,2-a]-indole core and highlights the 
utility of our hydroacylation protocol in the construction of complex molecular scaffolds.  
3.6 Experimental Details 
3.6.1 General experimental details 
All air-sensitive procedures were conducted under inert atmosphere in a nitrogen-filled dry 
box or by standard Schlenk techniques. All reactions were performed under an atmosphere of 
nitrogen unless otherwise stated. All glassware for moisture sensitive reactions was dried at 140 
°C in an oven. THF, DMF, CH2Cl2 and diethyl ether were degassed by purging with argon for 45 
minutes and dried with a solvent purification system by passing through a one-meter column of 
activated alumina. Anhydrous cyclopentyl methyl ether (CPME), acetonitrile, toluene and 1,4-
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dioxane were purchased from Sigma-Aldrich. Flash column chromatography was performed on 
SiliFlash P60 silica gel (40-63m, 60 Å) using hexanes/EtOAc or hexanes/ether mixtures. 
Reaction products were visualized on TLC by UV light or by staining with KMnO4 or 2,4-
dinitro-phenylhydrazine. 
 
HRMS (ESI) analysis was performed on an Agilent 6540 QTOF spectrometer at the Iowa 
State University Chemical Instrumentation Facility. Optical rotations were measured on an 
Atago AP-300 automatic polarimeter.  HPLC analyses were carried out on a Water Alliance 
HPLC system with an e2695 Separations Module and a 2489 (UV/Vis) dual wavelength detector.  
NMR spectra were acquired on Varian MR-400 and Bruker Avance III 600 spectrometers at the 
Iowa State University Chemical Instrumentation Facility. Chemical shifts are reported in ppm 
relative to a residual solvent peak (CDCl3 = 7.26 ppm for 
1
H and 77.16 ppm for 
13
C; C6D6 = 7.16 
for 
1
H and 128.06 for 
13
C). Coupling constants are reported in hertz.  
3.6.2 Materials 
N-Vinylindole-2-carboxaldehyde 9 was synthesized according to a literature procedure 
from ethyl indole-2-carboxylate.
11
 3′,4′,5′-Trimethoxyacetophenone 26 was synthesized from 
3′,4′,5′-trimethoxybenzoic acid according to a literature procedure.22 Activated manganese 
dioxide, Martin Sulfurane, iodobenzene, sodium tert-butoxide (NaOtBu), tert-butyldimethylsilyl 
chloride (TBSCl), benzenesulfonyl chloride, tetrabutylammonium hydrogensulfate (TBAHS), 
imidazole, ethyl chloroformate, diethyl carbonate, p-toluenesulfonyl hydrazide, oxalyl chloride, 
lithium aluminum hydride were purchased from Sigma-Aldrich and used without further 
purification. Phenylmagnesium bromide (3.0 M in diethyl ether), DIBAL-H (1.0 M in toluene), 
borane-THF complex (1.0 M in THF), n-butyllithium (2.5 M in hexane), sec-butyllithium (1.4 M 
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in cyclohexane), tert-butyllithium (1.7 M in pentane) were also purchased from Sigma-Aldrich 
and used without further purification. [Rh(COD)Cl]2, Pd2(dba)3, rac-BINAP, (R)-MeO-BIPHEP, 
silver tetrafluoroborate were purchased from Strem Chemicals and used without further 
purification. Ethyl indole-2-carboxylate, indole and cesium carbonate were purchased from AK 
Scientific and used without further purification. 
3.6.3 Synthesis of (R)-3-Phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (10)  
 
 
 
 
 
In a nitrogen-filled glovebox, N-vinylindole-2-carboxaldehyde 9 (500 mg, 2.02 mmol, 
1.00 equiv), [Rh(COD)Cl]2 (2.50 mg, 0.00500 mmol, 0.00250 equiv), (R)-MeO-BIPHEP (5.80 
mg, 0.0100 mmol, 0.00500 equiv), AgBF4 (1.90 mg, 0.0100 mmol, 0.00500 equiv) and 1,4-
dioxane (14.0 mL) were added to a 20 mL scintillation vial. The vial was sealed with a 
PTFE/silicone-lined septum cap and removed from the glovebox. The reaction mixture was 
stirred at 100 °C in an oil bath for 12 h. The vial was removed from the oil bath and allowed to 
cool to room temperature. The reaction mixture was filtered through a short plug of silica gel 
(eluting with 100 mL of 3:2 hexanes:EtOAc). The crude reaction mixture was concentrated 
under reduced pressure. The mixture was purified by flash column chromatography (90:10 
hexane:EtOAc) to give (R)-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one 10 as a light 
yellow solid in 83% yield (415 mg, 1.68 mmol). The enantiomeric excess was determined by 
HPLC analysis (220 nm, 25 °C) tR 17.7 min (major); tR 21.1 min (minor) [Chiracel AD-H (0.46 
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cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 97%. 
[α]D
24
 = +232.2° (c 0.51, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 3.07 (dd, J = 18.4, 4.0 Hz, 1H), 
3.68 (dd, J = 18.4, 8.0 Hz, 1H), 5.74 (dd, J = 8.0, 4.0 Hz, 1H), 6.93 – 6.95 (m, 1H), 7.11 – 7.21 
(m, 5H), 7.32 – 7.39 (m, 3H), 7.77 – 7.79 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 50.4, 57.3, 
99.3, 111.8, 121.7, 124.3, 125.4, 126.1, 128.6, 129.4, 132.6, 135.0, 136.3, 140.1, 192.2. HRMS 
(ESI): Calcd. for C17H14NO ([M+H]
+
): 248.1070, Found: 248.1069. 
3.6.4 Synthesis of (1S,3R)-1,3-Diphenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-ol (11)
  
 
 
 
 
 
A 3.0 M solution of phenylmagnesium bromide (0.670 mL, 2.00 mmol, 2.50 equiv) in 
diethyl ether was added to a solution of (R)-3-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one 
10 (200 mg, 0.808 mmol, 1.00 equiv) in THF (5.0 mL) under a nitrogen atmosphere. The 
reaction mixture was heated at 65 °C and stirred for 16 h. The mixture was cooled in an ice/water 
bath and then quenched with saturated aqueous NH4Cl (20 mL). The organic layer was separated 
and the aqueous phase was extracted with ether (3 × 30 mL). The organic layers were combined, 
dried over MgSO4, filtered, and concentrated under reduced pressure. The crude product was 
purified by flash column chromatography on silica gel (85:15 hexane:EtOAc) to give (1S,3R)-
1,3-diphenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-ol 11 as a yellow oil in 90% yield (237 mg, 
0.728 mmol) as a 6.1:1 diastereomeric ratio. The enantiomeric excess was determined by HPLC 
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analysis (220 nm, 25 °C) tR 13.6 min [(1R,3R)]; tR 16.2 min [(1S,3S)], tR 20.5 min [(1S,3R)]; tR 
36.3 min [(1R,3S)] [Chiracel AD-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) 
hexane/i-PrOH, 93:7, 1.0 mL/min] to be 96% for the (1R,3R)-diastereomer and 97% for the 
(1S,3R)-diastereomer. [α]D
24
 = +78.7° (c 0.25, CHCl3). 
1
H NMR (600 MHz, C6D6) δ 1.87 (s, 
1H), 2.72 (dd, J = 13.3, 4.2 Hz, 1H), 2.95 (dd, J = 13.3, 8.1 Hz, 1H), 5.02 (dd, J = 8.1, 4.2 Hz, 
1H), 6.27 (s, 1H), 6.88 – 6.96 (m, 3H), 7.02 – 7.03 (m, 3H), 7.06 (dd, J = 7.8, 7.8 Hz, 1H), 7.12 
(dd, J = 7.8, 7.8 Hz, 1H), 7.17 – 7.21 (m, 3H), 7.47 (d, J = 8.0 Hz, 2H), 7.72 (d, J = 8.0 Hz, 1H). 
13
C NMR (151 MHz, C6D6) δ 57.6, 59.7, 78.7, 93.85, 111.3, 120.45, 122.0, 122.1, 126.1, 
126.75, 127.7, 128.35, 128.5, 129.0, 132.85, 133.7, 141.3, 145.7, 148.8. HRMS (ESI): Calcd. 
for C23H20NO ([M+H]
+
): 326.1539, Found: 326.1546. 
3.6.5 Synthesis of (1S,2R,3S)-1,3-Diphenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-2-ol (13)  
 
 
 
Martin sulfurane
23
 (465 mg, 0.691 mmol, 1.50 equiv) was added to the solution of 
(1S,3R)-1,3-diphenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-ol 11 (150 mg, 0.461 mmol, 1.00 
equiv) in CH2Cl2 (5.0 mL) under a nitrogen atmosphere.  The reaction was stirred for 30 min at 
23 °C. The reaction was quenched with sat. aq NaHCO3 solution, extracted with EtOAc, and 
washed with 1 M NaOH (4x). The organic layer was dried over MgSO4, filtered, and 
concentrated under reduced pressure. The crude product was immediately purified by flash 
column chromatography using silica gel, pre-treated with 0.1% triethylamine, (95:5 
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hexane:EtOAc) to give (R)-1,3-diphenyl-3H-pyrrolo[1,2-a]indole, 12 as a bluish white solid (132 
mg, 0.429 mmol). 
After isolation, compound 12 (60.0 mg, 0.195 mmol) was immediately dissolved in 
anhydrous THF (2.0 mL), cooled to 0 °C under a nitrogen atmosphere and a 1.0 M solution of 
BH3
.
THF (3.50 mL, 3.51 mmol, 18.0 equiv) was added. The reaction mixture was stirred at room 
temperature overnight. The reaction mixture was then cooled to 0 °C and treated with 15% 
aqueous sodium hydroxide (0.25 mL) and 30% hydrogen peroxide (0.50 mL). This mixture was 
stirred at room temperature for 2 hours and extracted with EtOAc. The organic layer was washed 
with water and brine, dried over MgSO4, and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography on silica gel (80:20 hexane:EtOAc) to 
give (1S,2R,3S)-1,3-diphenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-2-ol 13 as a yellow solid in 
52% yield (35.6 mg, 0.109 mmol) over three steps as a 9:1 mixture of diastereomers. The 
enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 17.8 min 
[(1R,2S,3S)]; tR 23.0 min [(1S,2R,3R)]; tR 28.3 min [(1S,2R,3S)]; tR 38.0 min [(1R,2S,3R)] 
[Chiracel AD-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 
mL/min] to be 97% for the (1R,2S,3S)-diastereomer and 96% for the (1S,2R,3S)-diastereomer. 
[α]D
24
 = +107.6° (c 0.23, CHCl3). 
1
H NMR (600 MHz, C6D6) δ 1.37 (d, J = 6.1 Hz, 1H), 3.96 
(m, 1H), 4.18 (d, J = 8.1 Hz, 1H), 4.63 (d, J = 7.2 Hz, 1H), 6.26 (s, 1H), 6.72 (d, J = 8.2 Hz, 1H), 
6.98 (t, J = 7.6 Hz, 1H), 7.05 – 7.09 (m, 5H), 7.22 (t, J = 7.6 Hz, 3H), 7.40 (d, J = 7.6 Hz, 3H), 
7.68 (d, J = 7.9 Hz, 1H).
 13
C NMR (151 MHz, C6D6) δ 52.7, 68.1, 91.5, 95.7, 111.2, 120.1, 
121.2, 121.3, 127.5, 127.7, 128.35, 128.6, 129.96, 129.00, 129.2, 133.2, 138.5, 140.5, 143.2. 
HRMS (ESI): Calcd. for C23H20NO ([M+H]
+
): 326.1539, Found: 326.1535. 
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3.6.6 Synthesis of 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indole (17)  
 
 
 
 
To a stirred solution of indole 14 (11.0 g, 93.9 mmol, 1.00 equiv) in anhydrous diethyl 
ether (200 mL) at 0 °C, oxalyl chloride (9.50 mL, 113 mmol, 1.20 equiv) was added dropwise 
over 30 min. The reaction mixture was stirred at the same temperature for 2 h. The resulting 
yellow crystals of 3-indolylglyoxylyl chloride were filtered and washed with anhydrous diethyl 
ether.  
3-Indolylglyoxylyl chloride (19.0 g, 91.5 mmol, 1.00 equiv) was refluxed for 30 min in a 
mixture of ethanol (60 mL) and triethylamine (13.4 mL, 96.1 mmol, 1.05 equiv). The reaction 
mixture was cooled to 0 °C and the solid ethyl indolylglyoxylate 15 was isolated by filtration. 
The solid was washed with cold diethyl ether, dried under reduced pressure and used directly for 
the next step.  
A solution of ethyl indolylglyoxylate 15 (18.0 g, 82.9 mmol, 1.00 equiv) in THF (100 
mL) was added dropwise to a suspension of LiAlH4 (11.6 g, 290 mmol, 3.50 equiv) in THF (300 
mL) at 0 °C. The reaction mixture was refluxed for 4 h, cooled to 0 °C and quenched with a 
saturated aqueous solution of potassium sodium tartrate (400 mL). The resulting solution was 
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then filtered and washed with EtOAc (500 mL). The combined organic extracts were dried over 
MgSO4 and the solvent was evaporated under reduced pressure. The crude product of 16 was 
dried and used directly for the next step without further purification.  
To a cooled solution (0 °C) of tryptophol 16 (12.4 g, 76.7 mmol, 1.00 equiv) and 
imidazole (11.6 g, 169 mmol, 2.20 equiv) in anhydrous DMF (120 mL), TBS-Cl (13.1 g, 84.3 
mmol, 1.10 equiv) was added, and the reaction mixture was stirred for 16 h at room temperature. 
Ethyl acetate (250 mL) was then added and the organic phase was washed with brine (200 mL). 
The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The 
crude product was purified by flash column silica gel (98:2 hexane:EtOAc) to give 3-(2-((tert-
butyldimethylsilyl)oxy)ethyl)-1H-indole 17 as a yellow solid in 81% yield over four steps (21.0 
g, 76.2 mmol). 
1
H NMR (400 MHz, CDCl3) δ 0.05 (s, 6H), 0.93 (s, 9H), 3.02 (t, J = 7.4 Hz, 2H), 
3.91 (t, J = 7.4 Hz, 2H), 7.04 (s, 1H), 7.13 (ddd, J = 7.8, 7.4, 1.2 Hz, 1H), 7.20 (ddd, J = 8.1, 7.4, 
1.2 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.96 (s, 1H). 
13
C NMR (101 
MHz, CDCl3) δ -5.1, 18.5, 26.1, 29.1, 64.05, 111.2, 113.0, 118.95, 119.3, 121.9, 122.2, 127.7, 
136.2.  
3.6.7 Synthesis of 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-(phenylsulfonyl)-1H-indole 
(18)
18
 
 
 
 
To a stirred mixture of 17 (6.00 g, 21.8 mmol, 1.00 equiv) and tetrabutylammonium 
hydrogensulfate (1.10 g, 3.30 mmol, 0.150 equiv) in toluene (90 mL) at 0 °C was added aq. 
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NaOH (50 wt %, 90 mL) followed by benzenesulfonyl chloride (4.20 mL, 32.7 mmol, 1.50 
equiv). The resulting suspension was allowed to warm to room temperature and vigorously 
stirred at this temperature for 15 h. The reaction mixture was diluted with water (250 mL) and 
extracted with EtOAc (250 mL). The organic layer was washed with water (250 mL) and brine 
(250 mL), dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash column silica gel (99:1 hexane:EtOAc) to give 3-(2-((tert-
butyldimethylsilyl)oxy)ethyl)-1-(phenylsulfonyl)-1H-indole 18 as a white solid in 99% yield 
(9.00 g, 21.6 mmol). 
1
H NMR (400 MHz, CDCl3) δ -0.02 (s, 6H), 0.87 (s, 9H), 2.88 (t, J = 6.7 
Hz, 2H), 3.87 (t, J = 6.7 Hz, 2H), 7.22 – 7.25 (m, 1H), 7.29 – 7.33 (m, 1H), 7.40 – 7.44 (m, 3H), 
7.49 – 7.53 (m, 2H), 7.87 (d, J = 7.5 Hz, 2H), 7.99 (d, J = 8.3 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ -5.2, 18.4, 26.1, 28.7, 62.7, 113.8, 119.7, 120.45, 123.2, 123.6, 124.75, 126.85, 129.3, 
131.4, 133.8, 135.2, 138.5. HRMS (ESI): Calcd. for C22H29NO3SSiNa ([M+Na]
+
): 438.1530, 
Found: 438.1538. 
3.6.8 Synthesis of ethyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-(phenylsulfonyl)-1H-
indole-2-carboxylate (19)  
 
 
 
To a solution of lithium diisopropylamide (19.3 mmol, 1.00 equiv) prepared from 
diisopropylamine (2.80 mL, 20.2 mmol, 1.05 equiv) and n-butyllithium (13.5 mL, 1.43 M in 
hexane; 19.3 mmol, 1.00 equiv) in dry THF (50 mL) under argon at -78 °C was added dropwise 
via syringe over 5 min a solution of 18 (8.00 g, 19.3 mmol, 1.00 equiv) in dry THF (50 mL). The 
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mixture was stirred for 1 h at -78 °C and then allowed to warm slowly to 0 °C over 3 h. The 
resulting solution was cooled to -78 °C and treated with a solution of ethyl chloroformate (2.20 
mL, 23.1 mmol, 1.20 equiv) in THF (10 mL). The reaction mixture was stirred for 3 h at the 
same temperature and then warmed to room temperature overnight. The reaction mixture was 
quenched with a saturated aqueous NH4Cl solution (100 mL) at 0 °C and extracted with diethyl 
ether (2 x 250 mL). The combined organic extracts were washed with water (200 mL), brine 
(200 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography on silica gel (95:5 hexane:ether) to give 3-
(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-(phenylsulfonyl)-1H-indole-2-carboxylate 19 as a 
yellow oil in 90% yield (8.50 g, 17.4 mmol). 
1
H NMR (400 MHz, CDCl3) δ -0.10 (s, 6H), 0.79 
(s, 9H), 1.41 (t, J = 7.2 Hz, 3H), 3.00 (t, J = 6.9 Hz, 2H), 3.78 (t, J = 6.9 Hz, 2H), 4.45 (q, J = 7.2 
Hz, 2H), 7.22 – 7.28 (m, 1H), 7.35 – 7.43 (m, 3H), 7.46 – 7.58 (m, 2H), 7.89 (d, J = 7.4 Hz, 2H), 
8.02 (d, J = 8.4 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ -5.4, 14.2, 18.4, 26.0, 28.4, 62.2, 63.1, 
115.5, 121.3, 124.1, 126.9, 127.0, 127.3, 128.9, 129.1, 130.5, 133.8, 137.1, 137.7, 162.4. HRMS 
(ESI): Calcd. for C25H34NO5SSi ([M+H]
+
): 488.1921, Found: 488.1925. 
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3.6.9 NaOtBu-Mediated synthesis of ethyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-
indole-2-carboxylate (20)  
 
 
 
 
To a solution of 19 (0.500 g, 1.03 mmol, 1.00 equiv) in 1,4-dioxane (7.5 mL), NaOtBu 
(0.148 g, 1.54 mmol, 1.50 equiv) was added under nitrogen atmosphere. The reaction mixture 
was stirred at 80 °C for 3 h, cooled to room temperature and filtered through a short plug of 
celite (eluting with 150 mL EtOAc). The crude reaction mixture was concentrated under reduced 
pressure. The crude reaction product obtained was a mixture of compounds 20, 21 and 22. The 
crude mixture was purified by flash column chromatography on silica gel (90:10 hexane:ether) to 
give ethyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indole-2-carboxylate 20 as a white solid 
in 20% yield (0.0710 g, 0.204 mmol). 
1
H NMR (400 MHz, CDCl3) δ -0.03 (s, 6H), 0.85 (s, 9H), 
1.43 (t, J = 7.1 Hz, 3H), 3.36 (t, J = 7.3 Hz, 2H), 3.86 (t, J = 7.3 Hz, 2H), 4.43 (q, J = 7.1 Hz, 
2H), 7.09 – 7.19 (m, 1H), 7.28 – 7.34 (m, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 
8.76 (s, 1H). 
13
C NMR (101 MHz, CDCl3) δ -5.2, 14.6, 18.5, 26.1, 28.8, 60.9, 63.8, 111.7, 120.2, 
121.3, 121.4, 123.8, 125.7, 128.7, 135.9, 162.4. HRMS (ESI): Calcd. for C21H34NO3Si 
([M+C2H5]
+
): 376.2302, Found: 376.2308. 
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3.6.10 Synthesis of ethyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indole-2-carboxylate 
(20)  
 
 
 
 
Ethyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indole-2-carboxylate 19 (10.0 g, 20.5 
mmol, 1.00 equiv) was dissolved in a mixture of THF (150 mL) and EtOH (75 mL) at room 
temperature. Cesium carbonate (20.4 g, 61.5 mmol, 3.00 equiv) was added to the clear solution. 
The resulting mixture was stirred at reflux for 16 h, cooled and concentrated under reduced 
pressure. The mixture was treated with water (200 mL) and extracted with diethyl ether (3 × 200 
mL). The organic extracts were combined, dried over MgSO4, filtered, and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography on silica gel 
(90:10 hexane:ether) to give ethyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indole-2-
carboxylate 20 as a white solid in 95% yield (6.80 g, 19.6 mmol). 
1
H NMR and 
13
C NMR spectra 
of the isolated product comply with the characterization data of 20 as reported above.  HRMS 
(ESI): Calcd. for C21H34NO3Si ([M+C2H5]
+
): 376.2302, Found: 376.2311. 
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3.6.11 Synthesis of (E)-4-methyl-N'-(1-(3,4,5-
trimethoxyphenyl)ethylidene)benzenesulfonohydrazide (6)  
 
 
 
 
 
1-(3,4,5-Trimethoxyphenyl)ethanone 26 (10.0 g, 47.6 mmol, 1.00 equiv), p-
toluenesulfonyl hydrazide (9.10 g, 47.6 mmol, 1.00 equiv) and dry methanol (120 mL) were 
charged in a round-bottom flask equipped with a reflux condenser. The reaction mixture was 
heated to 60 °C and stirred for 1 h. The mixture was cooled to 0 °C, and the product was 
collected by filtration on a Buchner funnel, washed with diethyl ether, and then dried under 
reduced pressure to afford the pure product (E)-4-methyl-N-(1-(3,4,5-
trimethoxyphenyl)ethylidene)benzenesulfonohydrazide 6 as a light yellow solid in 61% yield 
(11.0 g, 29.1 mmol). 
1
H NMR (400 MHz, CDCl3) δ 2.14 (s, 3H), 2.41 (s, 3H), 3.85 (s, 3H), 3.86 
(s, 6H), 6.86 (s, 2H), 7.31 (d, J = 8.2 Hz, 2H) 7.92 (d, J = 8.2 Hz, 2H), 8.35 (s, 1H). 
13
C NMR 
(101 MHz, CDCl3) δ 13.8, 21.6, 56.1, 60.9, 103.8, 128.3, 129.5, 132.9, 135.4, 139.5, 144.3, 
152.7, 152.9. 
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3.6.12 Synthesis of ethyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-(1-(3,4,5-
trimethoxyphenyl)vinyl)-1H-indole-2-carboxylate (27)  
 
 
 
 
A 50 mL pressure reaction tube was charged with indole 20 (0.200 g, 0.575 mmol, 1.00 
equiv), N-tosylhydrazone 6 (0.327 g, 0.863 mmol, 1.50 equiv), iodobenzene (0.100 mL, 0.860 
mmol, 1.50 equiv), Pd2(dba)3 (0.0527 g, 0.0575 mmol, 0.100 equiv), NaOtBu (0.155 g, 1.61 
mmol, 2.80 equiv) and CPME (25 mL). The flask was immersed in a preheated oil bath and 
stirred at 120 °C for 24 h. The crude reaction mixture was allowed to cool to room temperature, 
EtOAc was added and stirred for 10 min. The reaction mixture was filtered through celite 
(eluting with 50 mL EtOAc) and the solvent was evaporated under reduced pressure. The crude 
product was purified by flash column chromatography on silica gel (80:20 hexane:ether) to give 
ethyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-(1-(3,4,5-trimethoxyphenyl)vinyl)-1H-indole-2-
carboxylate 27 as a colorless oil in 40% yield (0.125 g, 0.232 mmol). 
1
H NMR (400 MHz, 
CDCl3) δ -0.02 (s, 6H), 0.86 (s, 9H), 1.20 (t, J = 7.1 Hz, 3H), 3.35 (t, J = 7.3 Hz, 2H), 3.82 (s, 
3H), 3.70 (s, 6H), 3.88 (t, J = 7.3 Hz, 2H), 4.19 (q, J = 7.1 Hz, 2H), 5.32 (s, 1H), 5.90 (s, 1H), 
6.33 (s, 2H), 7.19 (ddd, J = 8.0, 6.6, 1.3 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.34 (d, J = 8.0 Hz, 1H), 
7.77 (d, J = 8.0 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) δ -5.2, 14.3, 18.5, 26.1, 29.1, 56.2, 60.7, 
61.0, 64.0, 103.1, 111.1, 111.6, 120.9, 121.2, 122.8, 125.8, 126.8, 127.7, 133.6, 138.8, 139.3, 
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144.3, 153.3, 161.8. HRMS (ESI): Calcd. for C30H42NO6Si ([M+H]
+
): 540.2776, Found: 
540.2772. 
3.6.13 Synthesis of 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-(1-(3,4,5-
trimethoxyphenyl)vinyl)-1H-indole-2-carboxaldehyde (28) 
 
 
 
 
A 1.0 M solution of DIBAL-H in toluene (0.830 mL, 0.840 mmol, 3.50 equiv) was added 
to a solution of 27 (125 mg, 0.239 mmol, 1.00 equiv) in anhydrous dichloromethane (1.0 mL) at 
–78 °C under a nitrogen atmosphere. The resulting solution was stirred for 1 h at the same 
temperature. The mixture was then quenched with saturated aqueous NH4Cl (10 mL). The 
organic layer was separated and the aqueous phase was extracted with diethyl ether (3 × 10 mL). 
The organic layers were combined, dried over MgSO4, filtered, and concentrated under reduced 
pressure. The crude product was directly taken to the next step without further purification. 
Activated manganese dioxide (311 mg, 3.60 mmol, 15.0 equiv) was added to an 
acetonitrile (1.0 mL) solution of S1 (115 mg, 0.239 mmol, 1.00 equiv) in a round-bottom flask. 
The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 24 h. The 
reaction mixture was filtered through celite, washed with a 1:1 mixture of hexane:EtOAc, and 
the filtrate was concentrated under reduced pressure. The crude product was purified by flash 
column silica gel chromatography (80:20 hexane:ether) to give 3-(2-((tert-
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butyldimethylsilyl)oxy)ethyl)-1-(1-(3,4,5-trimethoxyphenyl)vinyl)-1H-indole-2-carboxaldehyde 
28 as colorless oil in 84% yield (96.0 mg, 0.200 mmol) over two steps. 
1
H NMR (400 MHz, 
C6D6) δ -0.03 (s, 6H), 0.91 (s, 9H), 3.20 (s, 6H), 3.34 (t, J = 6.5 Hz, 2H), 3.76 (s, 3H), 3.89 (t, J 
= 6.5 Hz, 2H), 5.07 (s, 1H), 5.63 (s, 1H), 6.41 (s, 2H), 7.09 (ddd, J = 8.0, 7.0, 0.9 Hz, 1H), 7.20 
(ddd, J = 8.4, 7.0, 1.1 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.70 (dt, J = 8.1, 0.9 Hz, 1H), 10.12 (s, 
1H). 
13
C NMR (101 MHz, C6D6) δ -5.3, 18.5, 26.1, 28.25, 30.5, 55.75, 60.5, 63.9, 104.0, 111.9, 
112.7, 121.5, 122.0, 125.9, 126.0, 127.4, 133.3, 133.4, 140.0, 140.7, 143.4, 154.4, 181.3. HRMS 
(ESI): Calcd. for C28H38NO5Si ([M+H]
+
): 496.2514, Found: 496.2516. 
3.6.14 Synthesis of (R)-9-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(3,4,5-trimethoxyphenyl)-
2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (29)  
 
 
 
In a nitrogen-filled glovebox, 28 (20.0 mg, 0.0400 mmol, 1.00 equiv), [Rh(COD)Cl]2 
(0.500 mg, 0.00100 mmol, 0.0250 equiv), (R)-MeO-BIPHEP (1.20 mg, 0.00200 mmol, 0.0500 
equiv), AgBF4 (0.400 mg, 0.00200 mmol, 0.0500 equiv) and THF (0.50 mL) were added to a 1-
dram vial. The vial was sealed with a PTFE/silicone-lined septum cap and removed from the 
glovebox. The reaction mixture was stirred at 60 °C in an oil bath for 12 h. The vial was 
removed from the oil bath and allowed to cool to room temperature. The reaction mixture was 
filtered through a short plug of silica gel (eluting with 20 mL of 3:2 hexanes:EtOAc). The crude 
reaction mixture was concentrated under reduced pressure. The crude reaction mixture was 
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purified by flash column silica gel chromatography (80:20 hexanes:ether) to give (R)-9-(2-((tert-
butyldimethylsilyl)oxy)ethyl)-3-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-
one 29 as a white solid in 90% yield (18.0 mg, 0.0360 mmol). The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 14.3 min (minor); tR 17.3 min (major) 
[Chiracel AD-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 
mL/min] to be 97%. [α]D
25
 = -76.9° (c 0.52, CHCl3). 
1
H NMR (400 MHz, C6D6) δ 0.070 (s, 3H), 
0.077 (s, 3H), 0.97 (s, 9H), 2.79 (dd, J = 18.2, 4.4 Hz, 1H), 3.09 (dd, J = 18.2, 8.0 Hz, 1H), 3.20 
(s, 6H), 3.55 (t, J = 7.0 Hz, 2H), 3.78 (s, 3H), 4.18 (t, J = 7.0 Hz, 2H), 4.76 (dd, J = 8.0, 4.4 Hz, 
1H), 6.14 (s, 2H), 6.95 (dd, J = 6.4, 2.6 Hz, 1H), 7.08 – 7.03 (m, 2H), 7.78 (dd, J = 6.1, 2.6 Hz, 
1H). 
13
C NMR (101 MHz, C6D6) δ -5.1, 18.5, 26.2, 28.5, 30.5, 50.8, 55.8, 57.2, 60.5, 64.15, 
103.5, 110.4, 112.0, 113.95, 121.2, 123.2, 125.5, 125.9, 128.1, 133.3, 134.0, 135.2, 136.0, 139.3, 
154.8, 191.2. HRMS (ESI): Calcd. for C28H38NO5Si ([M+H]
+
): 496.2514, Found: 496.2517. 
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CHAPTER 4 
COUPLING CATALYTIC ALKENE HYDROACYLATION AND -ARYLATION: 
ENANTIOSELECTIVE SYNTHESIS OF HETEROCYCLIC KETONES WITH -CHIRAL 
QUATERNARY STEREOCENTERS 
 
Modified from a paper published in ACS Catalysis
1
 
 
Avipsa Ghosh, James A. Walker Jr., Arkady Ellern, and Levi M. Stanley* 
4.1 Abstract 
We report a catalytic strategy that combines alkene hydroacylation and enantioselective -
(hetero)arylation reactions to form a wide variety of nitrogen-containing heterocyclic ketones bearing -
chiral quaternary stereogenic centers. Exo-selective, intramolecular Ni-catalyzed hydroacylations of N-
homoallylindole- and N-homoallylpyrrole-2-carboxaldehydes form -substituted six-membered 
heterocyclic ketones in up to 95% yield, while N-heterocyclic carbene (NHC)-catalyzed hydroacylations 
of N-allylindole- and N-allylpyrrole-2-carboxaldehydes form -substituted five-membered heterocyclic 
ketones in up to 99% yield. The racemic five- and six-membered products of Ni- and NHC-catalyzed 
hydroacylation reactions are readily transformed into heterocyclic ketones containing an -chiral 
quaternary stereogenic center by enantioselective Ni-catalyzed -arylation and -heteroarylation 
reactions.  The chiral, non-racemic products of sequential alkene hydroacylation and -(hetero)arylation 
reactions are formed in moderate-to-high yields (44-99%) with excellent enantioselectivities (typically 
>95% ee). The identity of the precatalyst for Ni-catalyzed -(hetero)arylation is dictated by the identity 
of the –substituted heterocyclic ketone starting material. -(Hetero)arylations of six-membered 
heterocyclic ketones occur at 65-85 °C in the presence of a catalyst generated in situ from Ni(COD)2 
and (R)-BINAP or (R)-DIFLUORPHOS. -(Hetero)arylation of five-membered heterocyclic ketones 
must be conducted at room temperature in the presence of an [((R)-BINAP)Ni(2-NC-Ph)] precatalyst 
or a catalyst generated in situ from Ni(COD)2, (R)-DIFLUORPHOS and benzonitrile. 
                                                          
1 Ghosh, A.; Walker Jr., J. A.; Ellern, A.; Stanley, L. M. ACS Catal. 2016, 6, 2673-2680. 
124 
 
 
 
4.2 Introduction 
Nitrogen-containing heterocycles possessing quaternary stereogenic centers are common 
structural motifs present in biologically active natural products and small molecules.
1
 Despite many 
advances over the past decades, enantioselective synthesis of quaternary stereogenic centers remains a 
significant synthetic challenge.
2
 The composition of current pharmaceutical agents provides a snapshot 
into this challenge. In 2011, 12% of the top 200 prescription drugs sold in United States contained 
quaternary stereogenic centers.
2a, 3
 However, the majority of these compounds are synthesized from 
naturally occurring compounds (steroids, opioids, taxane and diterpenoids) with the natural product 
precursor providing the quaternary stereogenic centers.
2a, 4
 Thus, approaches to molecular scaffolds, 
particularly heterocyclic scaffolds, containing quaternary stereogenic centers offer the potential to create 
and provide access to new classes of biologically active compounds. 
Extensive development over the past decade has rendered palladium- and nickel-catalyzed -
arylation of carbonyl enolates a practical strategy to form benzylic quaternary stereogenic centers alpha 
to a carbonyl group.
5
 However, the majority of the metal-catalyzed, enantioselective -arylation studies 
focus on reactions of ketones with carbocyclic backbones
6
 or lactones.
6c, 7
NN
CHO
n
Ni(0)
n = 1, 2
O
N
O
Arn
ArXNi(0)
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N
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R
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Enantioselective -arylation of nitrogen-containing heterocycles to form benzylic 
quaternary stereogenic centers has been studied to a much lesser extent and is largely limited to 
reactions of oxindoles.
8
 We focused on our studies developing strategies to synthesize indole and 
pyrrole derivatives containing benzylic quaternary stereogenic centers due to the presence of this 
structural feature in the indole alkaloid haplophytine
9
 and polycyclic indoles with 
antiandrogenic,
10
 antiarrhythmic,
11
 and antihypertensive
12
 activities (Figure 4.1). 
 
Figure 4.1 Biologically active indoles derivatives containing benzylic quaternary stereogenic 
centers. 
Glorius et al. recently reported a direct method to form cyclic ketones containing -
quaternary stereogenic centers by chiral N-heterocyclic carbene (NHC)-catalyzed intramolecular 
hydroacylation.
13
 They report the formation of chiral, non-racemic five- and six-membered 
carbocyclic ketones and two five-membered nitrogen-containing heterocyclic ketones. However, 
a general strategy that encompasses formation of both five- and six-membered nitrogen-
containing heterocyclic ketones with -chiral quaternary stereogenic centers has not been 
reported. We sought to develop a versatile strategy combining intramolecular alkene 
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hydroacylation with enantioselective -arylation to provide access to a wide variety of indole 
and pyrrole derivatives containing benzylic quaternary stereogenic centers. 
Intramolecular hydroacylation of alkenes has emerged as a promising, atom-economic 
transformation to generate a wide variety of carbocyclic and heterocyclic ketones.
14
 These 
transformations generally occur in the presence of transition-metal or NHC catalysts, and the 
selection of the specific catalyst type determines the regiochemical outcome of the reaction.
 
In 
2014, we reported enantioselective Rh-catalyzed hydroacylations of N-vinylindole-2-
carboxaldehydes to form -substituted dihydropyrroloindolones15 and N-allylindole- and N-
allylpyrrole-2-carboxaldehydes to form -substituted dihydropyridoindolones and 
dihydroindolizinones that occur exclusively with endo selectivity.
16
  We envisioned forming -
substituted dihydropyrroloindolones and dihydropyridoindolones by exo-selective Ni- or NHC-
catalyzed intramolecular hydroacylations of N-allyl- and N-homoallylindole-2-carboxaldehydes 
due to the complementary regioselectivity often observed with these types of catalysts.
17
 We 
further hypothesized that these five- and six-membered -substituted ketones could serve as 
substrates for enantioselective -arylation reactions to access heterocyclic ketones bearing -
chiral quaternary stereocenters. Due to wide range of carbonyl functionalization reactions, this 
sequence of alkene hydroacylation and -arylation reactions is poised to serve as a strategic 
approach to the synthesis of a range of complex chiral heterocycles possessing benzylic 
quaternary stereocenters.
18
 
 Herein, we report a catalytic strategy that combines alkene hydroacylation and -
arylation to generate five- and six-membered nitrogen-containing heterocyclic ketones bearing 
-chiral quaternary stereocenters (Figure 4.2). Our studies reveal that exo-selective Ni-catalyzed 
hydroacylations of N-homoallylindole-2-carboxaldehydes form six-membered heterocyclic 
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ketones in higher yields and require lower catalyst loading compared to Ni-catalyzed 
hydroacylation of N-allylindole-2-carboxaldehydes to form five-membered heterocyclic ketones. 
This reactivity is complementary to NHC-catalyzed hydroacylations which are known to form 
five-membered nitrogen-containing, -substituted heterocyclic ketones in excellent yields.13, 17m 
Our studies reveal that nitrogen-containing five- and six-membered heterocyclic ketones exhibit 
significantly different reactivity towards Ni-catalyzed, enantioselective -arylations compared to 
previously studied carbocyclic ketones.
6a
 Finally, we have successfully demonstrated a 
sequential “one-pot” synthesis of a dihydropyridoindolone by exo-selective alkene 
hydroacylation and enantioselective -arylation reactions using two distinct nickel catalysts.  
 
Figure 4.2 Coupling alkene hydroacylation and ketone -arylation reactions. 
4.3 Results and Discussion 
4.3.1 Exo-Selective Intramolecular Hydroacylation  
Initial studies to develop intramolecular, exo-selective Ni-catalyzed hydroacylations of N-
allylindole-2-carboxaldehydes were guided by hydroacylations of 2-allylbenzaldehyde catalyzed 
by Ni(0) complexes of NHC ligands.
17a
 To test whether hydroacylation of N-allylindole-2-
carboxaldehyde 1a could occur under similar reaction conditions to those reported for 
carbocyclic ketone formation, we studied the reaction of 1a in the presence of catalysts generated 
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in situ from Ni(COD)2 and various NHC ligands at 130 °C (Table 4.1, entries 1-4). We found 
that exo-selective hydroacylation of 1a occurs to form dihydropyrroloindolone 2a in low yields 
(8-34%), with the reaction catalyzed by a Ni complex containing the N-adamantylcarbene (IAd) 
ligand L4 forming the desired product in the highest yield. The yield of the model 
hydroacylation of 1a improved to 60% when the reaction was conducted at 165 °C and further to 
72% when the reaction occurred in the presence of 15 mol % of the catalyst (Table 4.1, entries 5 
and 6). In contrast, an NHC catalyst, generated in situ from 10 mol % 3 and 20 mol % 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), led to the formation of 2a in 97% yield when the 
reaction was conducted at 60 °C (Table 4.1, entry 7).
19
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Table 4.1 Identification of Catalysts for exo-Selective Hydroacylation of N-allyl- and N-
Homoallylindole-2-carboxaldehyde
a,b
 
 
entry 1 precatalyst mol % ligand temp (°C) yield (%)
c 
1 1a Ni(COD)2 10 L1 130 16 
2 1a Ni(COD)2 10 L2 130 8 
3 1a Ni(COD)2 10 L3 130 9 
4 1a Ni(COD)2 10 L4 130 34 (30) 
5 1a Ni(COD)2 10 L4 165 60 (60) 
6 1a Ni(COD)2 15 L4 165 72 (70) 
7 1a 3 10 -- 60 99 (97) 
8 1b Ni(COD)2 5 L4 165 99 (95) 
9 1b 3 10 -- 60 30 
a
 Reaction conditions for Ni-catalyzed hydroacylation: 1a-b (0.200 mmol), Ni(COD)2 (0.010-
0.030 mmol), ligand L1-L4 (0.012-0.036 mmol), and mesitylene (1.0 mL). 
b
 Reaction conditions 
for NHC-catalyzed hydroacylation: 1a-b (0.200 mmol), 3 (0.020 mmol), DBU (0.040 mmol), 
and 1,4-dioxane (1.0 mL). 
c
 Yield of 2a or 2b determined
 
by 
1
H NMR spectroscopy using 
dibromomethane as the internal standard; isolated yield of 2a or 2b is shown in parentheses. 
L1  (R = tBu; ItBu)
L2  (R = 2,4,6-(Me)3C6H2; IMes)
L3  (R = 2,6-(iPr)2C6H3; IPr)
L4  (R = Ad; IAd)
N N
O
H
O
Me
Ni(COD)2 (x mol %)
mesitylene, 165 °C, 16 h
ligand L1-L4 (1.2x mol %)
1a  (n = 1)
1b  (n = 2)
or
3 (x mol %)
DBU (2x mol %)
1,4-dioxane, 60 °C, 12 h
2a (n = 1)
2b (n = 2)
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In general, formation of six-membered rings by transition metal-catalyzed intramolecular 
hydroacylation reactions is challenging compared to the formation of five-membered rings.
20
 
Surprisingly, the Ni-catalyzed hydroacylation of N-homoallylindole-2-carboxaldehyde 1b forms 
the six-membered heterocyclic ketone 2b in 95% yield with only 5 mol % Ni catalyst (Table 1, 
entry 8). However, a catalyst generated in situ from 10 mol % 3 and 20 mol % DBU at 60 °C 
forms 2b in only 30% yield (Table 4.1, entry 9). 
With a practical Ni catalyst system in hand, we evaluated the hydroacylations of various 
N-homoallylindole-2-carboxaldehydes containing substitution at the 4-, 5-, 6-positions on the 
indole backbone (Scheme 4.1). A variety of N-homoallylindole-2-carboxaldehydes containing 
electron-donating and electron-withdrawing substituents are excellent substrates for the Ni-
catalyzed exo-selective intramolecular hydroacylations. Hydroacylations of electron-rich 4-MeO, 
5-Me, 5-MeO, 6-MeO-substituted N-homoallylindole-2-carboxaldehydes occur with 5 mol % Ni 
catalyst and form dihydropyridoindolones 2c-2e and 2g in 88-92% yield. Hydroacylations of 
electron-deficient 5-F, 6-CF3-substituted N-homoallylindole-2-carboxaldehydes also form 
dihydropyridoindolones 2f and 2h in 96% and 75% yields. Intramolecular hydroacylation of N-
homoallylpyrrole-2-carboxaldehyde 1i forms product 2i in 80% yield with 15 mol % Ni catalyst. 
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Scheme 4.1 Intramolecular exo-Selective Ni-Catalyzed Hydroacylation
a
  
 
a
 Reaction conditions: 1a-l (0.100 mmol), Ni(COD)2 (0.005-0.015 mmol), ligand L4 (0.006-
0.018 mmol) and mesitylene (0.5 mL); yields of 2 are isolated yields after column 
chromatography. 
b
 Reaction run in the presence of 15 mol % Ni(COD)2 and 18 mol % ligand L4. 
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Although substitution at the 4-, 5-, and 6-positions of the indole core is well-tolerated, 
substitution on the double bond of the N-homoallyl moiety had a detrimental effect on Ni-
catalyzed intramolecular hydroacylation. The hydroacylation of 1-(3-methylbut-3-en-1-yl)-1H-
indole-2-carboxaldehyde 1j requires 15 mol % Ni catalyst to form 2j in 75% yield, while the 
hydroacylation of 1-(hex-3-en-1-yl)-1H-indole-2-carboxaldehyde 1k affords 2k in only 15% 
yield. The hydroacylation of 1-(3-methylbut-3-en-1-yl)-1H-pyrrole-2-carboxaldehyde 1l 
generated 2l in 20% yield. The formation of six-membered ketones by an exo-selective pathway 
was exclusive; formation of seven-membered ketone products by an endo-selective pathway was 
not observed. 
The results of NHC-catalyzed intramolecular hydroacylations of N-allylindole-2-
carboxaldehyde and N-allylpyrrole-2-carboxaldehydes containing a range of 1-substituted allyl 
units are shown in Scheme 4.2. Hydroacylations of 1m-p containing phenyl, 4-methoxyphenyl 
and 4-chlorophenyl substituents at the terminal carbon of the allyl unit forms the hydroacylation 
products 2m-p in excellent yields (80-99%). 
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Scheme 4.2 Intramolecular exo-Selective NHC-Catalyzed Hydroacylation
a
  
 
a
 Reaction conditions: 1a, 1m-p (0.200 mmol), 3 (0.020 mmol), DBU (0.040 mmol), and 1,4-
dioxane (1.0 mL); Yields of 2 are isolated yields after column chromatography; 
b
 24 h reaction 
time. 
4.3.2 -Arylation of Nitrogen-containing Six-membered Heterocyclic Ketones 
Initial studies to develop catalytic, enantioselective -arylations of -methyl 
dihydropyridoindolones were guided by -arylations of 2-methyl-1-indanones and 2-methyl-1-
tetralones catalyzed by a Ni(0) complex of BINAP.
6a
  To test the feasibility of nitrogen-
containing heterocyclic ketones as substrates for -arylations, we evaluated the reaction of 8-
methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one 2b with 1-chloro-4-(trifluoromethyl)benzene 
4a catalyzed by complexes prepared in situ from Ni(COD)2 and a selection of aromatic 
bisphosphine ligands L5-L8 containing axial chiral backbones (Table 4.2, entries 1-3, entry 6). 
At 80 °C, complexes generated in situ from Ni(COD)2 and ligands L5-L8 catalyzed the 
formation of -arylated product 5a in yields ranging from 45-77% with 95-97% ee. However, 
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we found that subtle changes in temperature had a marked influence on the yield of 5a.  For 
example, the yield of 5a increased from 60% to 72% to 99% as the temperature of the reaction 
decreased from 80 °C to 70 °C to 65 °C (compare entries 6-8) when the -arylation of 2b was 
run in the presence of Ni(COD)2 and L8. Lower reaction temperatures likely minimize catalyst 
inactivation through thermal decomposition of the Ni(II) complex formed after oxidative 
addition of aryl chloride 4a which leads to the pronounced influence of temperature on the yield 
of 5a (Figure 4.3).
6a, 21
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Table 4.2 Identification of Catalyst for Ni-catalyzed -Arylation of 8-Methyl-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one
a
 
 
entry ligand temp (°C) time (h) conv
b
 (%) yield
c
 (%) ee
d
 (%) 
1 L5 80 48 99 77 95 
2 L6 80 48 99 72 97 
3 L7 80 48 80 45 97 
4 L7 70 48 75 42 99 
5 L7 60 48 75 69 99 
6 L8 80 48 99 60 97 
7 L8 70 48 99 72 98 
8 L8 65 48 99 99 99 
9 L8 65 24 75 60 98 
10 L8 60 48 60 55 98 
11 L8 60 60 85 80 99 
a
 Reaction conditions: 2b (0.200 mmol), 4a (0.400 mmol), NaOtBu (0.400 mmol), Ni(COD)2 
(0.020 mmol), ligand L5-L8 (0.024 mmol), and toluene (1.0 mL). 
b
 Conversion of 2b was 
determined
 
by 
1
H NMR spectroscopy. 
c
 Isolated yield after column chromatography. 
d
 
Determined by chiral HPLC analysis. 
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Figure 4.3 Proposed Reaction Mechanism for Ni-catalyzed -Arylation of 8-Methyl-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one (2b) with Aryl Chloride 
 
Scheme 4.3 summarizes the results of -arylations of 2b with a range of aryl chlorides 
catalyzed by the complex generated in situ from Ni(COD)2 and (R)-BINAP. A variety of 
electron-rich, electron-neutral and electron-deficient aryl chlorides react to generate -arylated 
products with high yields (75-99%) and excellent enantioselectivities (97-99% ee). Reactions of 
aryl chlorides containing electron-withdrawing groups at the para-position and electron-donating 
groups at the meta-position form 5a-d in high yields when the reactions are performed at 65 °C. 
The reaction of 2b with methyl 4-chlorobenzoate 4c is notable as it generated tert-butyl ester 5c 
as the only -arylated product, presumably due to complete transesterification in the presence of 
NaOtBu. Reactions of electron-neutral aryl chlorides and aryl chlorides with electron-donating 
groups at the para-position and electron-withdrawing groups at the meta-position require a 
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reaction temperature of 70 °C to form products 5e-i and 5k in high yields. 2-Chloronaphthalene 
4j also reacted with 2b at 70 °C to generate 5j in 95% yield and 99% ee. Although the -
arylation of 2b tolerates a range of functional groups on the aryl chloride partners, ortho-
substituted aryl chlorides do not react under our standard reaction conditions.  The -arylation of 
dihydroindolizinone 2k with 1-chloro-3-methoxybenzene formed 5l in 70% yield and 91% ee. 
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Scheme 4.3 Ni-Catalyzed Enantioselective -Arylation of Dihydropyridoindolone and 
Dihydroindolizinone with Aryl Chlorides
a,b
 
 
a
 Reactions conditions: 2b or 2k (0.100 mmol), 4a-k (0.200 mmol), NaOtBu (0.200 mmol), 
Ni(COD)2 (0.010 mmol),  L8 (0.012 mmol), and toluene (0.5 mL); 
b
 Yields of 5 are isolated 
yields after column chromatography; enantiomeric excesses of 5 were determined by chiral 
HPLC analysis. 
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The absolute configuration of the quaternary stereocenter in 5d was unambiguously 
determined by X-ray crystallographic analysis to be (R). Thus, the catalyst generated from (R)-
BINAP leads to the formation of (R)-5d (Figure 4.4). 
 
Figure 4.4 Determination of absolute stereochemistry of 5d by X-ray crystallographic analysis 
Single crystal X-ray structure determination of 5d was performed by Dr. Arkady Ellern 
using Cu radiation to determine the absolute configuration of the molecule. The systematic 
absences in the diffraction data were consistent for the stated space group. The position of almost 
all non-hydrogen atoms were found by direct methods. The remaining atoms were located in an 
alternating series of least-squares cycles on difference Fourier maps. All non-hydrogen atoms 
were refined in full matrix anisotropic approximation. All hydrogen atoms were placed in the 
structure factor calculation at idealized positions and were allowed to ride on the neighboring 
atoms with relative isotropic displacement coefficients. Flack, Hooft, and Parsons parameters 
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were calculated with PLATON software. Flack, Hooft, and Parsons parameters of 0.12(11), 
0.08(9), and 0.03(10) in combination with the enantiomeric purity of 5d (99% ee by chiral HPLC 
analysis) are consistent with our assignment of the absolute configuration as (R). CCDC 1447403 
contains the supplementary crystallographic data for this paper. These data can be obtained free 
of charge from the Cambridge Crystallographic Data Centre via 
http://www.ccdc.cam.ac.uk/data_request/cif. 
4.3.3 α-Heteroarylation of Nitrogen-containing Six-membered Heterocyclic Ketones 
 Encouraged by the ability to form -arylated heterocyclic ketones with indole and 
pyrrole backbones in high yields and enantioselectivities, we evaluated the enantioselective Ni-
catalyzed -heteroarylation of 2b with 2-chloropyridine 6a. The catalyst generated in situ from 
Ni(COD)2 and (R)-BINAP L8 did not yield any -heteroarylated product with >95% recovery of 
2b after 48 h. However, the complex generated in situ from Ni(COD)2 and (R)-DIFLUORPHOS 
L7 at 80 °C catalyzed the formation of -heteroarylated product 7a in 72% isolated yield and 
99% ee (Scheme 4.4). 
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Scheme 4.4 Ni-Catalyzed Enantioselective -Heteroarylation of Dihydropyridoindolone with 
Heteroaryl Chlorides
a,b
 
 
a
 Reaction conditions: 2b (0.100 mmol), 6a-i (0.200 mmol), NaOtBu (0.200 mmol), Ni(COD)2 
(0.010 mmol), L7 (0.012 mmol), and toluene (0.5 mL); 
b
 Yields of 7 are  isolated yields after 
column chromatography; enantiomeric excesses of 7 were determined by chiral HPLC analysis; 
c
 
Reaction run at 80 °C. 
Scheme 4.4 summarizes the results of -heteroarylation reactions of 2b with a range of 2-
chloropyridines containing electron-donating and electron-withdrawing substituents at the 4-, 5- 
and 6-positions of the pyridine ring, as well as 5-chloro-2-(trifluoromethyl)pyridine and 3-
N
toluene, 85 °C, 48 h
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chlorothiophene. Ni-catalyzed -heteroarylation of 2b with 2-chloro-5-fluoropyridine forms the 
heteroarylated ketone 7b in 82% yield with 98% ee. -Heteroarylation of 2b with electron-
deficient heteroaryl chlorides, 6-chloronicotinonitrile 6c and 2-chloro-5-trifluoromethylpyridine 
6d, generated the heteroarylated products 7c and 7d in 93% and 55% yield, but the 
enantioselectivities were poor (29-65% ee). The decrease in enantioselectivity results from 
uncatalyzed nucleophilic aromatic substitution of these electron-deficient heteroaryl chlorides by 
the sodium enolate of 2b. Additions of 2b to 6c and 6d at 85 °C in the absence of catalyst formed 
the -arylated products 7c and 7d in 42% and 22% yields by 1H NMR analysis (Scheme 4.5).  
Scheme 4.5 Background reaction of 2b with electron-deficient heteroaryl chlorides 6c-d in 
presence of NaOtBu 
 
 
a
 Reaction conditions: 2b (0.100 mmol), 6c-d (0.200 mmol), NaOtBu (0.200 mmol) and toluene 
(0.5 mL); 
b
 Yields of 7 are determined by 
1
H NMR spectroscopy of crude reaction mixture using 
dibromomethane as internal standard. 
-Heteroarylation of 2b with electron-rich heteroaryl chlorides, 2-chloro-4-
methoxypyridine, 2-chloro-6-methylpyridine and 2-chloro-6-methoxypyridine, formed the -
heteroarylated ketones 7e-g in moderate-to-good yields (50-75%) with moderate to high 
enantioselectivities (75-95%). 5-Chloro-2-(trifluoromethyl)pyridine and 3-chlorothiophene 
proved to be excellent substrates for –heteroarylation of 2b.  Reactions of these heteroaryl 
chlorides formed 7h and 7i in high yields (80-92%) with excellent enantioselectivities (94-99%). 
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4.3.4 -Arylation of Nitrogen-containing Five-membered Heterocyclic Ketones 
The ability to form a range of dihydropyridoindolones with -chiral quaternary 
stereocenters in high yield with excellent stereocontrol led us to investigate Ni-catalyzed -
arylation reactions of five-membered heterocyclic ketones. Surprisingly, -arylation of 2a with 
chlorobenzene at 70 °C in the presence of a catalyst generated in situ from Ni(COD)2 and (R)-
BINAP L8  formed the -arylated product 9a in only 19% yield, while the analogous reaction 
with 1-chloro-3-methoxybenzene at 65 °C generated a 5% yield of the coupled product 9b 
(Equation 4.1). 
 
To understand the relative reactivity of the five-membered and six-membered 
heterocyclic ketones towards Ni-catalyzed –arylation reaction, we ran competition experiments 
between them with three different aryl chlorides (Scheme 4.6). In each case, formation of the 
dihydropyridoindolone product (5a, 5d, 5k) dominated over the formation of 
dihydropyrroloindolone product (9b, 9c, 9a). However, the ratio of the dihydropyridoindolone vs 
dihydropyrroloindolone product formed, varied significantly with the identity of the aryl chloride 
employed in the reaction. Ni-Catalyzed -arylation with 1-chloro-4-(trifluoromethyl)benzene 
resulted in 5.2:1 ratio of the dihydropyridoindolone vs dihydropyrroloindolone product, while 3-
methoxychlorobenzene formed the products in 3.9:1 ratio. The competition experiment with 
simple chlorobenzene resulted in the formation of 1.9:1 ratio of the six-membered vs five-
membered heterocycle. 
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Scheme 4.6 Competition experiments to demonstrate relative reactivities of 
dihydropyridoindolones vs dihydropyrroloindolones towards -arylation reactions 
 
 
 
2a & 2b (0.100 mmol), ArCl (0.200 mmol), NaOtBu (0.200 mmol), Ni(COD)2 (0.010 mmol), 
and ligand L8 (0.012 mmol) in toluene (0.5 mL); ratio determined
 
by 
1
H NMR spectroscopy of 
crude reaction mixture; 
a 
run at 70 °C 
The poor yields observed in -arylations of dihydropyrroloindolone 2a may result from 
decomposition of the [L8]Ni(Ar)(Cl) intermediate formed after oxidative addition becoming 
competitive with the productive reaction pathway at elevated temperatures. To test the 
plausibility of this hypothesis, we performed the -arylation of 2a in the presence of a single 
component [L8]Ni(2-NC-Ph) precatalyst (Equation 4.2) that is known to oxidatively add aryl 
halides at 25 °C and attenuate decomposition of the oxidative addition product [L8]Ni(Ar)(Cl).6a, 
21-22
  
The reactions of 2a with chlorobenzene and bromobenzene formed 9a in 38% and 47% 
yield, respectively, when the reactions were performed at 25 °C in the presence of 10 mol % 
[L8]Ni(2-NC-Ph) (Equation 4.3). -Arylations of dihydropyrroloindolone 2a occurred in the 
highest yields when performed at 25 °C in the presence of 15 mol % [L8]Ni(2-NC-Ph) (Scheme 
5). -Arylations of 2a with bromobenzene, 3-methoxybromobenzene and 4-
trifluoromethylbromobenzene formed 9a-9c in 44-78% yield and 99% ee. 
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Scheme 4.7 Ni-Catalyzed Enantioselective -Arylation of Dihydropyrroloindolone and 
Dihydropyrrolizinones with Aryl Bromides
a
 
 
a
 Reaction conditions: 2a, 2m-p (0.200 mmol), 8a-g (0.400 mmol), NaOtBu (0.400 mmol), and 
[L8]Ni(2-NC-Ph) (0.020-0.030 mmol), and toluene (1.0 mL); yields of 9 are isolated yields 
after column chromatography; enantiomeric excesses of 9 were determined by chiral HPLC 
analysis. 
b
 Reaction run in the presence of 15 mol % catalyst. 
c
 Reaction run at 10 °C. 
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The identification of a catalyst system enabling the synthesis of dihydropyrroloindolones 
with -chiral quaternary stereocenters by enantioselective -arylation led us to investigate the 
analogous -arylations of 2-methyl-2,3-dihydro-1H-pyrrolizin-1-one 2m (Scheme 4.7). Aryl 
bromides with electron-deficient groups at the meta and para positions (-F, -CF3) and an 
electron-donating group (-OMe) at the meta position reacted with 2m in the presence of 10 mol 
% [L8]Ni(2-NC-Ph) to form the -arylated ketones 9d-h in high yields (80-99%) with excellent 
enantioselectivities (98-99%). The -arylation of 2m with p-bromoanisole occurred with high 
enantioselectivity, but formed product 9i in 52% yield. 2-Bromonapthalene also reacted with 2m 
to form 9j in 96% yield and 99% ee. 
This methodology can also be applied to heterocyclic ketones containing -substitution 
beyond a methyl group. These reactions form -arylated products in high yield and high 
enantioselectivity. As shown in Scheme 5, dihydropyrrolizinones 2n-p with substituted and 
unsubstituted benzyl groups at the -position reacted with bromobenzene in the presence of 10 
mol % [L8]Ni(2-NC-Ph) to form -arylated ketones 9k-9m in 69-91% yield and 99% ee. The 
chemoselectivity of the -arylation is highlighted by the reaction of dihydropyrrolizinone 2p (R 
= 4-ClC6H4CH2). Dihydropyrrolizinone 2p reacted exclusively with bromobenzene to form -
arylated ketone 9m in high yield and ee. 
To test the relative reactivity of the five- and six-membered heterocyclic ketones towards 
-arylation reactions in the presence of benzonitrile ligated Ni(0)-L8 complex at ambient 
temperature, we conducted competition reactions between them with three different aryl 
bromides (Scheme 4.8). Again, in each case, formation of the dihydropyridoindolone product 
(5a, 5d, 5k) slightly dominated over the formation of dihydropyrroloindolone product (9b, 9c, 
9a). However, the identity of the aryl bromide employed in the reaction did not have as 
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significant impact on the product ratios as that in scheme 4.6. -Arylation with 1-bromo-4-
(trifluoromethyl)benzene resulted in 1.2:1 ratio of the dihydropyridoindolone vs 
dihydropyrroloindolone product, while 3-methoxybromobenzene formed the products in 1.5:1 
ratio. The competition experiment with simple bromobenzene resulted in the formation of 1.4 : 1 
ratio of the six-membered vs five-membered heterocycle. 
Scheme 4.8 Competition Experiments to Demonstrate Relative Reactivities of 
Dihydropyridoindolones vs Dihydropyrroloindolones Towards -Arylation Reactions 
 
 
2a & 2b (0.100 mmol), ArBr (0.200 mmol), NaOtBu (0.200 mmol) and [L8]Ni(2-NC-Ph) 
(0.015 mmol) in toluene (0.5 mL); ratio determined
 
by 
1
H NMR spectroscopy of crude reaction 
mixture 
4.3.5 -Heteroarylation of Nitrogen-containing Five-membered Heterocyclic Ketones 
After successfully demonstrating -arylations of dihydropyrrolizinones with aryl 
bromides in the presence of benzonitrile ligated Ni(0)-L8 complex, we sought to identify a 
benzonitrile-ligated Ni(0)-L7 complex to enable the formation of -heteroarylated derivatives. 
We conducted -heteroarylations of dihydropyrrolizinone 2m with various heteroaryl bromides 
in the presence of a catalyst generated in situ from 10 mol % Ni(COD)2, 12 mol % ligand L7, 
and 2 equivalents of benzonitrile (Equation 4.4, Scheme 4.9). Dihydropyrrolizinone 2m reacts 
with 2-bromopyridine to form the -heteroarylated product 11a in 99% isolated yield and 97% 
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ee. Reactions of 5- and 6-substituted-2-bromopyridines with 2m generated -heteroarylated 
ketones 11b-d in 48-71% yield with 95% ee.  However, the -heteroarylation of 2m with 6-
bromonicotinonitrile was unproductive and the corresponding ketone 11e was not observed 
under our reaction conditions. The reaction of 5-bromo-2-(trifluoromethyl)pyridine with 2m 
forms 11f in low yield, but the enantioselectivity of the -heteroarylation remains high (92% ee). 
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Scheme 4.9 Ni-Catalyzed Enantioselective -Heteroarylation of Dihydropyrrolizinone with 
Heteroaryl Bromides
a
 
 
 
 
a 
Reaction conditions: 2m (0.200 mmol), 10a-f (0.400 mmol), NaOtBu (0.400 mmol), Ni(COD)2 
(0.020 mmol), ligand L7 (0.024 mmol), benzonitrile (0.400 mmol) and toluene (1.0 mL). Yields 
of 11 are  isolated yields after column chromatography. Enantiomeric excesses of 11 were 
determined by chiral HPLC analysis. 
4.3.6 One-pot Sequential Alkene Hydroacylation and -Arylation Processes 
One-pot multicatalytic transformations are attractive processes for sustainable chemical 
synthesis because these processes improve efficiency and eliminate waste and labor associated 
with isolation and purification of intermediate products. However, these processes are often 
challenging to achieve due to the incompatibility of catalysts, reagents, and solvents employed in 
each step.
23
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Table 4.3 Identification of Reaction Conditions for One-pot Synthesis of (R)-8-(3-
Methoxyphenyl)-8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (5d) via Sequential 
Hydroacylation/-Arylation 
 
 
 
 Hydroacylation
d
 -Arylation 
Entry Mesitylene 
(mL) 
Conv
a
 
of 1b 
(%) 
Catalyst 
loading 
(x mol %) 
Toluene 
(mL) 
Final 
conc  
(M) 
Conv
a
 
of 2b 
(%) 
Yield
b
 
5d 
(%) 
ee
c 
(%) 
1
e
 0.50 99 10 0.50 0.10 20 15 ND 
2
f
 0.50 99 10 0.50 0.10 22 19 ND 
3 0.50 99 10 0.50 0.10 43 40 (40) 98 
4 0.50 99 10 0 0.20 0 0 -- 
5 0.25 99 10 0.50 0.13 45 40 ND 
6 0.13 99 10 0.50 0.16 50 40 ND 
7 0.25 99 10 0.25 0.20 30 10 ND 
8 0.13 99 10 0.37 0.20 50 30 ND 
9 0.50 99 15 0.50 0.10 70 54 (51) 99 
10 0.50 99 20 0.50 0.10 99 75 (70) 98 
Reaction conditions: 1b (0.100 mmol), 4d (0.200 mmol), NaOtBu (0.200 mmol) 
a
 Conversion of 
1b and 2b were determined
 
by 
1
H NMR spectroscopy. 
b
 NMR yield using dibromomethane as 
internal standard, isolated yield of 5d is shown in parentheses. 
c
 Determined by chiral HPLC 
analysis. 
d
 The crude reaction mixture was exposed to air for 5-10 mins before addition of 
reagents for –arylation under inert atmosphere. e The crude reaction mixture was not exposed to 
air before addition of reagents for –arylation. f  Bubbled N2 for 15 mins before addition of 
reagents for –arylation under inert atmosphere. ND = Not determined 
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To test the feasibility of Ni(0)/IAd-catalyzed exo-selective intramolecular alkene 
hydroacylation and enantioselective Ni(0)/(R)-BINAP-catalyzed -arylation reactions in a single 
pot, we conducted a series of sequential reactions involving hydroacylation of N-
homoallylindole-2-carboxaldehyde 1b and -arylation of the resulting ketone 2b with 1-chloro-
3-methoxybenzene (Table 4.3). 
In a typical sequence, Ni(COD)2, (R)-BINAP, NaOtBu, 1-chloro-3-methoxybenzene and 
toluene were added to the reaction mixture under nitrogen atmosphere upon completion of the 
hydroacylation reaction.  The enantioselectivity of these sequential reactions was high (>95% 
ee), but the yield of –arylated ketone 5d was low (30-40%). However, the yield of the 
sequential hydroacylation and –arylation could be improved significantly by exposing the 
reaction mixture to air for 5-10 minutes before addition of reagents for –arylation and 
increasing the catalyst loading to 20 mol %. Under these conditions, the one-pot, sequential 
hydroacylation and –arylation generated ketone 5d in 70% yield and 98% ee (Scheme 4.10). 
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Scheme 4.10 One-pot Sequential Hydroacylation and -Arylation Reactionsa 
 
a 
Reaction conditions: 1b (0.100 mmol), Ni(COD)2 (0.005 mmol), IAd (0.006 mmol) and 
mesitylene (0.5 mL); 4d (0.200 mmol), NaOtBu (0.200 mmol), Ni(COD)2 (0.020 mmol), and 
ligand L8 (0.024 mmol) and toluene (0.5 mL). Yield of 5d is the isolated yield after column 
chromatography. Enantiomeric excess of 5d was determined by chiral HPLC analysis. 
4.4 Conclusions 
In summary, we have developed a convenient catalytic strategy that combines alkene 
hydroacylation and enantioselective -(hetero)arylation reactions to form a wide variety of five- 
and six-membered nitrogen-containing heterocyclic ketones bearing non-racemic, -chiral 
quaternary stereocenters. The potential to further functionalize the remaining carbonyl moiety 
makes this sequential reaction an attractive strategy to access wide range of complex chiral 
heterocycles having benzylic quaternary stereocenters. This sequential alkene hydroacylation/-
arylation protocol can also be performed in one-pot procedure with good yield and high 
enantioselectivity.  
The intramolecular Ni-catalyzed hydroacylations proceed with complete exo-
selectivity to form the six-membered nitrogen-containing heterocyclic ketones in moderate-
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to-high yields from various indole and pyrrole substrates, while NHC-catalyzed 
hydroacylations of N-allylindoles and N-allylpyrroles occur with exo-selectivity to form -
substituted five-membered heterocyclic ketones in high yields. The five- and six-membered 
nitrogen-containing heterocyclic ketones formed by hydroacylation reactions are convenient 
substrates for Ni-catalyzed -(hetero)arylation reactions that occur in moderate-to-high 
yields with excellent enantioselectivities. The six-membered heterocyclic ketones react with 
(hetero)aryl chlorides in the presence of catalyst complex generated in situ from Ni(COD)2 
and (R)-BINAP or (R)-DIFLUORPHOS at 65-85 °C, while reactions of five-membered 
heterocyclic ketones demand milder reaction conditions to form the desired coupling 
products with chiral quaternary stereocenters in moderate-to-high yields. Studies to develop 
additional tandem and sequential processes that combine olefin hydroacylation reactions 
with additional catalytic transformations are ongoing in our laboratory. 
4.5 Experimental Details 
4.5.1 General experimental details 
All air-sensitive procedures were conducted under inert atmosphere in a nitrogen-filled 
dry box or by standard Schlenk techniques. All reactions were performed under an atmosphere of 
nitrogen unless otherwise stated. All glassware for moisture sensitive reactions was dried at 140 
°C in an oven. Toluene and N,N-dimethylformamide, tetrahydrofuran were degassed by purging 
with argon for 45 minutes and dried with a solvent purification system by passing through a one-
meter column of activated alumina. Anhydrous 1,4-dioxane was purchased from Sigma-Aldrich 
and used as received. Mesitylene was purchased from Sigma-Aldrich and was freshly distilled 
from sodium benzophenone ketyl under vacuum. Flash column chromatography was performed 
on SiliFlash® P60 silica gel (40-63μm, 60Å) or using a Teledyne Isco Combiflash® Rf system 
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with RediSep GoldTM columns using hexanes/ethyl acetate, hexanes/diethyl ether, 
hexanes/dichloromethane mixtures. Reaction products were visualized on TLC by UV light or by 
staining with KMnO4 or 2,4-dinitro-phenylhydrazine. 
HRMS (ESI) analysis was performed at the Iowa State University Chemical 
Instrumentation Facility on an Agilent 6540 QTOF spectrometer. Optical rotations were 
measured on an Atago AP-300 automatic polarimeter.  HPLC analyses were carried out on a 
Water Alliance HPLC system with an e2695 Separations Module and a 2489 (UV/Vis) dual 
wavelength detector.  NMR spectra were acquired on Varian MR-400, Bruker DRX-400 and 
Bruker Avance III 600 spectrometers at the Iowa State University Chemical Instrumentation 
Facility. Chemical shifts are reported in ppm relative to a residual solvent peak (CDCl3 = 7.26 
ppm for 
1
H and 77.36 ppm for 
13
C; DMSO-d6 = 2.50 for 
1
H and 39.52 for 
13
C). 
19
F
 
NMR shifts 
are reported in ppm relative to trifluoroacetic acid as an external standard (F3CCO2H = -76.55 
ppm). Coupling constants are reported in hertz.  
4.5.2 Materials 
5-Methylindole-2-carboxaldehyde, 5-methoxyindole-2-carboxaldehyde, and 6-
methoxyindole-2-carboxaldehyde were synthesized according to reported literature procedures.
24
 
4-Methoxyindole-2-carboxaldehyde and 6-trifluoromethylindole-2-carboxaldehyde were 
synthesized according to the known literature procedure.
24e, 25
 5-Fluoroindole-2-carboxaldehyde 
was synthesized according to a literature procedure.
24e, 26
 Indole-2-carboxaldehyde was 
synthesized from ethyl indole-2-carboxylate according to a known literature procedure.
24e
 Ethyl 
indole-2-carboxylate, 4-bromobut-1-ene S2a and pyrrole-2-carboxaldehyde S1h were purchased 
from AK Scientific and used without further purification. 3-Methylbut-3-en-1-ol, (E)-hex-3-en-
1-ol, allyl bromide, cinnamyl bromide, activated manganese dioxide, sodium tert-butoxide, 
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lithium aluminum hydride, benzonitrile, anhydrous 1,4-dioxane, 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU) were purchased from Sigma-Aldrich and used without further purification. 4-bromo-
2-methylbut-1-ene S2b was synthesized from 3-methylbut-3-en-1-ol according to a known 
literature procedure.
27
 (E)-Hex-3-en-1-yl 4-methylbenzenesulfonate S2c was synthesized from 
(E)-hex-3-en-1-ol according to a known literature procedure.
28
 Substituted cinnamyl bromides 
S2d and S2e were synthesized according to the known literature procedure.
24a, 29
 1a, 1m, 1n were 
synthesized according to the known literature procedure.
24e
 Organocatalyst 3 was synthesized 
according to the known literature procedure.
30
 IAd, ItBu, IMes, IPr were synthesized according 
to the known literature procedure.
31
 Aryl chlorides 4a, 4c, 4e-f, 4j, heteroaryl chlorides 6b, 6e-h 
were purchased from Combi-blocks and used without further purification. Aryl chloride 4g, 
heteroaryl chlorides 6c-d, aryl bromides 8a-f and heteroaryl bromides 10a-f were purchased 
from AK scientific and used without further purification. Aryl chloride 4d, heteroaryl chloride 6i 
were purchased from TCI America and used without further purification. Aryl chloride 4i and 
aryl bromide 8g were purchased from Alfa Aesar and used without further purification. Aryl 
chloride 4h was purchased from Oakwood Chemicals and used without further purification. Aryl 
chloride 4k and heteroaryl chloride 6a were purchased from Sigma-Aldrich and used without 
further purification. Aryl chloride 4b was purchased from Acros Organics and used without 
further purification. Ni(COD)2, (R)-BINAP, rac-BINAP, (R)-SEGPHOS, (R)-xylyl-BINAP, (S)-
DIFLUORPHOS, (R)-DIFLUORPHOS, (R)-CTH-P-PHOS were purchased from Strem 
Chemicals and used without further purification. [(R)-BINAP]Ni(ƞ2-NC-Ph) was synthesized 
according to the known literature procedure.
6a
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4.5.3 General Procedure A: Synthesis of N-Homoallylindole-2-carboxaldehydes (1b-h, 1j-k) 
and N-Homoallylpyrrole-2-carboxaldehydes (1i, 1l)        
       
 
                  
 
N-Homoallylindole-2-carboxaldehydes (1b-h, 1j-k) and N-homoallylpyrrole-2-
carboxaldehydes (1i, 1l) were prepared from the appropriate homoallyl bromides or tosylates 
(S2a-c) and indole- and pyrrole-2-carboxaldehydes (S1a-h). To the appropriate indole-2-
carboxaldehyde (S1a-g) or pyrrole-2-carboxaldehyde S1h (1.0 equiv) and Cs2CO3 (1.2 equiv) 
was added DMF (0.27 M S1). The resulting mixture was stirred at room temperature for 0.5 h. 
The appropriate homoallylic bromide or tosylate S2 (1.2 equiv) was added dropwise. The 
mixture was heated to 90 °C and stirred at the same temperature for 24 h. The reaction mixture 
was cooled to room temperature, quenched with water, and the resulting solution was extracted 
with EtOAc (3x). The combined organic layers were washed with water, washed with brine, 
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dried over Mg2SO4, and concentrated under reduced pressure. The crude product was purified by 
flash column chromatography on silica gel (hexane:EtOAc) to give the appropriate N-
homoallylindole-2-carboxaldehyde (1b-h, 1j-k) or N-homoallylpyrrole-2-carboxaldehyde (1i, 
1l). 
4.5.4 General Procedure B: Synthesis of 1-Cinnamyl-1H-pyrrole-2-carboxaldehydes (1o-p)       
 
 
 
1-Cinnamyl-1H-pyrrole-2-carboxaldehydes (1o-p) were prepared according to a modified 
literature procedure from the appropriate cinnamyl bromides (S2d-e) and pyrrole-2-
carboxaldehyde (S1h).
24e
  To the pyrrole-2-carboxaldehyde (1.0 equiv) and Cs2CO3 (1.2 equiv) 
was added DMF (0.27 M S1h).  The resulting mixture was stirred at room temperature for 0.5 h.  
The appropriate cinnamyl bromide (1.2 equiv) was added dropwise.  The mixture was stirred at 
room temperature until the reaction was judged to be complete by thin-layer chromatography. 
Water was added to the reaction mixture and the resulting solution was extracted with EtOAc 
(3x). The combined organic layers were washed with water, brine, dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography on silica gel (hexane:EtOAc) to give the appropriate 1-cinnamyl-1H-pyrrole-2-
carboxaldehydes (1o-p). 
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 1-(But-3-en-1-yl)-1H-indole-2-carboxaldehyde (1b): Prepared according to 
the general procedure A from S1b (3.00 g, 20.7 mmol) and S2a (3.35 g, 24.8 
mmol). The mixture was purified by flash column chromatography (95:5 
hexane:EtOAc) to give 1b as a light yellow solid in 62% yield (2.55 g, 12.8 mmol). 
1
H NMR 
(400 MHz, CDCl3) δ 2.36 (dt, J = 7.2, 7.2 Hz, 2H), 4.43  (t, J = 7.2 Hz, 2H), 4.82 – 4.89 (m, 2H), 
5.65 (ddt, J = 17.0, 10.2, 7.2 Hz, 1H), 6.99 – 7.04 (m, 2H), 7.23 – 7.24 (m, 2H), 7.55 (dd, J = 
8.1, 0.8 Hz, 1H), 9.69 (s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 35.0, 44.2, 110.9, 117.4, 118.1, 
121.0, 123.6, 126.5, 127.0, 134.7, 135.4, 140.3, 182.6. HRMS (ESI): Calcd. for C13H14NO
+
 
([M+H]
+
): 200.1070, Found: 200.1068. 
 
 1-(But-3-en-1-yl)-4-methoxy-1H-indole-2-carboxaldehyde (1c): Prepared 
according to the general procedure A from S1b (0.258 g, 1.47 mmol) and S2a 
(0.239 g, 1.77 mmol).  The mixture was purified by column chromatography 
(90:10 hexane:EtOAc) to give 1c as yellow oil in 34% yield (0.115 g, 0.502 mmol). 
1
H NMR 
(400 MHz, CDCl3)  2.53 (dt, J = 7.3, 7.3 Hz, 2H), 3.96 (s, 3H), 4.58 (t, J = 7.3 Hz, 2H), 4.97 – 
5.05 (m, 2H), 5.81 (ddt, J = 17.1, 10.2, 7.3 Hz, 1H), 6.50 (d, J = 8.0 Hz, 1H), 6.98 (d, J = 8.0 Hz, 
1H), 7.32 (t, J = 8.0 Hz, 1H), 7.35 (d, J = 0.8 Hz, 1H), 9.80 (s, 1H). 
13
C NMR (101 MHz, 
CDCl3)  35.1, 44.7, 55.6, 99.9, 103.7, 116.1, 117.5, 118.4, 128.4, 134.6, 134.9, 141.9, 155.4, 
182.3. HRMS (ESI) Calcd. for C14H16NO2
+
 ([M+H]
+
): 230.1176, Found: 230.1179. 
 
 1-(But-3-en-1-yl)-5-methyl-1H-indole-2-carboxaldehyde (1d): 
Prepared according to the general procedure A from S1c (0.242 g, 1.52 
mmol) and S2a (0.246 g, 1.82 mmol). The mixture was purified by flash 
column chromatography (95:5 hexane: EtOAc) to give 1d as a light yellow oil in 59% yield 
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(0.191 g, 0.895 mmol). 
1
H NMR (400 MHz, CDCl3) δ 2.48 (s, 3H), 2.55 (dt, J = 7.2, 7.2 Hz, 
2H), 4.62 (t, J = 7.2 Hz, 2H), 4.99 – 5.08 (m, 2H), 5.83 (ddt, J = 17.1, 10.2, 7.2 Hz, 1H), 7.19 (d, 
J = 0.64 Hz, 1H), 7.26 – 7.28 (m, 1H), 7.34 (d, J = 8.6 Hz, 1H), 7.52 – 7.53 (m, 1H), 9.87 (s, 
1H). 
13
C NMR (101 MHz, CDCl3) δ 21.6, 35.2, 44.5, 110.7, 117.5, 117.7, 122.9, 126.9, 129.3, 
130.6, 135.0, 135.6, 139.1, 182.8. HRMS (ESI): Calcd. for C14H16NO
+
 ([M+H]
+
): 214.1226, 
Found: 214.1225. 
 
 1-(But-3-en-1-yl)-5-methoxy-1H-indole-2-carboxaldehyde (1e): 
Prepared according to the general procedure A from S1d (0.343 g, 1.96 
mmol) and S2a (0.317 g, 2.35 mmol). The mixture was purified by flash 
column chromatography (90:10 hexanes:EtOAc) to give 1e as yellow solid in 60% yield (0.270 
g, 1.18 mmol). 
1
H NMR (400 MHz, CDCl3) δ 2.49 (dt, J = 7.0, 7.0 Hz, 2H), 3.82 (s, 3H), 4.54 
(t, J = 7.0 Hz, 2H), 4.95 – 5.01 (m, 2H), 5.71 – 5.82 (m, 1H), 7.05 – 7.11 (m, 3H), 7.27 (d, J = 
9.0 Hz, 1H), 9.80 (s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 35.1, 44.4, 55.8, 102.8, 111.9, 117.2, 
117.5, 119.2, 126.8, 134.8, 135.6, 136.1, 154.9, 182.5. HRMS (ESI) Calcd. for C14H16NO2
+
 
([M+H]
+
): 230.1176, Found: 230.1176. 
 
 1-(But-3-en-1-yl)-5-fluoro-1H-indole-2-carboxaldehyde (1f): Prepared 
according to the general procedure A from S1e (0.136 g, 0.834 mmol) and 
S2a (0.135 g, 1.00 mmol).  The mixture was purified by column 
chromatography (95:5 hexanes:EtOAc) to give 1f as yellow oil in 55% yield (0.100 g, 0.460 
mmol). 
1
H NMR (400 MHz, CDCl3)  2.52 (dt, J = 7.2, 7.2 Hz, 2H), 4.60 (t, J = 7.2 Hz, 2H), 
4.97 - 5.03 (m, 2H), 5.78 (ddt, J = 17.1, 10.2, 7.2 Hz, 1H), 7.17 (ddd, J = 9.1, 9.1, 2.5 Hz, 1H), 
7.22 (s, 1H), 7.34 - 7.37 (m, 2H), 9.87 (s, 1H). 
13
C NMR (101 MHz, CDCl3)  35.2, 44.7, 107.6 
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(d, J = 23.2 Hz, 1C), 112.1 (d, J = 9.1 Hz, 1C), 116.4 (d, J = 27.3 Hz, 1C), 117.5 (d, J = 6.1 Hz, 
1C), 117.8, 126.6 (d, J = 10.3 Hz, 1C), 134.7, 136.6, 137.2, 158.4 (d, J = 239.4 Hz, 1C), 182.9. 
19
F NMR (CDCl3, 376 MHz): δ -122.8 (m, 1F). HRMS (ESI) Calcd. for C13H13FNO
+
 ([M+H]
+
):  
218.0976, Found: 218.0970. 
 
 1-(But-3-en-1-yl)-6-methoxy-1H-indole-2-carboxaldehyde (1g): 
Prepared according to the general procedure A from S1f (0.283 g, 1.62 
mmol) and S2a (0.262 g, 1.94 mmol). The mixture was purified by flash 
column chromatography (90:10 hexane:EtOAc) to give 1g as a dark yellow oil in 57% yield 
(0.211 g, 0.920 mmol). 
1
H NMR (400 MHz, CDCl3)  δ 2.53 (dt, J = 7.2, 7.2 Hz, 2H), 3.89 (s, 
3H), 4.56 (t, J = 7.2 Hz,  2H), 4.99 – 5.07 (m, 2H), 5.82 (ddt, J = 17.1, 10.2, 7.2 Hz, 1H), 6.73 
(m, 1H), 6.83 (dd, J = 8.8, 2.2 Hz, 1H), 7.16 (s, 1H), 7.58 (d, J = 8.8 Hz, 1H), 9.73 (s, 1H). 
13
C 
NMR (101 MHz, CDCl3) δ 34.9, 44.4, 55.8, 92.3, 113.0, 117.5, 119.0, 121.2, 124.6, 135.0, 
135.2, 141.9, 160.3, 181.6. HRMS (ESI) Calcd. for C14H16NO2
+
 ([M+H]
+
): 230.1176, Found: 
230.1174. 
 
 1-(But-3-en-1-yl)-6-(trifluoromethyl)-1H-indole-2-carboxaldehyde 
(1h): Prepared according to the general procedure A from S1g (0.512 g, 
2.40 mmol) and S2a (0.389 g, 2.88 mmol).  The mixture was purified by 
column chromatography (90:10 hexanes:EtOAc) to give 1h as yellow oil in 17% yield (0.110 g, 
0.412 mmol). 
1
H NMR (400 MHz, CDCl3)  2.55 (dt, J = 7.2, 7.2 Hz, 2H), 4.66 (t, J = 7.2 Hz, 
2H), 4.99 - 5.04 (m, 2H), 5.79 (ddt, J = 17.1, 10.2, 7.2 Hz, 1H), 7.31 (m, 1H), 7.39 (dd, J = 8.4, 
1.0 Hz, 1H), 7.70 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 9.94 (s, 1H). 
13
C NMR (101 MHz, CDCl3)  
35.2, 44.8, 108.8 (q, J = 4.0 Hz, 1C), 117.4, 117.6 (q, J = 3.0 Hz, 1C), 118.1, 124.5, 124.9 (q, J = 
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272.7 Hz, 1C), 128.6, 128.9, 134.4, 137.4, 139.2, 183.1.
 19
F NMR (CDCl3, 376 MHz): δ -61.2. 
HRMS (ESI) Calcd C14H13F3NO
+
 ([M+H]
+
): 268.0944, Found: 268.0948. 
 
 1-(But-3-en-1-yl)-1H-pyrrole-2-carboxaldehyde (1i): Prepared according to the 
general procedure A from S1h (0.539 g, 5.67 mmol) and S2a (0.918 g, 6.80 mmol). 
The mixture was purified by flash column chromatography (95:5 hexane:EtOAc) to 
give 1k as a green oil in 57% yield (0.480 g, 3.22 mmol). 
1
H NMR (400 MHz, CDCl3) δ 2.47 
(dt, J = 7.0, 7.0 Hz, 2H), 4.34 (t, J = 7.0 Hz, 2H), 4.97 (s, 1H), 5.00 – 5.02 (m, 1H), 5.71 (ddt, J = 
17.6, 9.6, 7.0 Hz, 1H), 6.17 (dd, J = 3.6, 2.6 Hz, 1H), 6.89 – 6.90 (m, 2H), 9.51 (s, 1H). 13C 
NMR (101 MHz, CDCl3) δ 35.8, 48.8, 109.6, 117.7, 125.1, 131.4, 131.6, 134.4, 179.4. HRMS 
(ESI) Calcd C9H12NO
+
 ([M+H]
+
): 150.0913, Found: 150.0915. 
 
 1-(3-Methylbut-3-en-1-yl)-1H-indole-2-carboxaldehyde (1j): Prepared 
according to the general procedure A from S1a (0.500 g, 3.44 mmol) and 17% 
solution of S2b (3.620 g, 4.13 mmol) in THF. The mixture was purified by 
flash column chromatography (90:10 hexane:EtOAc) to give 1i  as a light yellow solid in 30% 
yield (0.220 g, 1.03 mmol). 
1
H NMR (400 MHz, CDCl3) δ 1.85 (s, 3H), 2.47 (t, J = 7.8 Hz, 2H), 
4.67 (t, J = 7.8 Hz, 2H), 4.72 (s, 1H), 4.81 (s, 1H), 7.17 – 7.21 (m, 1H), 7.25 (s, 1H), 7.42 (d, J = 
4.2 Hz, 2H), 7.75 (dd, J = 8.2, 0.8 Hz, 1H), 9.89 (s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 22.9, 
38.6, 43.8, 110.8, 112.6, 118.1, 121.1, 123.7, 126.7, 127.1, 135.5, 140.3, 142.7, 182.7. HRMS 
(ESI): Calcd. for C14H16NO
+
 ([M+H]
+
): 214.1226, Found: 214.1226. 
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 (E)-1-(Hex-3-en-1-yl)-1H-indole-2-carboxaldehyde (1k): Prepared 
according to the general procedure A from S1a (1.000 g, 6.89 mmol) and 
S2c (2.100 g, 8.27 mmol). The mixture was purified by flash column 
chromatography (90:10 hexane:EtOAc) to give 1j as a dark yellow oil in 
91% yield (1.43 g, 6.290 mmol) as a 6:1 mixture of 1j and its isomer. 
1
H NMR (400 MHz, 
CDCl3) δ 0.88 (t, J = 7.4 Hz, 3H), 1.89 – 1.96 (m, 2H), 2.44 – 2.49 (m, 2H), 4.56 (t, J = 7.2 Hz, 
2H), 5.39 - 5.42 (m, 2H), 7.15 – 7.18 (m, 1H), 7.11  (s, 1H), 7.30 - 7.32 (m, 2H), 7.63 (ddd, J = 
8.2, 1.0, 1.0 Hz, 1H), 9.78 (s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 13.6, 25.6, 33.8, 44.7, 111.0, 
117.9, 120.9, 123.5, 124.9, 126.5, 126.8, 135.0, 135.4, 140.4, 182.5. HRMS (ESI) Calcd 
C15H18NO
+
 ([M+H]
+
): 228.1383, Found: 228.1386. 
 
   1-(3-Methylbut-3-en-1-yl)-1H-pyrrole-2-carboxaldehyde (1l): Prepared 
according to the general procedure A from S1h (1.000 g, 10.52 mmol) and 17% 
solution of S2b (11.06 g, 12.62 mmol) in THF. The mixture was purified by flash 
column chromatography (90:10 hexane:EtOAc) to give 1l as a dark yellow oil in 43% yield 
(0.733 g, 4.49 mmol). 
1
H NMR (400 MHz, CDCl3) δ 1.71 (s, 3H), 2.41 (t, J = 7.4 Hz, 2H), 4.38 
(t, J = 7.4 Hz, 2H), 4.61 (m, 1H), 4.73 (m, 1H), 6.16 (dd, J = 4.0, 2.6 Hz, 1H), 6.87 – 6.89 (m, 
2H), 9.50 (d, J = 1.0 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 22.5, 39.6, 47.9, 109.6, 112.7, 
125.0, 131.3, 131.5, 142.1, 179.3. HRMS (ESI) Calcd C10H14NO
+
 ([M+H]
+
): 164.1070, Found: 
164.1074. 
 
 (E)-1-(3-(4-Methoxyphenyl)allyl)-1H-pyrrole-2-carboxaldehyde 
(1o): Prepared according to the general procedure B from S1h (0.156 g, 
1.65 mmol) and S2d (0.451 g, 1.98 mmol).  The mixture was purified 
by flash column chromatography (90:10 hexane:EtOAc gradient) to give the 1o as a white solid 
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in 39% yield (0.155 g, 0.643 mmol).  
1
H NMR (400 MHz, CDCl3)  3.80 (s, 3H), 5.10 (dd, J = 
6.4, 1.0 Hz, 2H), 6.19 (ddd, J = 15.8, 6.4, 6.4 Hz, 1H), 6.26 (dd, J = 4.0, 2.6 Hz, 1H), 6.43 (d, J = 
15.8 Hz, 1H), 6.83 (d, J = 8.8 Hz, 2H), 6.96 (dd, J = 4.0, 1.7 Hz, 1H), 7.03 (m, 1H), 7.28 (d, J = 
8.8 Hz, 2H), 9.57 (s, 1H).  
13
C NMR (101 MHz CDCl3)  51.0, 55.6, 110.3, 114.3, 123.1, 125.1, 
128.1, 129.3, 131.2, 131.7, 132.8, 158.8, 179.8. HRMS (ESI): Calcd. for C15H16NO2
+
 ([M+H]
+
): 
242.1176, found 242.1179. 
 
 (E)-1-(3-(4-Chlorophenyl)allyl)-1H-pyrrole-2-carboxaldehyde (1p): 
Prepared according to the general procedure B from S1h (0.200 g, 2.10 
mmol) and S2e (0.584 g, 2.52 mmol).  The mixture was purified by flash 
column chromatography (90:10 hexane:EtOAc) to give the 1p as a white solid in 74% yield 
(0.382 g, 1.55 mmol). 
1
H NMR (400 MHz, DMSO-d6)  5.09 (d, J = 5.6 Hz, 2H), 6.29 (dd, J = 
3.8, 2.6 Hz, 1H), 6.34 (d, J = 16.0 Hz, 1H), 6.47 (ddd, J = 16.0, 5.6, 5.6 Hz, 1H), 7.07 (dd, J = 
3.8, 1.6 Hz, 1H), 7.34 - 7.37 (m, 3H), 7.41 (d, J = 8.8 Hz, 1H), 9.54 (s, 1H). 
13
C NMR (101 
MHz, CDCl3)  50.8, 110.3, 110.4, 125.2, 126.2, 128.1, 129.05, 131.3, 131.7, 133.9, 135.05, 
179.8. HRMS (ESI): Calcd. For C14H13ClNO
+
 ([M+H]
+
): 246.0681, found 246.0683. 
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4.5.5 General Procedure C: Synthesis of 8-Methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-
ones (2b-h) 
 
 
 
 
In a nitrogen-filled glovebox, the appropriate N-homoallylindole-2-carboxaldehyde (1b-
h) (0.100 mmol, 1.0 equiv) was added to a 1-dram vial containing Ni(COD)2 (1.4 mg, 0.00500 
mmol, 0.050 equiv) and IAd (2.0 mg, 0.00600 mmol, 0.060 equiv) in mesitylene (0.5 mL).  The 
vial was sealed with a PTFE/silicone-lined septum cap and removed from the glovebox.  The 
reaction mixture was stirred at 165 °C in an oil bath for 10 h.  The vial was removed from the oil 
bath and allowed to cool to room temperature.  The reaction mixture was filtered through a short 
plug of silica gel (eluting with 20 ml of 3:2 hexanes:EtOAc).  The crude reaction mixture was 
concentrated under reduced pressure.  The crude reaction mixture was purified by flash column 
silica gel chromatography (hexanes:EtOAc) to give the appropriate 8-methyl-7,8-
dihydropyrido[1,2-a]indol-9(6H)-ones (2b-h). 
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4.5.6 General Procedure D: Synthesis of 2-Methyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-
one (2a),  7,8-Dihydropyrido[1,2-a]indol-9(6H)-ones (2j-k) and 7-Methyl-6,7-
dihydroindolizin-8(5H)-ones (2i, 2l) 
 
   
 
 
 
 
 
In a nitrogen-filled glovebox, the appropriate N-allylindole-2-carboxaldehyde (1a) or N-
homoallylindole-2-carboxaldehyde (1j-k) or N-homoallylpyrrole-2-carboxaldehyde (1i, 1l) 
(0.100 mmol, 1.0 equiv) was added to a 1-dram vial containing Ni(COD)2 (4.1 mg, 0.0151 
mmol, 0.150 equiv) and IAd (6.1 mg, 0.0181 mmol, 0.180 equiv) in mesitylene (0.5 mL).  The 
vial was sealed with a PTFE/silicone-lined septum cap and removed from the glovebox.  The 
reaction mixture was stirred at 165 °C in an oil bath for 10 h.  The vial was removed from the oil 
bath and allowed to cool to room temperature.  The reaction mixture was filtered through a short 
plug of silica gel (eluting with 20 mL of 3:2 hexanes:EtOAc).  The crude reaction mixture was 
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concentrated under reduced pressure.  The crude reaction mixture was purified by flash column 
silica gel chromatography (hexanes:EtOAc) to give the appropriate 2-methyl-2,3-dihydro-1H-
pyrrolo[1,2-a]indol-1-one (2a), 7,8-dihydropyrido[1,2-a]indol-9(6H)-ones (2j-k) or 7-methyl-
6,7-dihydroindolizin-8(5H)-ones (2i, 2l). 
4.5.7 General Procedure E: Synthesis of 2-Methyl-2,3,-dihydro-1H-pyrrolizin-1-one (2m) 
and 2-Benzyl-2,3-dihydro-1H-pyrrolizin-1-ones (2n-p) 
 
           
 
 
2-methyl-2,3-dihydro-1H-pyrrolizin-1-one (2m) and 2-benzyl-2,3-dihydro-1H-pyrrolizin-
1-one (2n-p) were prepared according to a modified literature procedure from the appropriate 1-
allyl-1H-pyrrole-2-carboxaldehyde (1m-p).
30
  In a nitrogen-filled glovebox, to a 1-dram vial was 
added NHC 3 (5.7 mg, 0.0200 mmol, 0.1 equiv), the appropriate 1-allyl-1H-pyrrole-2-
carboxaldehyde 1m-p (0.200 mmol, 1.0 equiv), DBU (6.1 mg, 0.0400 mmol, 0.2 equiv), and 1,4-
dioxane (1.0 mL, 0.2 M 1).  The vial was sealed with a Teflon-lined septum cap.  The reaction 
vessel was removed from the glovebox, and the reaction mixture was stirred at 60 C for 12 h.  
The reaction was cooled to room temperature, and filtered through a plug of silica gel with 
EtOAc as eluent.  The filtrate was concentrated under reduced pressure.  The crude product was 
purified by flash column silica gel chromatography (hexane:EtOAc) to give the appropriate 2-
methyl-2,3-dihydro-1H-pyrrolizin-1-one (2m) and 2-benzyl-2,3-dihydro-1H-pyrrolizin-1-ones 
(2n-p). 
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2-Methyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2a): Prepared 
according to the general procedure D from 1a (19.0 mg, 0.103 mmol). The 
crude product was purified by silica gel chromatography with a CombiFlash system (4 g column, 
100:0→95:5 hexanes/EtOAc) to give 2a as a white solid in 70% yield (13.3 mg, 0.0718 mmol). 
1
H NMR (400 MHz, CDCl3) δ 1.44 (d, J = 7.4 Hz, 3H), 3.21 – 3.30 (m, 1H), 3.93 (dd, J = 10.8, 
4.8 Hz, 1H), 4.62 (dd, J = 10.8, 8.0 Hz, 1H), 7.00 (s, 1H), 7.18 (ddd, J = 8.2, 6.6, 1.2 Hz, 1H), 
7.32 – 7.40 (m, 2H), 7.75 (d, J = 8.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 15.8, 45.7, 48.1, 
99.4, 110.8, 121.7, 124.4, 125.3, 132.3, 135.27, 135.35, 196.3. HRMS (ESI): Calcd. for 
C12H12NO ([M+H]
+
): 186.0919, Found: 186.0918. 
 
8-Methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2b): Prepared 
according to the general procedure C from 1b (20.0 mg, 0.100 mmol). The 
mixture was purified by flash column chromatography (95:5 
hexane:EtOAc) to give 2b as a yellowish white solid in 95% yield (19.0 mg, 0.095 mmol). 
1
H 
NMR (400 MHz, CDCl3) δ 1.34 (d, J = 6.8 Hz, 3H), 2.15 (app qd, J = 11.2, 4.6 Hz, 1H), 2.41 
(app dq, J = 13.6, 4.6 Hz, 1H), 2.67 – 2.76 (m, 1H), 4.11 (ddd, J = 11.2, 11.2, 3.8 Hz, 1H), 4.38 
(ddd, J = 12.2, 3.8, 3.8 Hz, 1H), 7.16 (t, J = 7.2 Hz, 1H), 7.29 – 7.38 (m, 3H), 7.72 (d, J = 8.0 
Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 15.1, 31.2, 41.1, 41.3, 105.8, 110.5, 121.3, 123.6, 
125.7, 127.2, 133.7, 137.4, 193.1. HRMS (ESI): Calcd. for C13H14NO
+
 ([M+H]
+
): 200.1070, 
Found: 200.1068. 
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1-Methoxy-8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2c): 
Prepared according to the general procedure C from 1c (23.0 mg, 0.100 
mmol). The mixture was purified by flash column chromatography (95:5 
hexane:EtOAc) to give 2c as a yellow solid in 92% yield (21.2 mg, 0.092 mmol). 
1
H NMR (600 
MHz, CDCl3) δ 1.34 (d, J = 6.8 Hz, 3H), 2.14 – 2.22 (m, 1H), 2.42 (app dq, J = 13.6, 4.2 Hz, 
1H), 2.70 – 2.76 (m, 1H), 3.96 (s, 3H), 4.13 (ddd, J = 13.6, 11.0, 4.2 Hz, 1H), 4.37 (ddd, J = 
12.0, 4.2, 4.2 Hz, 1H), 6.50 (d, J = 8.0 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 
7.42 (s, 1H). 
13
C NMR (151 MHz, CDCl3) δ 15.1, 31.4, 41.3, 41.4, 55.8, 100.2, 103.4, 103.9, 
119.0, 127.0, 132.8, 139.0 155.6, 192.8. HRMS (ESI) Calcd. for C14H16NO2
+
 ([M+H]
+
): 
230.1176, Found: 230.1177. 
 
2,8-Dimethyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2d): 
Prepared according to the general procedure C from 1d (22.0 mg, 
0.103 mmol). The mixture was purified by flash column 
chromatography (95:5 hexane:EtOAc) to give 2d as a dark yellow solid in 88% yield (19.4 mg, 
0.0910 mmol). 
1
H NMR (400 MHz, CDCl3) δ 1.34 (d, J = 6.9 Hz, 3H), 2.16 (app dtd, J = 13.6, 
11.0, 4.8 Hz, 1H), 2.38 – 2.44 (m, 4H), 2.72  (app tt, J = 11.0, 6.8 Hz, 1H), 4.12 (ddd, J = 14.0, 
11.0, 4.0 Hz, 1H), 4.37 (ddd, J = 12.2, 4.0, 4.0 Hz, 1H), 7.18 – 7.20 (m, 2H), 7.24 (d, J = 8.4 Hz, 
1H), 7.48 (s, 1H). 
13
C NMR (101 MHz, CDCl3) δ 15.2, 21.8, 31.4, 41.1, 41.3, 105.3, 110.2, 
122.8, 127.5, 127.9, 130.7, 133.8, 136.1, 193.2.  HRMS (ESI): Calcd. for C14H16NO
+
 ([M+H]
+
): 
214.1226, Found: 214.1229. 
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2-Methoxy-8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one 
(2e): Prepared according to the general procedure C from 1e (23.0 
mg, 0.100 mmol). The mixture was purified by flash column 
chromatography (95:5 hexane:EtOAc) to give 2e as a light yellow solid in 90% yield (20.8 mg, 
0.0907 mmol). 
1
H NMR (400 MHz, CDCl3) δ 1.34 (d, J = 6.9 Hz, 3H), 2.17 (app dtd, J = 13.8, 
10.8, 4.8 Hz, 1H), 2.43 (app dq, J = 13.8, 4.4 Hz, 1H), 2.68 – 2.78 (m, 1H), 3.85 (s, 3H), 4.13 
(ddd, J = 13.8, 10.8, 4.4 Hz, 1H), 4.37 (ddd, J = 12.2, 4.4, 4.4 Hz, 1H), 7.05 (dd, J = 9.0, 2.4 Hz, 
1H), 7.08 (d, J = 2.4 Hz, 1H), 7.21 (s, 1H), 7.23 – 7.26 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
15.2, 31.4, 41.2, 41.2, 56.0, 102.9, 105.2, 111.5, 118.0, 127.5, 133.2, 134.1, 155.3, 192.9. HRMS 
(ESI) Calcd. for C14H16NO2
+
 ([M+H]
+
): 230.1176, Found: 230.1179. 
 
2-Fluoro-8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2f): 
Prepared according to the general procedure C from 1f (22.0 mg, 0.101 
mmol). The mixture was purified by flash column chromatography 
(95:5 hexane:EtOAc) to give 2g as a yellowish white solid in 96% yield (21.2 mg, 0.097 mmol). 
1
H NMR (400 MHz, CDCl3) δ 1.35 (d, J = 6.9 Hz, 3H), 2.19 (app dtd, J = 13.8, 11.0, 4.8 Hz, 
1H), 2.45 (app dq, J = 13.8, 4.0 Hz, 1H), 2.70 – 2.79 (m, 1H), 4.16 (ddd, J = 12.2, 11.0, 4.0 Hz, 
1H), 4.40 (ddd, J = 12.2, 4.4, 4.4 Hz, 1H), 7.15 (app td, J = 9.0, 2.4 Hz, 1H), 7.24 (s, 1H), 7.295 
(dd, J = 9.0, 4.4 Hz, 1H), 7.35 (dd, J = 9.0, 2.4 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 15.1, 
31.3, 41.2, 41.4, 106.55 (d, J = 5.0 Hz, 1C), 107.6 (d, J = 23.2 Hz, 1C), 111.5 (d, J = 10.1 Hz, 
1C), 115.1 (d, J = 27.3 Hz, 1C), 127.25 (d, J = 10.1 Hz, 1C), 134.2, 135.0, 158.6 (d, J = 238.4 
Hz, 1C), 193.0. 
19
F NMR (CDCl3, 376 MHz): δ -122.5 (m, 1F). HRMS (ESI) Calcd. for 
C13H13FNO
+ ([M+H]
+
): 218.0976, Found: 218.0979. 
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3-Methoxy-8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one 
(2g): Prepared according to the general procedure C from 1g (23.0 
mg, 0.100 mmol). The mixture was purified by flash column 
chromatography (95:5 hexane:EtOAc) to give 2f as a light yellow solid in 91% yield (21.0 mg, 
0.0916 mmol). 
1
H NMR (400 MHz, CDCl3) δ 1.34 (d, J = 6.8 Hz, 3H), 2.16 (app dtd, J = 13.8, 
10.9, 4.4 Hz, 1H), 2.42 (app dq, J = 13.8, 4.0 Hz, 1H), 2.67 - 2.76 (m, 1H), 3.89 (s, 3H), 4.09 
(ddd, J = 12.1, 10.9, 4.0 Hz, 1H), 4.33 (ddd, J = 12.1, 4.4, 4.4 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 
6.83 (dd, J = 8.8, 2.2 Hz, 1H), 7.25 (s, 1H), 7.58 (d, J = 8.8 Hz, 1H). 
13
C NMR (101 MHz, 
CDCl3) δ 15.2, 31.3, 41.11, 41.13, 55.9, 92.1, 106.5, 113.2, 121.7, 124.5, 133.3, 138.6, 159.4, 
192.5. HRMS (ESI) Calcd. for C14H16NO2
+
 ([M+H]
+
): 230.1176, Found: 230.1178. 
 
8-Methyl-3-(trifluoromethyl)-7,8-dihydropyrido[1,2-a]indol-
9(6H)-one (2h): Prepared according to the general procedure C from 
1h (27.0 mg, 0.101 mmol). The mixture was purified by flash column chromatography (92:8 
hexane:EtOAc) to give 2h as a white solid in 75% yield (20.3 mg, 0.0760 mmol). 
1
H NMR (400 
MHz, CDCl3) δ 1.37 (d, J = 6.8 Hz, 3H), 2.22 (app dtd, J = 13.8, 11.2, 4.8 Hz, 1H), 2.49 (app dq, 
J = 13.8, 4.0 Hz, 1H), 2.74 – 2.83 (m, 1H), 4.22 (ddd, J = 13.8, 11.2, 4.0 Hz, 1H), 4.485 (ddd, J 
= 12.2, 4.0, 4.0 Hz, 1H), 7.31 (s, 1H), 7.38 (dd, J = 8.5, 1.0 Hz, 1H), 7.67 (s, 1H), 7.81 (d, J = 8.5 
Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 15.0, 31.2, 41.49, 41.54, 106.6, 108.4 (q, J = 5.05 Hz, 
1C), 117.7 (q, J = 4.0 Hz, 1C), 124.3, 125.1 (q, J = 273.7 Hz, 1C), 127.4 (q, J = 32.3 Hz, 1C), 
129.2, 135.8, 136.2, 193.0. 
19
F NMR (CDCl3, 376 MHz): δ -61.5 (s, 3F). HRMS (ESI) Calcd 
C14H13F3NO
+
 ([M+H]
+
): 268.0944, Found: 268.0940. 
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7-Methyl-6,7-dihydroindolizin-8(5H)-one (2i): Prepared according to the 
general procedure D from 1k (15.0 mg, 0.100 mmol). The mixture was purified 
by flash column chromatography (92:8 hexane:EtOAc) to give 2k as a white solid in 80% yield 
(12.0 mg, 0.0800 mmol). 
1
H NMR (600 MHz, CDCl3) δ 1.29 (d, J = 6.8 Hz, 3H), 2.07 (qd, J = 
10.8, 4.4 Hz, 1H), 2.28 – 2.31 (m, 1H), 2.57 – 2.60 (m, 1H), 4.10 (ddd, J = 12.4, 12.4, 3.4 Hz, 
1H), 4.20 (ddd, J = 12.4, 4.4, 4.4 Hz, 1H), 6.25 (d, J = 1.2 Hz, 1H), 6.82 (m, 1H), 7.00 (d, J = 2.4 
Hz, 1H). 
13
C NMR (151 MHz, CDCl3) δ 15.4, 31.8, 40.3, 44.6, 110.8, 114.3, 125.7, 130.7, 
190.2. HRMS (ESI) Calcd C9H12NO
+
 ([M+H]
+
): 150.0913, Found: 150.0917. 
 
8,8-Dimethyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2j): Prepared 
according to the general procedure D from 1i (22.0 mg, 0.103 mmol). The 
mixture was purified by flash column chromatography (90:10 
hexane:EtOAc) to give 2i as a yellow solid in 75% yield (16.5 mg, 0.077 mmol). 
1
H NMR (600 
MHz, CDCl3) δ 1.32 (s, 6H), 2.25 (t, J = 6.0 Hz, 2H), 4.28 (t, J = 6.0 Hz, 2H), 7.17 (ddd, J = 8.0, 
5.4, 2.4 Hz, 1H), 7.30 (s, 1H), 7.35 – 7.39 (m, 2H), 7.73 (d, J = 8.0 Hz, 1H). 13C NMR (151 
MHz, CDCl3) δ 24.3, 36.9, 38.8, 41.6, 106.6, 110.6, 121.4, 123.6, 125.8, 127.5, 132.9, 137.5, 
195.6. HRMS (ESI): Calcd. for C14H16NO
+
 ([M+H]
+
): 214.1226, Found: 214.1225. 
 
8-Propyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2k): Prepared 
according to a modified version of general procedure D from 1j (68.0 mg, 
0.299 mmol). The mixture was purified by flash column chromatography 
(80:20 hexane:EtOAc) to give 2j as a yellow solid in 15% yield (10.5 mg, 0.0460 mmol). 
1
H 
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NMR (600 MHz, CDCl3) δ 0.98 (t, J = 7.2 Hz, 3H), 1.41 – 1.58 (m, 3H), 1.98 – 2.04 (m, 1H), 
2.19 (app dtd, J = 13.8, 9.4, 4.6 Hz, 1H), 2.48 (app dq, J = 13.8, 5.4 Hz, 1H), 2.62 – 2.66 (m, 
1H), 4.16 (ddd, J = 12.4, 9.4, 4.2 Hz, 1H), 4.39 (ddd, J = 12.4, 5.4, 5.4 Hz, 1H), 7.16 (ddd, J = 
8.0, 5.8, 2.0 Hz, 1H), 7.30 (s, 1H), 7.35 – 7.39 (m, 2H), 7.72 (d, J = 8.0 Hz, 1H). 13C NMR (151 
MHz, CDCl3) δ 14.4, 20.5, 28.3, 31.3, 40.7, 46.1, 106.0, 110.6, 121.4, 123.7, 125.8, 127.3, 
133.9, 137.5, 193.0. HRMS (ESI) Calcd C15H18NO
+
 ([M+H]
+
): 228.1383, Found: 228.1385. 
 
7,7-Dimethyl-6,7-dihydroindolizin-8(5H)-one (2l): Prepared according to a 
modified version of general procedure D from 1l (49.0 mg, 0.300 mmol). The 
mixture was purified by flash column chromatography (90:10 hexane:EtOAc) to give 2l as a 
white solid in 20% yield (10.0 mg, 0.0610 mmol). 
1
H NMR (400 MHz, CDCl3) δ 1.25 (s, 6H), 
2.11 (t, J = 9.0 Hz, 2H), 4.14 (t, J = 9.0 Hz, 2H), 6.25 (dd, J = 6.0, 3.6 Hz, 1H), 6.80 – 6.81 (m, 
1H), 7.00 (dd, J = 3.6, 1.6 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 24.6, 37.4, 40.6, 42.2, 111.0, 
114.9, 125.5, 129.6, 192.6. HRMS (ESI) Calcd C10H14NO
+
 ([M+H]
+
): 164.1070, Found: 
164.1068. 
 
2-Methyl-2,3-dihydro-1H-pyrrolizin-1-one (2m): Prepared according to general 
procedure E from 1m (27.0 mg, 0.200 mmol).  The reaction mixture was stirred at 
60 °C for 24 h.  The mixture was purified by flash column chromatography (90:10 
hexane:EtOAc) to give 2m as a white solid in 80% yield (21.6 mg, 0.160 mmol). 
1
H NMR (400 
MHz, CDCl3)  1.36 (d, J = 7.4 Hz, 3H), 3.10 - 3.18 (m, 1H), 3.85 (dd, J = 11.6, 4.6 Hz, 1H), 
4.50 (dd, J = 11.6, 8.0 Hz, 1H), 6.50 (dd, J = 4.0, 2.4 Hz, 1H), 6.71 (dd, J = 4.0, 0.8 Hz, 1H), 
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7.00 (m, 1H). 
13
C NMR (101 MHz, CDCl3)  15.9, 45.6, 50.3, 108.1, 117.1, 122.9, 132.2, 192.7. 
HRMS (ESI) Calcd C8H10NO
+
 ([M+H]
+
): 136.0757, found 136.0761. 
 
2-Benzyl-2,3-dihydro-1H-pyrrolizin-1-one (2n): Prepared according to a general 
modified version of general procedure E from 1n (42.0 mg, 0.199 mmol).  The 
mixture was purified by flash column chromatography (90:10 hexane:EtOAc) to 
give 2n as a yellow oil in 96% yield (40.3 mg, 0.191 mmol). 
1
H NMR (400 MHz, 
CDCl3)  2.79 (dd, J = 15.0, 12.0 Hz, 1H), 3.40 - 3.47 (m, 2H), 3.98 (dd, J = 12.0, 4.4 Hz, 1H), 
4.26 (dd, J = 12.0, 7.6 Hz, 1H), 6.51 (dd, J = 4.0, 2.2 Hz, 1H), 6.75 (dd, J = 4.0, 0.6 Hz, 1H), 
6.96 (m, 1H), 7.21 - 7.26 (m, 3H), 7.29 - 7.32 (m, 2H). 
13
C NMR (101 MHz, CDCl3)  36.8, 
47.9, 52.5, 108.4, 117.3, 123.2, 127.0, 129.08, 129.10, 132.5, 139.1, 191.0. HRMS (ESI): Calcd. 
for C14H14NO
+
 ([M+H]
+
): 212.1070, found 212.1072. 
2-(4-Methoxybenzyl)-2,3-dihydro-1H-pyrrolizin-1-one (2o):  Prepared 
according to a modified version of general procedure E from 1o (48.0 mg, 0.199 
mmol).  The mixture was purified by flash column chromatography (90:10 
hexane:EtOAc) to give 2o as a white solid in 99% yield (47.6 mg, 0.197 mmol). 
1
H NMR (400 MHz, CDCl3)  2.77 (dd, J = 14.0, 10.2 Hz, 1H), 3.32 (dd, J = 14.0, 4.4 Hz, 1H), 
3.37 - 3.43 (m, 1H), 3.78 (s, 3H), 3.97 (dd, J = 11.8, 4.4 Hz, 1H), 4.26 (dd, J = 11.8, 7.8 Hz, 1H), 
6.50 (dd, J = 4.0, 2.2 Hz, 1H), 6.75 (dd, J = 4.0, 0.8 Hz, 1H), 6.83 (d, J = 8.6 Hz, 2H), 6.96 (m, 
1H), 7.13 (d, J = 8.6 Hz, 2H). 
13
C NMR (101 MHz, CDCl3)  35.9, 47.8, 52.7, 55.6, 108.4, 
114.4, 117.3, 123.2, 130.1, 130.9, 132.6, 158.7, 191.2. HRMS (ESI): Calcd. for C15H16NO2
+
 
([M+H]
+
): 242.1176, found 242.1178.   
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2-(4-Chlorobenzyl)-2,3-dihydro-1H-pyrrolizin-1-one (2p): Prepared according 
to a modified version of general procedure E from 1p (49.0 mg, 0.199 mmol).  The 
mixture was purified by flash column chromatography (90:10 hexane:EtOAc) to 
give 2p as a white solid in 99% yield (48.5 mg, 0.197 mmol). 
1
H NMR (400 MHz, 
CDCl3)  2.75 (dd, J = 14.0, 9.8 Hz, 1H), 3.27 (dd, J = 14.0, 4.4 Hz, 1H), 3.31 - 3.37 (m, 1H), 
3.87 (dd, J = 11.8, 4.4 Hz, 1H), 4.21 (dd, J = 11.8, 7.8 Hz, 1H), 6.44 (dd, J = 4.0, 2.2 Hz, 1H), 
6.68 (dd, J = 4.0, 0.6 Hz, 1H), 6.89 (m, 1H), 7.08 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H). 
13
C NMR (101 MHz, CDCl3)  36.0, 47.7, 52.2, 108.6, 117.4, 123.4, 129.2, 130.5, 132.4, 132.9, 
137.4, 190.6. HRMS (ESI): Calcd. for C14H13ClNO
+
 ([M+H]
+
): 246.0680, found 246.0791. 
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4.5.8 General Procedure F: Synthesis of (R)-8-Aryl-8-methyl-7,8-dihydropyrido[1,2-
a]indol-9(6H)-ones (5a-d) and (R)-7-Aryl-7-methyl-6,7-dihydroindolizin-8(5H)-one (5l) 
 
 
              
 
                      
 
 
In a nitrogen-filled glovebox, 8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2b) 
(0.100 mmol, 1.0 equiv) or 7-methyl-6,7-dihydroindolizin-8(5H)-one (2k) (0.100 mmol, 1.0 
equiv), Ni(COD)2 (2.8 mg, 0.0100 mmol, 0.10 equiv), (R)-BINAP (7.5 mg, 0.0120 mmol, 0.12 
equiv), NaOtBu (19.3 mg, 0.200 mmol, 2.0 equiv), the appropriate aryl chloride (0.200 mmol, 
2.0 equiv), a magnetic stirring bar, and toluene (0.5 mL) were added to a 1-dram vial. The vial 
was sealed with a cap containing a PTFE septum and removed from the glovebox. The reaction 
mixture was stirred at 65 °C in an oil bath for 48 h.  The vial was removed from the oil bath and 
allowed to cool to room temperature.  The reaction mixture was filtered through short plug of 
silica gel (eluting with 20 mL of 3:2 hexanes:EtOAc).  The crude reaction mixture was 
concentrated under reduced pressure. The crude product was purified with a CombiFlash system 
with 5-20% ethyl acetate in hexanes as eluent to give the appropriate (R)-8-aryl-8-methyl-7,8-
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dihydropyrido[1,2-a]indol-9(6H)-ones (5a-d) and (R)-7-aryl-7-methyl-6,7-dihydroindolizin-
8(5H)-one (5l).  
4.5.9 General Procedure G: Synthesis of (R)-8-Aryl-8-methyl-7,8-dihydropyrido[1,2-
a]indol-9(6H)-ones (5e-k) 
 
  
 
 
In a nitrogen-filled glovebox, 8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2b) 
(0.100 mmol, 1.0 equiv), Ni(COD)2 (2.80 mg, 0.0100 mmol, 0.10 equiv), (R)-BINAP (7.5 mg, 
0.0120 mmol, 0.12 equiv), NaOtBu (19.3 mg, 0.200 mmol, 2.0 equiv), the appropriate aryl 
chloride 4e-k (0.200 mmol, 2.0 equiv), a magnetic stirring bar, and toluene (0.5 mL) were added 
to a 1-dram vial. The vial was sealed with a cap containing a PTFE septum and removed from 
the glovebox. The reaction mixture was stirred at 70 °C in an oil bath for 48 h.  The vial was 
removed from the oil bath and allowed to cool to room temperature.  The reaction mixture was 
filtered through short plug of silica gel (eluting with 20 mL of 3:2 hexanes:EtOAc).  The crude 
reaction mixture was concentrated under reduced pressure. The crude product was purified with 
a CombiFlash system with 5-20% ethyl acetate in hexanes as eluent to give the appropriate (R)-
8-aryl-8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-ones (5e-k).  
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4.5.10 General Procedure H: Synthesis of (S)-2-Aryl-2-methyl-2,3-dihydro-1H-pyrrolo[1,2-
a]indol-1-one (9a-c)      
 
 
 
 
 
In a nitrogen-filled glovebox, 2-methyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (2a) 
(0.200 mmol, 1.0 equiv), [(R)-BINAP]Ni(2-NC-Ph) (26.3 mg, 0.0300 mmol, 0.15 equiv), 
NaOtBu (38.4 mg, 0.400 mmol, 2.0 equiv), the appropriate aryl bromide 8a-c (0.400 mmol, 2.0 
equiv), a magnetic stirring bar, and toluene (1.0 mL) were added to a 1-dram vial. The vial was 
sealed with a cap containing a PTFE septum and removed from the glovebox. The reaction 
mixture was stirred at 25 °C in for 48 h.  The vial was removed from the oil bath and allowed to 
cool to room temperature.  The reaction mixture was filtered through short plug of silica gel 
(eluting with 20 ml of 3:2 hexanes:EtOAc).  The crude reaction mixture was concentrated under 
reduced pressure. The crude product was purified with a CombiFlash system with 5-20% ethyl 
acetate in hexanes as eluent to give the appropriate (S)-2-aryl-2-methyl-2,3-dihydro-1H-
pyrrolo[1,2-a]indol-1-one (9a-c).  
 
 
 
 
 
 
 
 
 
N N
O
9a-c2a
9a; Ar = C6H5
9b; Ar = 3-MeO-C6H4
9c; Ar = 4-CF3-C6H4
Ar
Me
+
8a-c
O
Me
Ar Br
8a; Ar = C6H5
8b; Ar = 3-MeO-C6H4
8c; Ar = 4-CF3-C6H4
toluene, 25 °C, 48 h
NaOtBu (2 equiv)
[(R)-BINAP]Ni(h2-NC-Ph)
(15 mol %)
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4.5.11 General Procedure I: Synthesis of (S)-2-Aryl-2-methyl-2,3-dihydro-1H-pyrrolizin-1-
ones (9d-j) and (S)-2-Phenyl-2-benzyl-2,3-dihydro-1H-pyrrolizin-1-ones (9k-m) 
 
 
 
 
 
 In a nitrogen-filled glovebox, 2-methyl-2,3,-dihydro-1H-pyrrolizin-1-one (2m) (0.200 
mmol, 1.0 equiv) or 2-benzyl-2,3-dihydro-1H-pyrrolizin-1-ones (2n-p) (0.200 mmol, 1.0 equiv), 
[(R)-BINAP]Ni(2-NC-Ph) (17.5 mg, 0.0200 mmol, 0.10 equiv), NaOtBu (38.4 mg, 0.400 
mmol, 2.0 equiv), the appropriate aryl bromide 8a-g (0.400 mmol, 2.0 equiv), a magnetic stirring 
bar, and toluene (1.0 mL) were added to a 1-dram vial. The vial was sealed with a cap containing 
a PTFE septum and removed from the glovebox. The reaction mixture was stirred at 25 °C for 48 
h.  The vial was removed from the oil bath and allowed to cool to room temperature.  The 
reaction mixture was filtered through short plug of silica gel (eluting with 20 ml of 3:2 
hexanes:EtOAc).  The crude reaction mixture was concentrated under reduced pressure. The 
crude product was purified with a CombiFlash system with 5-20% ethyl acetate in hexanes as 
eluent to give the appropriate (S)-2-aryl-2-methyl-2,3-dihydro-1H-pyrrolizin-1-ones (9d-j) and 
(S)-2-aryl-2-benzyl-2,3-dihydro-1H-pyrrolizin-1-ones (9k-m).  
 
N N
O
9d-m2m-p
9d; R  = Me, Ar = C6H5
9e; R  = Me, Ar = 4-CF3-C6H4
9f; R  = Me, Ar = 3-CF3-C6H4
9g; R  = Me, Ar = 3-F-C6H4
9h; R  = Me, Ar = 3-MeO-C6H4
9i; R  = Me, Ar = 4-MeO-C6H4
9j; R  = Me, Ar = napthyl
9k; R  = CH2-C6H4, Ar
 = C6H5
9l; R  = CH2-(4-MeO)-C6H4, Ar
 = C6H5
9m; R  = CH2-(4-Cl)-C6H4, Ar
 = C6H5
Ar
R
+
8a-g
O
R
Ar Br
8a; Ar = C6H5
8b; Ar = 4-CF3-C6H4
8c; Ar = 3-MeO-C6H4
8d; Ar = 3-CF3-C6H4
8e; Ar = 3-F-C6H4
8f; Ar = 4-MeO-C6H4
8g; Ar = napthyl
toluene, 25 °C, 48 h
NaOtBu (2 equiv)
[(R)-BINAP]Ni(h2-NC-Ph)
(10 mol %)
2m; R  = Me
2n; R  = CH2-C6H4
2o; R  = CH2-(4-MeO)-C6H4
2p; R  = CH2-(4-Cl)-C6H4
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 (R)-8-Methyl-8-(4-(trifluoromethyl)phenyl)-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one (5a): Prepared according 
to the general procedure F from 2b (20.0 mg, 0.100 mmol) and 1-
chloro-4-(trifluoromethyl)benzene 4a (36.2 mg, 0.200 mmol). The crude product was purified by 
silica gel chromatography with a CombiFlash system (4 g column, 100:0→90:10 
hexanes/EtOAc) to give 5a as a light yellow solid in 99% yield (34.3 mg, 0.099 mmol). The 
enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 20.4 min (major); tR 
27.8 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-
PrOH, 99:1, 1.0 mL/min] to be 99% ee. [α]D
24
 = +99.2° (c 0.89, CHCl3). 
1
H NMR (400 MHz, 
CDCl3) δ 1.66 (s, 3H), 2.59 (ddd, J = 14.4, 11.2, 4.9 Hz, 1H), 2.83 (ddd, J = 14.4, 3.8, 3.8 Hz, 
1H), 3.89 (ddd, J = 11.2, 11.2, 3.8 Hz, 1H), 4.30 (ddd, J = 11.2, 4.9, 3.8 Hz, 1H), 7.17 (ddd, J = 
7.9, 7.0, 0.8 Hz, 1H), 7.26 – 7.28 (m, 1H), 7.36 (ddd, J = 8.2, 7.0, 0.8 Hz, 1H), 7.41 – 7.44 (m, 
3H), 7.55 – 7.57 (m, 2H), 7.74 (d, J = 8.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 26.0, 36.7, 
39.1, 50.3, 107.3, 110.6, 121.6, 123.8, 124.3 (q, J = 273.7 Hz, 1C), 126.1 (q, J = 4.0 Hz, 1C), 
126.2, 127.1, 127.4, 129.7 (q, J = 33.3 Hz, 1C), 133.6, 137.6, 146.1, 192.8. 
19
F NMR (CDCl3, 
376 MHz): δ -62.9 (s, 3F). HRMS (ESI): Calcd. for C20H17F3NO
+
 ([M+H]
+
):  344.1257, Found: 
344.1265. 
 
 (R)-8-(4-Fluorophenyl)-8-methyl-7,8-dihydropyrido[1,2-
a]indol-9(6H)-one (5b): Prepared according to the general 
procedure F from 2b (20.0 mg, 0.100 mmol) and 1-chloro-4-
fluorobenzene 4b (26.2 mg, 0.200 mmol). The crude product was purified by silica gel 
chromatography with a CombiFlash system (4 g column, 100:0→94:6 hexanes/EtOAc) to give 
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5b as a light yellow solid in 95% yield (28.0 mg, 0.0954 mmol). The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 28.6 min (major); tR 38.2 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 99:1, 1.0 
mL/min] to be 99% ee. [α]D
23
 = +152.1° (c 0.53, CHCl3). 
1
H NMR (600 MHz, CDCl3) δ 1.62 (s, 
3H), 2.56 (ddd, J = 14.4, 11.4, 4.8 Hz, 1H), 2.76 (ddd, J = 14.4, 3.6, 3.6 Hz, 1H), 3.88 (ddd, J = 
11.4, 11.4, 3.6 Hz, 1H), 4.27 (ddd, J = 11.4, 4.8, 3.6 Hz, 1H), 6.97 – 7.00 (m, 2H), 7.16 (ddd, J = 
7.8, 6.6, 0.5 Hz, 1H), 7.24 – 7.27 (m, 3H), 7.35 (ddd, J = 8.1, 7.0, 0.8 Hz, 1H), 7.42 (s, 1H), 7.73 
(d, J = 8.1 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 26.3, 36.9, 39.1, 49.8, 107.0, 110.6, 116.0 
(d, J = 21.3 Hz, 1C), 121.5, 123.7, 126.1, 127.4, 128.3 (d, J = 7.9 Hz, 1C), 133.7, 137.489 (d, J = 
3.4 Hz, 1C), 137.492, 162.0 (d, J = 247.5 Hz, 1C), 193.4. 
19
F NMR (CDCl3, 565 MHz): δ -116.0 
(s, 1F). HRMS (ESI): Calcd. for C19H17FNO
+
 ([M+H]
+
): 294.1289, Found: 294.1293. 
 
 (R)-tert-Butyl 4-(8-methyl-9-oxo-6,7,8,9-
tetrahydropyrido[1,2-a]indol-8-yl)benzoate (5c): Prepared 
according to the general procedure F from 2b (20.0 mg, 0.100 mmol) and methyl 4-
chlorobenzoate 4c (34.2 mg, 0.200 mmol). The crude product was purified by silica gel 
chromatography with a CombiFlash system (4 g column, 100:0→85:15 
hexanes/dichloromethane) to give 5c as a light yellow solid in 85% yield (32.1 mg, 0.0855 
mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 15.4 min 
(major); tR 25.5 min (minor) [Chiracel OJ-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., 
Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 99% ee. [α]D
25
 = +63.2° (c 0.66, CHCl3). 
1
H 
NMR (400 MHz, CDCl3) δ 1.54 (s, 9H), 1.64 (s, 3H), 2.58 (ddd, J = 14.4, 11.6, 4.8 Hz, 1H), 
2.82 (ddd, J = 14.4, 3.4, 3.4 Hz, 1H), 3.85 (ddd, J = 11.6, 11.6, 3.4 Hz, 1H), 4.27 (ddd, J = 11.6, 
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4.8, 3.4 Hz, 1H), 7.15 (ddd, J = 8.0, 6.7, 1.0 Hz, 1H), 7.22 – 7.26 (m, 1H), 7.31 – 7.35 (m, 3H), 
7.42 (s, 1H), 7.72 (dt, J = 8.0, 1.0 Hz, 1H), 7.94 – 7.87 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
26.0, 28.5, 36.7, 39.2, 50.5, 81.4, 107.1, 110.6, 121.5, 123.7, 126.1, 126.6, 127.4, 130.3, 131.2, 
133.7, 137.5, 146.5, 165.6, 193.1. HRMS (ESI): Calcd. for C24H26NO3
+
 ([M+H]
+
): 376.1907, 
Found: 376.1910. 
 
 (R)-8-(3-Methoxyphenyl)-8-methyl-7,8-dihydropyrido[1,2-
a]indol-9(6H)-one (5d): Prepared according to general procedure F 
from 2b (20.0 mg, 0.100 mmol) and 1-chloro-3-methoxybenzene 
4d (28.6 mg, 0.200 mmol). The crude product was purified by silica gel chromatography with a 
CombiFlash system (4 g column, 100:0→92:8 hexanes/EtOAc) to give 5d as a light yellow solid 
in 93% yield (28.5 mg, 0.093 mmol). m.p. = 159 - 161 °C. The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 30.6 min (major); tR 41.2 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 99:1, 1.0 
mL/min] to be 99% ee. [α]D
24
 = +125.6° (c 0.61, CHCl3). 
1
H NMR (600 MHz, CDCl3) δ 1.64 (s, 
3H), 2.56 (ddd, J = 14.1, 11.6, 4.6 Hz, 1H), 2.81 (ddd, J = 14.1, 3.4, 3.4 Hz, 1H), 3.76 (s, 3H), 
3.93 (ddd, J = 11.6, 11.6, 3.4 Hz, 1H), 4.26 – 4.28 (m, 1H), 6.77 (d, J = 6.1 Hz, 1H), 6.86 – 6.88 
(m, 2H), 7.16 (t, J = 7.1 Hz, 1H), 7.23 (t, J = 7.9 Hz, 1H),  7.26 – 7.27 (m, 1H), 7.35 (t, J = 7.1 
Hz, 1H), 7.43 (s, 1H), 7.74 (d, J = 7.9 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) δ 26.3, 36.7, 39.2, 
50.3, 55.5, 106.7, 110.6, 112.1, 113.2, 119.0, 121.4, 123.6, 125.8, 127.4, 130.1, 133.9, 137.5, 
143.3, 160.2, 193.5. 
19
F NMR (CDCl3, 376 MHz): δ -63.1.  HRMS (ESI): Calcd. for 
C20H20NO2
+
 ([M+H]
+
): 306.1489, Found: 306.1491. 
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 (R)-8-Methyl-8-(p-tolyl)-7,8-dihydropyrido[1,2-a]indol-9(6H)-
one (5e): Prepared according to the general procedure G from 2b 
(20.0 mg, 0.100 mmol) and 1-chloro-4-methylbenzene 4e (25.4 mg, 0.200 mmol). The crude 
product was purified by silica gel chromatography with a CombiFlash system (4 g column, 
100:0→90:10 hexanes/EtOAc) to give 5e as a yellow solid in 83% yield (24.0 mg, 0.0829 
mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 19.2 min 
(major); tR 25.6 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., 
Ltd.) hexane/i-PrOH, 99:1, 1.0 mL/min] to be 99% ee. [α]D
23
 = +115.8° (c 0.52, CHCl3). 
1
H 
NMR (600 MHz, CDCl3) δ 1.61 (s, 3H), 2.28 (s, 3H), 2.54 (ddd, J = 14.3, 11.8, 4.9 Hz, 1H), 
2.79 (ddd, J = 14.3, 3.4, 3.4 Hz, 1H), 3.90 (ddd, J = 11.8, 11.8, 3.4 Hz, 1H), 4.26 (ddd, J = 11.8, 
4.9, 3.4 Hz, 1H), 7.09 – 7.10 (m, 2H), 7.13 – 7.17 (m, 3H), 7.24 – 7.25 (m, 1H), 7.33 (ddd, J = 
8.2, 6.9, 1.0 Hz, 1H), 7.41 (s, 1H), 7.73 (dd, J = 8.2, 1.0 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) δ 
20.9, 26.1, 36.4, 38.9, 49.7, 106.3, 110.2, 121.0, 123.3, 125.5, 126.2, 127.1, 129.6, 133.7, 136.7, 
137.2, 138.3, 193.5. HRMS (ESI): Calcd. for C20H20NO
+
 ([M+H]
+
): 290.1539, Found: 290.1545. 
 
 (R)-8-(4-Methoxyphenyl)-8-methyl-7,8-dihydropyrido[1,2-
a]indol-9(6H)-one (5f): Prepared according to the general 
procedure G from 2b (20.0 mg, 0.100 mmol) and 1-chloro-4-
methoxybenzene 4f (28.6 mg, 0.200 mmol). The crude product was purified by silica gel 
chromatography with a CombiFlash system (4 g column, 100:0→90:10 hexanes/EtOAc) to give 
5f as a white solid in 92% yield (28.3 mg, 0.0927 mmol). The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 17.5 min (major); tR 23.6 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 
184 
 
mL/min] to be 97% ee. [α]D
23
 = +109.9° (c 0.56, CHCl3). 
1
H NMR (600 MHz, CDCl3) δ 1.62 (s, 
3H), 2.55 (ddd, J = 14.6, 11.8, 4.8 Hz, 1H), 2.77 (ddd, J = 14.6, 3.6, 3.6 Hz, 1H), 3.76 (s, 3H), 
3.91 (ddd, J = 11.8, 11.8, 3.6 Hz, 1H), 4.28 (ddd, J = 11.8, 4.8, 3.6 Hz, 1H), 6.84 (d, J = 8.8 Hz, 
2H), 7.16 (t, J = 7.4 Hz, 1H), 7.21 (d, J = 8.8 Hz, 2H), 7.27 – 7.28 (m, 1H), 7.35 (t, J = 7.4 Hz, 
1H), 7.42 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) δ 26.4, 36.8, 39.2, 
49.7, 55.6, 106.7, 110.6, 114.6, 121.4, 123.6, 125.8, 127.4, 128.0, 133.6, 134.0, 137.5, 158.8, 
193.9. HRMS (ESI): Calcd. for C20H20NO2
+
 ([M+H]
+
): 306.1489, Found: 306.1499. 
  
 (R)-8-Methyl-8-(3-(trifluoromethyl)phenyl)-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one (5g): Prepared according to 
the general procedure G from 2b (20.0 mg, 0.100 mmol) and 1-chloro-3-
(trifluoromethyl)benzene 4g (36.2 mg, 0.200 mmol). The crude product was purified by silica gel 
chromatography with a CombiFlash system (4 g column, 100:0→90:10 hexanes/EtOAc) to give 
5g as an orange solid in 90% yield (31.0 mg, 0.0903 mmol). The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 13.7 min (major); tR 18.5 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 98:2, 1.0 
mL/min] to be 99% ee. [α]D
24
 = +119.6° (c 0.60, CHCl3). 
1
H NMR (600 MHz, CDCl3) δ 1.66 (s, 
3H), 2.59 (ddd, J = 14.6, 11.0, 4.8 Hz, 1H), 2.85 (ddd, J = 14.6, 3.8, 3.8 Hz, 1H), 3.93 (ddd, J = 
12.4, 11.0, 3.8 Hz, 1H), 4.31 (ddd, J = 12.4, 4.8, 4.8 Hz, 1H), 7.17 (t, J = 7.8 Hz, 1H), 7.28 (d, J 
= 8.2 Hz, 1H), 7.40 (ddd, J = 7.8, 7.1, 0.7 Hz, 1H), 7.39 – 7.42 (m, 1H), 7.44 – 7.45 (m, 2H), 
7.50 (d, J = 7.5 Hz, 1H), 7.61 (s, 1H), 7.74 (d, J = 8.2 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) δ 
26.1, 36.6, 39.1, 50.2, 107.5, 110.6, 121.6, 123.2 (q, J = 3.0, 1C), 123.8, 124.3 (q, J = 271.8, 1C), 
124.4 (q, J = 4.5, 1C), 126.2, 127.4, 129.7, 130.4 (q, J = 3.0, 1C), 131.6 (q, J = 31.7, 1C), 133.5, 
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137.6, 143.1, 192.7. 19F NMR (CDCl3, 565 MHz): δ -63.05 (s, 3F). HRMS (ESI): Calcd. for 
C20H17F3NO
+
 ([M+H]
+
): 344.1257, Found: 344.1264. 
 
 (R)-8-(3-Fluorophenyl)-8-methyl-7,8-dihydropyrido[1,2-a]indol-
9(6H)-one (5h): Prepared according to the general procedure G from 
2b (20.0 mg, 0.100 mmol) and 1-chloro-3-fluorobenzene 4h (26.2 mg, 0.200 mmol). The crude 
product was purified by silica gel chromatography with a CombiFlash system (4 g column, 
100:0→94:6 hexanes/EtOAc) to give 5h as a yellow oil in 75% yield (22.0 mg, 0.0750 mmol). 
The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 18.7 min 
(major); tR 24.0 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., 
Ltd.) hexane/i-PrOH, 98:2, 1.0 mL/min] to be 99% ee. [α]D
23
 = +148.6° (c 0.70, CHCl3). 
1
H 
NMR (600 MHz, CDCl3) δ 1.63 (s, 3H), 2.57 (ddd, J = 14.4, 11.6, 4.8 Hz, 1H), 2.77 (ddd, J = 
14.4, 3.6, 3.6 Hz, 1H), 3.91 (ddd, J = 11.6, 11.6, 3.6 Hz, 1H), 4.28 (ddd, J = 11.6, 4.8, 3.6 Hz, 
1H), 6.90 – 6.93 (m, 1H), 7.00 – 7.04 (m, 2H), 7.16 (ddd, J = 8.2, 7.0, 1.0 Hz, 1H), 7.23 – 7.28 
(m, 2H), 7.35 (ddd, J = 8.2, 1.0, 1.0 Hz, 1H), 7.43 (s, 1H), 7.73 (d, J = 8.2 Hz, 1H). 
13
C NMR 
(151 MHz, CDCl3) δ 26.2, 36.8, 39.1, 50.2, 107.2, 110.6, 113.9 (d, J = 22.6, 1C), 114.5 (d, J = 
19.6, 1C), 121.5, 122.4 (d, J = 3.0, 1C), 123.8, 126.1, 127.4, 130.7 (d, J = 7.5, 1C), 133.7, 137.6, 
144.5 (d, J = 6.0, 1C), 163.4 (d, J = 247.6, 1C), 192.9. 
19
F NMR (CDCl3, 565 MHz): δ -112.3 (s, 
1F). HRMS (ESI): Calcd. for C19H17FNO
+
 ([M+H]
+
): 294.1289, Found: 294.1293. 
 
 (R)-8-(Benzo[d][1,3]dioxol-5-yl)-8-methyl-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one (5i): Prepared according to 
the general procedure G from 2b (20.0 mg, 0.100 mmol) and 5-
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chlorobenzo[d][1,3]dioxole 4i (31.4 mg, 0.200 mmol). The crude product was purified by silica 
gel chromatography with a CombiFlash system (4 g column, 100:0→85:15 hexanes/EtOAc) to 
give 5i as a yellow solid in 82% yield (26.3 mg, 0.0823 mmol). The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 26.0 min (major); tR 36.1 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 
mL/min] to be 99% ee. [α]D
23
 = +132.2° (c 0.48, CHCl3). 
1
H NMR (600 MHz, CDCl3) δ 1.59 (s, 
3H), 2.53 (ddd, J = 14.2, 11.8, 4.8 Hz, 1H), 2.72 (ddd, J = 14.2, 3.2, 3.2 Hz, 1H), 3.94 (ddd, J = 
11.8, 11.8, 3.2 Hz, 1H), 4.26 (ddd, J = 11.8, 4.8, 3.2 Hz, 1H), 5.90 (d, J = 9.7 Hz, 2H), 6.69 (s, 
2H), 6.80 (s, 1H), 7.15 (t, J = 8.0 Hz, 1H), 7.26 – 7.27 (m, 1H), 7.34 (t, J = 7.4 Hz, 1H), 7.40 (s, 
1H), 7.72 (d, J = 8.0 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) δ 26.5, 36.9, 39.2, 50.1, 101.5, 
106.9, 107.2, 108.7, 110.6, 120.0, 121.4, 123.7, 125.9, 127.4, 133.9, 135.5, 137.5, 146.9, 148.5, 
193.5. HRMS (ESI): Calcd. for C20H18NO3
+
 ([M+H]
+
): 320.1281, Found: 320.1287. 
 
 (R)-8-Methyl-8-(naphthalen-2-yl)-7,8-dihydropyrido[1,2-
a]indol-9(6H)-one (5j): Prepared according to the general 
procedure G from 2b (20.0 mg, 0.100 mmol) and 2-chloronaphthalene 4j (32.6 mg, 0.200 
mmol). The crude product was purified by silica gel chromatography with a CombiFlash system 
(4 g column, 100:0→85:15 hexanes/EtOAc) to give 5j as a yellow solid in 95% yield (31.1 mg, 
0.0956 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 
23.2 min (major); tR 37.0 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical 
Ind., Ltd.) hexane/i-PrOH, 98:2, 1.0 mL/min] to be 99% ee. [α]D
24
 = +24.4° (c 0.57, CHCl3). 
1
H 
NMR (600 MHz, CDCl3) δ 1.72 (s, 3H), 2.62 (ddd, J = 14.6, 12.8, 4.5 Hz, 1H), 2.94 (ddd, J = 
14.6, 3.6, 3.6 m, 1H), 3.90 (ddd, J = 12.2, 12.2, 3.6 Hz, 1H), 4.28 (ddd, J = 12.2, 4.5, 3.6 Hz, 
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1H), 7.14 (t, J = 7.4 Hz, 1H), 7.21 – 7.23 (m, 1H), 7.32 (t, J = 7.4 Hz, 1H), 7.42 – 7.49 (m, 4H), 
7.65 (s, 1H), 7.71 – 7.78 (m, 3H), 7.83 (d, J = 8.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 26.2, 
36.8, 39.3, 50.6, 106.9, 110.6, 121.4, 123.7, 124.3, 125.9, 125.9, 126.4, 126.6, 127.4, 127.7, 
128.4, 129.1, 132.6, 133.6, 134.0, 137.5, 139.1, 193.7. HRMS (ESI): Calcd. for C23H20NO
+
 
([M+H]
+
): 326.1539, Found: 326.1543. 
 
 (R)-8-Methyl-8-phenyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one 
(5k): Prepared according to the general procedure G from 2b (20.0 mg, 
0.100 mmol) and chlorobenzene 4k (22.6 mg, 0.200 mmol). The crude product was purified by 
silica gel chromatography with a CombiFlash system (4 g column, 100:0→95:5 hexanes/EtOAc) 
to give 5k as a yellow solid in 99% yield (27.4 mg, 0.0995 mmol). The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 16.7 min (major); tR 21.7 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 98:2, 1.0 
mL/min] to be 98% ee. [α]D
23
 = +148.7° (c 0.54, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 1.62 (s, 
3H), 2.54 (ddd, J = 14.2, 12.0, 4.8 Hz, 1H), 2.79 (ddd, J = 14.2, 3.4, 3.4 Hz, 1H), 3.86 (ddd, J = 
12.0, 12.0, 3.4 Hz, 1H), 4.24 (ddd, J = 12.0, 4.8, 3.4 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 7.18 – 
7.34 (m, 7H), 7.41 (s, 1H), 7.72 (d, J = 8.1 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 26.3, 36.7, 
39.2, 50.3, 106.7, 110.6, 121.4, 123.6, 125.9, 126.6, 127.3, 127.4, 129.2, 134.0, 137.4, 141.7, 
193.7. HRMS (ESI): Calcd. for C19H18NO
+
 ([M+H]
+
): 276.1383, Found: 276.1388. 
 
 (R)-7-(3-Methoxyphenyl)-7-methyl-6,7-dihydroindolizin-8(5H)-one 
(5l): Prepared according to the general procedure F from 2k (30.0 mg, 
0.201 mmol) and 1-chloro-3-methoxybenzene 4d (57.3 mg, 0.402 mmol). The crude product was 
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purified by silica gel chromatography with a CombiFlash system (4 g column, 100:0→90:10 
hexanes/EtOAc) to give 5l as a colorless oil in 70% yield (43.0 mg, 0.141 mmol). The 
enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 27.2 min (major); tR 
31.7 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-
PrOH, 98:2, 1.0 mL/min] to be 91% ee. [α]D
25
 = +123.4° (c 0.87, CHCl3). 
1
H NMR (400 MHz, 
CDCl3) δ 1.56 (s, 3H), 2.44 (ddd, J = 14.2, 12.0, 4.6 Hz, 1H), 2.60 (ddd, J = 14.2, 3.4, 3.4 Hz, 
1H), 3.76 (s, 3H), 3.86 (ddd, J = 12.0, 12.0, 3.4 Hz, 1H), 4.03 (ddd, J = 12.0, 4.6, 3.4 Hz, 1H), 
6.25 (dd, J = 4.0, 2.4 Hz, 1H), 6.74 – 6.86 (m, 4H), 7.11 (dd, J = 4.0, 1.4 Hz, 1H), 7.22 (t, J = 8.0 
Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 26.3, 37.6, 42.6, 49.3, 55.5, 111.1, 112.0, 113.3, 115.2, 
119.1, 125.8, 130.0, 130.8, 144.1, 160.1, 190.4. HRMS (ESI): Calcd. for C16H18NO2
+
 ([M+H]
+
): 
256.1332, Found: 256.1335. 
 
 (S)-2-Methyl-2-phenyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one (9a): 
Prepared according to the general procedure H from 2a (37.0 mg, 0.200 
mmol) and 1-chloro-3-methoxybenzene 8a (63.0 mg, 0.399 mmol). The 
mixture was purified by flash column chromatography (98:2 hexane:EtOAc) to give 9a as a 
white solid in 78% yield (40.7 mg, 0.156 mmol).  The enantiomeric excess was determined by 
HPLC analysis (254 nm, 25 C) tR 12.8 min (major); tR 18.5 min (minor) [Chiracel (AS-H) (from 
Diacel Chemical Ind., Ltd.) hexane/i-PrOH 95:5, 1.0 ml/min] to be 99% ee. []D
24
 = -228.9  (c 
0.59, CHCl3). The NMR data is consistent with the data available in literature.
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1
H NMR (400 
MHz, CDCl3)  1.84 (s, 3H), 4.48 (d, J = 11.0 Hz, 1H), 4.76 (d, J = 11.0 Hz, 1H), 7.14 (s, 1H), 
7.21 - 7.30 (m, 2H), 7.31 - 7.35 (m, 4H), 7.38 - 7.46 (m, 2H), 7.81 (ddd, J = 8.4, 1.2, 1.2 Hz, 
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1H). 
13
C NMR (101 MHz, CDCl3)  22.6, 56.9, 57.5, 101.0, 111.0, 121.9, 124.6, 125.7, 126.2, 
127.7, 129.2, 132.7, 132.8, 135.6, 142.5, 196.3. 
 
 (S)-2-(3-Methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrolo[1,2-
a]indol-1-one (9b): Prepared according to the general procedure H 
from 2a (37.0 mg, 0.199 mmol) and 1-bromo-3-methoxybenzene 8b 
(74.7 mg, 0.399 mmol). The crude product was purified by silica gel chromatography with a 
CombiFlash system (4 g column, 100:0→92:8 hexanes/EtOAc) to give a mixture of 9b and 
possibly, its rotameric isomer in 85:15 ratio, as a yellow solid in 44% combined yield (25.7 mg, 
0.0882 mmol). The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 
32.7 min (major); tR 50.0 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical 
Ind., Ltd.) hexane/i-PrOH, 98:2, 1.0 mL/min] to be 99% ee. [α]D
24
 = -193.5° (c 0.15, CHCl3). 
1
H 
NMR (400 MHz, CDCl3) δ 1.81 (s, 3H), 3.77 (s, 3H), 4.47 (d, J = 11.0 Hz, 1H), 4.75 (d, J = 11.0 
Hz, 1H), 6.79 – 6.81 (s, 1H), 6.88 – 6.90 (m, 2H), 7.12 (s, 1H), 7.20 – 7.26 (m, 2H), 7.37 – 7.45 
(m, 2H), 7.80 (d, J = 8.4 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 23.6, 55.6, 56.9, 57.4, 101.1, 
111.0, 112.5, 112.9, 118.6, 121.9, 124.6, 125.7, 130.2, 132.7, 134.8, 135.7, 144.1, 160.2, 196.2. 
HRMS (ESI): Calcd. for C19H18NO2
+
 ([M+H]
+
): 292.1332, Found: 292.1334. The extra peaks in 
1
H and 
13
C NMR might have resulted due to the presence of rotameric isomer of 9b. 
 
 (S)-2-Methyl-2-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-
pyrrolo[1,2-a]indol-1-one (9c): Prepared according to the general 
procedure H from 2a (37.0 mg, 0.199 mmol) and 1-bromo-4-
(trifluoromethyl)benzene 8c (89.9 mg, 0.399 mmol). The crude product 
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was purified by silica gel chromatography with a CombiFlash system (4 g column, 100:0→90:10 
hexanes/EtOAc) to give a mixture of 9c and possibly its rotameric isomer in 86:14 ratio, as a 
light yellow solid in 68% combined yield (44.6 mg, 0.135 mmol). The enantiomeric excess was 
determined by HPLC analysis (220 nm, 25 °C) tR 13.0 min (major); tR 15.8 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 
mL/min] to be 99% ee. [α]D
25
 = -133.3° (c 0.85, CHCl3). 
1
H NMR (600 MHz, CDCl3) δ 1.86 (s, 
3H), 4.52 (d, J = 11.0 Hz, 1H), 4.75 (d, J = 11.0 Hz, 1H), 7.15 (s, 1H), 7.24 (ddd, J = 8.2, 6.7, 
1.1 Hz, 1H), 7.40 – 7.48 (m, 4H), 7.59 (d, J = 8.2 Hz, 2H), 7.82 (d, J = 8.2 Hz, 1H). 13C NMR 
(151 MHz, CDCl3) δ 23.8, 56.5, 57.5, 101.6, 111.0, 122.2, 124.3 (q, J = 271.8 Hz, 1C), 124.8, 
126.1, 126.2 (q, J = 4.5 Hz, 1C), 126.8, 130.0 (q, J = 33.2 Hz, 1C), 132.8, 134.4, 135.8, 146.4 (q, 
J = 1.5 Hz, 1C), 195.3. 19F NMR (CDCl3, 376 MHz): δ -62.9 (s, 3F). HRMS (ESI): Calcd. for 
C19H15F3NO
+
 ([M+H]
+
): 330.1100, Found: 330.1107.  
The extra peaks in 
1
H and 
13
C NMR might have resulted due to the presence of rotameric isomer 
of 9c. Variable-temperature NMR measurements (Bruker 400 MHz) on a sample of 9c in 
DMSO-d6 at temperatures ranging from 20 °C to 135 °C, upper limit of the instrument, did not 
show coalescence of peaks. Additional NMR studies (1-D selective chemical-exchange NMR) 
were carried out to confirm the presence of rotameric isomer.
33
 However, the results were 
inconclusive. 
 
 (S)-2-Methyl-2-phenyl-2,3-dihydro-1H-pyrrolizin-1-one (9d): Prepared 
according to the general procedure I from 2m (27.0 mg, 0.200 mmol) and 1-
bromobenzene 8a (63.0 mg, 0.399 mmol). The crude product was purified by 
flash column chromatography (98:2 hexane:EtOAc) to give 9d as a white solid in 80% yield 
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(33.8 mg, 0.160 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 
C) tR 28.0 min (major); tR 46.4 min (minor) [Chiracel OJ-H (0.46 cm x 25 cm) (from Diacel 
Chemical Ind., Ltd.) hexane/i-PrOH 80:20, 1.0 ml/min] to be 99% ee. []D
24
 = -262.4 (c 0.78, 
CHCl3). The NMR data is consistent with the data available in literature.
10
 
1
H NMR (400 MHz, 
CDCl3)  1.74 (s, 3H), 4.33 (d, J = 11.8 Hz, 1H), 4.56 (d, J = 11.8 Hz, 1H), 6.58 (dd, J = 4.0, 2.4 
Hz, 1H), 6.82 (dd, J = 4.0, 0.6 Hz, 1H), 7.05 – 7.06 (m, 1H), 7.21 - 7.25 (m, 1H), 7.27 – 7.33 (m, 
4H). 
13
C NMR (101 MHz, CDCl3)  23.5, 57.3, 59.0, 109.5, 117.6, 123.3, 126.2, 127.5, 129.1, 
131.6, 142.9, 192.9. 
 
 (S)-2-Methyl-2-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolizin-1-
one (9e): Prepared according to the general procedure I from 2m (27.0 mg, 
0.199 mmol) and 1-bromo-4-(trifluoromethyl)benzene 8b (89.9 mg, 0.399 
mmol). The crude product was purified by silica gel chromatography with a 
CombiFlash system (4 g column, 100:0→90:10 hexanes/EtOAc) to give 9e as a light yellow 
solid in 90% yield (50.0 mg, 0.179 mmol). The enantiomeric excess was determined by HPLC 
analysis (220 nm, 25 °C) tR 21.0 min (major); tR 29.1 min (minor) [Chiracel AS-H (0.46 cm x 25 
cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 98:2, 1.0 mL/min] to be 99% ee. [α]D
23
 = 
-68.0° (c 0.62, CHCl3). 
1
H NMR (600 MHz, CDCl3) δ 1.78 (s, 3H), 4.38 (d, J = 11.8 Hz, 1H), 
4.57 (d, J = 11.8 Hz, 1H), 6.62 (dd, J = 4.0, 2.2 Hz, 1H), 6.86 (dd, J = 4.0, 1.0 Hz, 1H), 7.10 (d, J 
= 2.2 Hz, 1H), 7.43 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H). 
13
C NMR (151 MHz, CDCl3) δ 
23.6, 57.4, 58.6, 110.0, 118.1, 123.6, 124.3 (q, J = 271.8 Hz, 1C), 126.1 (q, J = 4.5 Hz, 1C), 
126.8, 129.8 (q, J = 33.2 Hz, 1C), 131.3, 146.8, 191.5. 
19
F NMR (CDCl3, 376 MHz): δ -62.9 (s, 
3F). HRMS (ESI): Calcd. for C15H13F3NO
+
 ([M+H]
+
): 280.0944, Found: 280.0949. 
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 (S)-2-Methyl-2-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolizin-
1-one (9f): Prepared according to the general procedure I from 2m (27.0 
mg, 0.199 mmol) and 1-bromo-3-(trifluoromethyl)benzene 8d (89.9 mg, 
0.399 mmol). The crude product was purified by silica gel chromatography with a CombiFlash 
system (4 g column, 100:0→90:10 hexanes/EtOAc) to give 9f as a yellow oil in 88% yield (49.0 
mg, 0.175 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) 
tR 17.5 min (major); tR 25.0 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 98:2, 1.0 mL/min] to be 99% ee. [α]D
23
 = -67.3° (c 0.74, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 1.78 (s, 3H), 4.39 (d, J = 11.8 Hz, 1H), 4.56 (d, J = 11.8 
Hz, 1H), 6.62 (dd, J = 4.0, 2.0 Hz, 1H), 6.86 (dd, J = 4.0, 1.0 Hz, 1H), 7.10 (dd, J = 2.0, 1.0 Hz, 
1H), 7.42 – 7.53 (m, 3H), 7.58 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 23.8, 57.3, 58.6, 110.0, 
118.1, 123.1 (q, J = 4.0 Hz, 1C), 123.7, 124.3 (q, J = 273.7 Hz, 1C), 124.5 (q, J = 4.0 Hz, 1C), 
129.7, 129.9 (q, J = 2.0 Hz, 1C), 131.3, 131.4 (q, J = 32.3 Hz, 1C), 143.8, 191.6. 
19
F NMR 
(CDCl3, 376 MHz): δ -62.8 (s, 3F). HRMS (ESI): Calcd. for C15H13F3NO
+
 ([M+H]
+
): 280.0944, 
Found: 280.0947. 
 
  (S)-2-(3-Fluorophenyl)-2-methyl-2,3-dihydro-1H-pyrrolizin-1-one (9g): 
Prepared according to the general procedure I from 2m (27.0 mg, 0.199 
mmol) and 1-bromo-3-fluorobenzene 8e (69.9 mg, 0.399 mmol). The crude 
product was purified by silica gel chromatography with a CombiFlash system (4 g column, 
100:0→90:10 hexanes/EtOAc) to give 9g as a light yellow oil in 92% yield (42.3 mg, 0.184 
mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 25.2 min 
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(major); tR 35.5 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., 
Ltd.) hexane/i-PrOH, 98:2, 1.0 mL/min] to be 99% ee. [α]D
24
 = -80.6° (c 0.84, CHCl3). 
1
H NMR 
(400 MHz, CDCl3) δ 1.74 (s, 3H), 4.35 (d, J = 11.8 Hz, 1H), 4.55 (d, J = 11.8 Hz, 1H), 6.60 (dd, 
J = 4.0, 2.4 Hz, 1H), 6.85 (dd, J = 4.0, 0.8 Hz, 1H), 6.92 – 6.97 (m, 1H), 7.01 – 7.09 (m, 3H), 
7.27 – 7.31 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 23.5, 57.2, 58.8, 109.9, 113.6 (d, J = 23.2 
Hz, 1C), 114.5 (d, J = 21.2 Hz, 1C), 117.9, 121.9 (d, J = 3.0 Hz, 1C), 123.5, 130.6 (d, J = 9.1 Hz, 
1C), 131.4, 145.4 (d, J = 7.1 Hz, 1C), 163.3 (d, J = 247.4 Hz, 1C), 191.8. 
19
F NMR (CDCl3, 376 
MHz): δ -112.3 (m, 1F). HRMS (EI): Calcd. for C14H13FNO
+
 ([M+H]
+
): 230.0976, Found: 
230.0979. 
 
 (S)-2-(3-Methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrolizin-1-one 
(9h): Prepared according to the general procedure I from 2m (27.0 mg, 
0.199 mmol) and 1-bromo-3-methoxybenzene 8c (74.7 mg, 0.399 mmol). 
The crude product was purified by silica gel chromatography with a CombiFlash system (4 g 
column, 100:0→90:10 hexanes/EtOAc) to give 9h as a light yellow oil in 99% yield (48.0 mg, 
0.199 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 
25.6 min (major); tR 28.6 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical 
Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 98% ee. [α]D
24
 = -95.1° (c 0.95, CHCl3). 
1
H 
NMR (600 MHz, CDCl3) δ 1.74 (s, 3H), 3.77 (s, 3H), 4.33 (d, J = 11.6 Hz, 1H), 4.56 (d, J = 11.6 
Hz, 1H), 6.59 (dd, J = 4.0, 2.2 Hz, 1H), 6.79 (ddd, J = 8.2, 2.2, 0.8 Hz, 1H), 6.83 (dd, J = 4.0, 0.8 
Hz, 1H), 6.88 – 6.85 (m, 2H), 7.06 – 7.07 (m, 1H), 7.24 (t, J = 8.2 Hz, 1H). 13C NMR (151 
MHz, CDCl3) δ 23.5, 55.6, 57.4, 59.0, 109.6, 112.3, 112.8, 117.7, 118.6, 123.3, 130.1, 131.7, 
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144.5, 160.2, 192.5. HRMS (ESI): Calcd. for C15H16NO2
+
 ([M+H]
+
): 242.1176, Found: 
242.1180. 
 
 (S)-2-(4-Methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrolizin-1-one (9i): 
Prepared according to the general procedure I from 2m (27.0 mg, 0.199 
mmol) and 1-bromo-4-methoxybenzene 8f (74.2 mg, 0.399 mmol). The crude 
product was purified by silica gel chromatography with a CombiFlash system 
(4 g column, 100:0→90:10 hexanes/EtOAc) to give 9i as a yellow oil in 52% yield (25.0 mg, 
0.104 mmol). The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 
18.0 min (major); tR 25.0 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical 
Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 99% ee. [α]D
25
 = -87.7° (c 0.36, CHCl3). 
1
H 
NMR (400 MHz, CDCl3) δ 1.73 (s, 3H), 3.78 (s, 3H), 4.33 (d, J = 11.6 Hz, 1H), 4.54 (d, J = 11.6 
Hz, 1H), 6.59 (dd, J = 4.0, 2.2 Hz, 1H), 6.82 – 6.86 (m, 3H), 7.06 (m, 1H), 7.20 – 7.22 (m, 2H). 
13
C NMR (101 MHz, CDCl3) δ 23.6, 55.6, 56.8, 59.1, 109.5, 114.5, 117.6, 123.2, 127.4, 131.7, 
134.9, 158.9, 193.0. HRMS (ESI): Calcd. for C15H16NO2
+
 ([M+H]
+
): 242.1176, Found: 
242.1180. 
 
 (S)-2-Methyl-2-(naphthalen-2-yl)-2,3-dihydro-1H-pyrrolizin-1-one (9j): 
Prepared according to the general procedure I from 2m (27.0 mg, 0.199 
mmol) and 2-bromonaphthalene 8g (82.7 mg, 0.399 mmol). The crude 
product was purified by silica gel chromatography with a CombiFlash 
system (4 g column, 100:0→90:10 hexanes/EtOAc) to give 9j as a light yellow solid in 96% 
yield (50.3 mg, 0.192 mmol). The enantiomeric excess was determined by HPLC analysis (220 
195 
 
nm, 25 °C) tR 24.1 min (major); tR 36.0 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from 
Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 99% ee. [α]D
23
 = -287.1° (c 
0.81, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 1.87 (s, 3H), 4.42 (d, J = 11.8 Hz, 1H), 4.66 (d, J = 
11.8 Hz, 1H), 6.62 (dd, J = 4.0, 2.2 Hz, 1H), 6.88 (dd, J = 4.0, 1.0 Hz, 1H), 7.10 (dd, J = 2.2, 1.0 
Hz, 1H), 7.31 (dd, J = 8.6, 2.0 Hz, 1H), 7.43 – 7.50 (m, 2H), 7.77 – 7.82 (m, 4H). 13C NMR (101 
MHz, CDCl3) δ 23.6, 57.6, 58.9, 109.6, 117.8, 123.4, 124.4, 125.1, 126.4, 126.7, 127.8, 128.5, 
129.1, 131.8, 132.7, 133.5, 140.1, 192.7. HRMS (ESI): Calcd. for C18H16NO
+
 ([M+H]
+
): 
262.1226, Found: 262.1231. 
 
 (S)-2-Benzyl-2-phenyl-2,3-dihydro-1H-pyrrolizin-1-one (9k): Prepared 
according to the modified version of  the general procedure I from 2n (42.0 mg, 
0.199 mmol) and bromobenzene 8a (63.0 mg, 0.398 mmol) at 10 °C.  The 
mixture was purified by flash column chromatography (98:2 hexane:EtOAc) to give 9k as a 
white solid in 69% yield (39.6 mg, 0.138 mmol). The enantiomeric excess was determined by 
HPLC analysis (254 nm, 25 C) tR 35.2 min (major); tR 48.9 min (minor) [Chiracel OJ-H (0.46 
cm x 25 cm) (from Diacel Chemical Ind., Ltd.) hexane/i-PrOH 80:20, 1.0 ml/min] to be 99% ee. 
[]D
24
 = -219.1 (c 0.78, CHCl3). 
1
H NMR (600 MHz, CDCl3)  3.33 (d, J = 13.8 Hz, 1H), 3.63 
(d, J = 13.8 Hz, 1H), 4.52 (d, J =12.0 Hz, 1H), 4.56 (d, J = 12.0 Hz, 1H), 6.45 (dd, J = 4.2, 2.4 
Hz, 1H), 6.73 (dd, J = 4.2, 1.2 Hz, 1H), 6.91 (m, 1H), 7.07 – 7.08 (m, 2H), 7.16 – 7.19 (m, 3H), 
7.26 – 7.28 (m, 1H), 7.34 (t, J = 8.0 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H). 13C NMR (101 MHz, 
CDCl3)  43.2, 53.5, 62.0, 109.3, 117.4, 123.3, 126.7, 127.2, 127.3, 128.3, 129.1, 130.5, 132.2, 
136.7, 141.9, 191.3. HRMS (ESI): Calcd. for C20H18NO
+
 ([M+H]
+
): 288.1383, found 288.1390. 
 
196 
 
 (S)-2-(4-Methoxybenzyl)-2-phenyl-2,3-dihydro-1H-pyrrolizin-1-one 
(9l): Prepared according to the general procedure I from 2o (48.0 mg, 0.199 
mmol) and bromobenzene 8a (63.0 mg, 0.398 mmol).  The mixture was 
purified by flash column chromatography (98:2 hexane:EtOAc) to give 9l 
as a white solid in 91% yield (57.6 mg, 0.181 mmol). []D
24
 = -81.2 (c 1.22, CHCl3)  The 
enantiomeric excess was determined by HPLC analysis (254 nm, 25 C) tR 29.4 min (major); tR 
42.1 min (minor) [Chiracel AD-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-
PrOH, 95:5, 1.0 ml/min] to be 99%.   
1
H NMR (400 MHz, CDCl3)  3.15 (d, J = 14.0 Hz, 1H), 
3.51 (d, J = 14.0 Hz, 1H), 3.65 (s, 3H), 4.43 (d, J = 11.8 Hz, 1H), 4.48 (d, J = 11.8 Hz, 1H) 6.37 
(dd, J = 4.0, 2.2 Hz, 1H), 6.61 - 6.65 (m, 3H), 6.82 – 6.83 (m, 1H), 6.89 (d, J = 8.6 Hz, 2H), 7.16 
– 7.20 (m, 1H), 7.25 (t, J = 7.2 Hz, 2H), 7.34 (d, J = 8.6 Hz, 2H).  13C NMR (101 MHz, CDCl3) 
 42.4, 53.5, 55.5, 62.2, 109.2, 114.0, 117.4, 123.3, 126.7, 127.5, 128.6, 129.0, 131.5, 132.3, 
142.1, 158.7, 191.5. HRMS (ESI) Calcd. for C21H20NO2
+
 ([M+H]
+
): 
 
318.1489, found 318.1494. 
 
 (S)-2-(4-Chlorobenzyl)-2-phenyl-2,3-dihydro-1H-pyrrolizin-1-one (9m): 
Prepared according to the general procedure I from 2p (49.0 mg, 0.199 mmol) 
and bromobenzene 8a (63.0 mg, 0.399 mmol).  The mixture was purified by 
flash column chromatography (98:2 hexane:EtOAc) to give 9m as a white 
solid in 84% yield (54.0 mg, 0.168 mmol).  The enantiomeric excess was determined by HPLC 
analysis (220 nm, 25 C) tR 25.7 min (major); tR 30.6 min (minor) [Chiracel AS-H (0.46 cm x 25 
cm) (from Diacel Chemical Ind., Ltd.) hexane/i-PrOH 95:5, 1.0 ml/min] to be 99%. []D
24
 = -
70.1 (c 0.68, CHCl3).  
1
H NMR (600 MHz, CDCl3)  3.27 (d, J = 13.8 Hz, 1H), 3.60 (d, J = 
13.8 Hz, 1H), 4.46 (d, J = 12.0 Hz, 1H), 4.59 (d, J = 12.0 Hz, 1H), 6.47 (dd, J = 3.6, 1.8 Hz, 1H), 
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6.73 (d, J = 3.6 Hz, 1H), 6.93 (m, 1H), 6.99 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 7.27 - 
7.28 (m, 1H), 7.34 (t, J = 7.8 Hz, 2H), 7.40 (d, J = 7.8 Hz, 2H). 
13
C NMR (101 MHz, CDCl3)  
42.6, 53.4, 61.9, 109.5, 117.6, 123.4, 126.7, 127.7, 128.7, 129.2, 131.8, 132.1, 133.1, 135.1, 
141.6, 191.0. HRMS (ESI) Calcd. for C20H17ClNO
+
 ([M+H]
+
): 322.0993, found 322.0998. 
 
4.5.12 General Procedure J: Synthesis of (R)-8-Methyl-8-(pyridin-2-yl)-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one (7a) 
 
 
 
 
 
In a nitrogen-filled glovebox, 8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2b) 
(0.100 mmol, 1.0 equiv), Ni(COD)2 (2.8 mg, 0.0100 mmol, 0.10 equiv), (R)-DIFLUORPHOS 
(9.2 mg, 0.0120 mmol, 0.12 equiv), NaOtBu (19.3 mg, 0.200 mmol, 2.0 equiv), 2-chloropyridine 
6a (0.200 mmol, 2.0 equiv), a magnetic stirring bar, and toluene (0.5 mL) were added to a 1-
dram vial. The vial was sealed with a cap containing a PTFE septum and removed from the 
glovebox. The reaction mixture was stirred at 80 °C in an oil bath for 48 h.  The vial was 
removed from the oil bath and allowed to cool to room temperature.  The reaction mixture was 
filtered through short plug of silica gel (eluting with 20 mL of 3:2 hexanes:EtOAc). The crude 
reaction mixture was concentrated under reduced pressure. The crude product was purified with 
a CombiFlash system with 5-20% ethyl acetate in hexanes as eluent to give (R)-8-methyl-8-
(pyridin-2-yl)-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (7a).  
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4.5.13 General Procedure K: Synthesis of (R)-8-Heteroaryl-8-methyl-7,8-
dihydropyrido[1,2-a]indol-9(6H)-ones (7b-i) 
 
 
 
 
 
 
 
 
In a nitrogen-filled glovebox, 8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (2b) 
(0.100 mmol, 1.0 equiv), Ni(COD)2 (2.8 mg, 0.0100 mmol, 0.10 equiv), (R)-DIFLUORPHOS 
(9.2 mg, 0.0120 mmol, 0.12 equiv), NaOtBu (19.3 mg, 0.200 mmol, 2.0 equiv), the appropriate 
heteroaryl chloride 6b-i (0.200 mmol, 2.0 equiv), a magnetic stirring bar, and toluene (0.5 mL) 
were added to a 1-dram vial. The vial was sealed with a cap containing a PTFE septum and 
removed from the glovebox. The reaction mixture was stirred at 85 °C in an oil bath for 48 h.  
The vial was removed from the oil bath and allowed to cool to room temperature.  The reaction 
mixture was filtered through short plug of silica gel (eluting with 20 mL of 3:2 hexanes:EtOAc).  
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The crude reaction mixture was concentrated under reduced pressure. The crude product was 
purified with a CombiFlash system with 5-10% ethyl acetate in hexanes as eluent to give the 
appropriate (R)-8-heteroaryl-8-methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-ones (7b-i).  
4.5.14 General Procedure L: Synthesis of (R)-2-Heteroaryl-2-methyl-2,3-dihydro-1H-
pyrrolizin-1-one (11a-d) and (S)-2-Methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-2,3-dihydro-
1H-pyrrolizin-1-one (11f) 
 
 
 
 
 
In a nitrogen-filled glovebox, 2-methyl-2,3-dihydro-1H-pyrrolizin-1-one (2m) (0.200 
mmol, 1.0 equiv), Ni(COD)2 (5.5 mg, 0.0200 mmol, 0.10 equiv), (R)-DIFLUORPHOS (18.4 mg, 
0.0240 mmol, 0.12 equiv),  NaOtBu (38.4 mg, 0.400 mmol, 2.0 equiv), benzonitrile (41.2 mg, 
0.400 mmol, 2.0 equiv), the appropriate heteroaryl bromide 10a-f (0.400 mmol, 2.0 equiv), a 
magnetic stirring bar, and toluene (1.0 mL) were added to a 1-dram vial. The vial was sealed 
with a cap containing a PTFE septum and removed from the glovebox. The reaction mixture was 
stirred at 25 °C for 48 h.  The vial was removed from the oil bath and allowed to cool to room 
temperature.  The reaction mixture was filtered through short plug of silica gel (eluting with 20 
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mL of 3:2 hexanes:EtOAc).  The crude reaction mixture was concentrated under reduced 
pressure. The crude product was purified with a CombiFlash system with 5-20% ethyl acetate in 
hexanes as eluent to give the appropriate (R)-2-heteroaryl-2-methyl-2,3-dihydro-1H-pyrrolizin-1-
one (11a-d) and (S)-2-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-2,3-dihydro-1H-pyrrolizin-1-
one (11f).  
 (R)-8-Methyl-8-(pyridin-2-yl)-7,8-dihydropyrido[1,2-a]indol-
9(6H)-one (7a): Prepared according to the general procedure J from 2b 
(20.0 mg, 0.100 mmol) and 2-chloropyridine 6a (22.8 mg, 0.200 
mmol). The crude product was purified by silica gel chromatography with a CombiFlash system 
(4 g column, 100:0→90:10 hexanes/EtOAc) to give 7a as a light yellow solid in 72% yield (20.0 
mg, 0.0724 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) 
tR 21.2 min (major); tR 28.6 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 99:1, 1.0 mL/min] to be 99% ee. [α]D
23
 = -79.2° (c 0.78, 
CHCl3). 
1
H NMR (600 MHz, CDCl3) δ 1.66 (s, 3H), 2.49 (ddd, J = 13.8, 11.6, 5.0 Hz, 1H), 3.24 
(ddd, J = 13.8, 3.2, 3.2 Hz, 1H), 4.01 (ddd, J = 11.6, 11.6, 3.2 Hz, 1H), 4.29 (ddd, J = 11.6, 5.0, 
3.2 Hz, 1H), 7.12 – 7.15 (m, 2H), 7.25 – 7.28 (m, 2H), 7.33 (ddd, J = 8.4, 6.8, 1.2 Hz, 1H), 7.40 
(s,  1H), 7.57 (ddd, J = 8.4, 8.4, 1.2 Hz, 1H), 7.71 (dt, J = 8.2, 0.8 Hz, 1H), 8.57 (m, 1H). 
13
C 
NMR (151 MHz, CDCl3) δ 25.4, 35.5, 39.5, 52.7, 106.8, 110.7, 121.4, 122.2, 122.5, 123.7, 
125.9, 127.4, 133.8, 137.3, 137.6, 149.6, 160.7, 193.2. HRMS (ESI): Calcd. for C18H17N2O
+
 
([M+H]
+
): 277.1335, Found: 277.1339. 
 
 (R)-8-(5-Fluoropyridin-2-yl)-8-methyl-7,8-dihydropyrido[1,2-
a]indol-9(6H)-one (7b): Prepared according to the general 
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procedure K from 2b (20.0 mg, 0.100 mmol) and 2-chloro-5-fluoropyridine (6b) (26.4 mg, 0.200 
mmol). The crude product was purified by silica gel chromatography with a CombiFlash system 
(4 g column, 100:0→90:10 hexanes/EtOAc) to give 7b as a yellow oil in 82% yield (24.2 mg, 
0.0822 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 
20.0 min (major); tR 26.1 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical 
Ind., Ltd.) hexane/i-PrOH, 99:1, 1.0 mL/min] to be 98% ee. [α]D
23
 = +112.0° (c 0.52, CHCl3). 
1
H 
NMR (400 MHz, CDCl3) δ 1.64 (s, 3H), 2.48 (ddd, J = 13.9, 11.6, 5.0 Hz, 1H), 3.20 (ddd, J = 
13.9, 3.6, 3.6 Hz, 1H), 4.03 (ddd, J = 11.6, 11.6, 3.6 Hz, 1H), 4.30 (ddd, J = 11.6, 5.0, 3.6 Hz, 
1H), 7.14 (ddd, J = 8.0, 6.8, 1.0 Hz, 1H), 7.28 – 7.30 (m, 3H), 7.34 (ddd, J = 8.4, 6.8, 1.0 Hz, 
1H), 7.40 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 8.41 (t, J = 1.6 Hz, 1H). 
13
C NMR (101 MHz, 
CDCl3) δ 25.5, 35.4, 39.4, 52.2, 107.1, 110.7, 121.5, 123.1 (d, J = 4.2 Hz, 1C), 123.7, 124.0 (d, J 
= 18.3 Hz, 1C), 126.1, 127.4, 133.5, 137.6, 137.8, 156.7 (d, J = 3.7 Hz, 1C), 158.8 (d, J = 257.2 
Hz, 1C), 193.0. 
19
F NMR (CDCl3, 376 MHz): δ -129.4 (m, 1F). HRMS (ESI): Calcd. for 
C18H16FN2O
+
 ([M+H]
+
): 295.1241, Found: 295.1243. 
 
 (R)-6-(8-Methyl-9-oxo-6,7,8,9-tetrahydropyrido[1,2-a]indol-8-
yl)nicotinonitrile (7c): Prepared according to the general 
procedure K from 2b (20.0 mg, 0.100 mmol) and 6-chloronicotinonitrile 6c (27.8 mg, 0.200 
mmol). The crude product was purified by silica gel chromatography with a CombiFlash system 
(4 g column, 100:0→90:10 hexanes/EtOAc) to give 7c as a light yellow solid in 93% yield (28.1 
mg, 0.0932 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) 
tR 22.5 min (major); tR 39.0 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 29% ee. [α]D
25
 = +4.2° (c 0.95, 
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CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 1.67 (s, 3H), 2.51 (ddd, J = 14.0, 11.0, 5.0 Hz, 1H), 3.24 
(ddd, J = 14.0, 3.9, 3.9 Hz, 1H), 4.05 (ddd, J = 12.6, 11.0, 3.9 Hz, 1H), 4.32 (ddd, J = 12.6, 5.0, 
3.9 Hz, 1H), 7.16 (ddd, J = 8.2, 6.9, 0.8 Hz, 1H), 7.29 (dd, J = 8.4, 0.8 Hz, 1H), 7.37 (ddd, J = 
8.4, 6.9, 1.0 Hz, 1H), 7.41 (s, 1H), 7.46 (dd, J = 8.4, 0.8 Hz, 1H), 7.72 (ddd, J = 8.2, 0.8, 0.8 Hz, 
1H), 7.86 (dd, J = 8.4, 2.2 Hz, 1H), 8.83 (dd, J = 2.2, 0.8 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) 
δ 25.3, 35.0, 39.3, 53.0, 107.7, 108.8, 110.7, 116.8, 121.7, 122.4, 123.8, 126.4, 127.4, 133.2, 
137.8, 140.2, 152.3, 165.5, 191.8. HRMS (ESI): Calcd. for C19H16N3O
+
 ([M+H]
+
): 302.1288, 
Found: 302.1296. 
 
 (R)-8-Methyl-8-(5-(trifluoromethyl)pyridin-2-yl)-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one (7d): Prepared according 
to the general procedure K from 2b (20.0 mg, 0.100 mmol) and 
2-chloro-5-(trifluoromethyl)pyridine 6d (36.4 mg, 0.200 mmol). The crude product was purified 
by silica gel chromatography with a CombiFlash system (4 g column, 100:0→90:10 
hexanes/EtOAc) to give 7d as a yellow oil in 55% yield (19.0 mg, 0.0552 mmol). The 
enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 17.4 min (major); tR 
19.7 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-
PrOH, 98:2, 0.5 mL/min] to be 65% ee. [α]D
23
 = +34.0° (c 0.76, CHCl3). 
1
H NMR (400 MHz, 
CDCl3) δ 1.68 (s, 3H), 2.51 (ddd, J = 13.9, 11.6, 5.0 Hz, 1H), 3.26 (ddd, J = 13.9, 3.8, 3.8 Hz, 
1H), 4.05 (ddd, J = 12.2, 11.6, 3.8 Hz, 1H), 4.32 (ddd, J = 12.2, 5.0, 3.8 Hz, 1H),  7.15 (ddd, J = 
8.0, 6.8, 0.8 Hz, 1H), 7.28 – 7.30 (m, 1H), 7.36 (ddd, J = 8.0, 6.8, 0.6 Hz, 1H), 7.41 (s, 1H), 7.43 
– 745 (m, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.81 (dd, J = 8.4, 2.0 Hz, 1H), 8.83 (d, J = 2.0 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 25.4, 35.2, 39.4, 52.8, 107.4, 110.7, 121.6, 122.0, 123.7, 123.8 
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(q, J = 273.6 Hz, 1C), 125.5 (q, J = 33.3 Hz, 1C), 126.2, 127.4, 133.4, 134.3 (q, J = 4.0 Hz, 1C), 
137.7, 146.5 (q, J = 4.0 Hz, 1C), 164.9 (q, J = 2.0 Hz, 1C), 192.3. 
19
F NMR (CDCl3, 376 MHz): 
δ -62.7 (s, 3F). HRMS (ESI): Calcd. for C19H16F3N2O
+
 ([M+H]
+
): 345.1209, Found: 345.1218. 
  
 (R)-8-Methyl-8-(6-methylpyridin-2-yl)-7,8-dihydropyrido[1,2-
a]indol-9(6H)-one (7e): Prepared according to the general procedure 
K from 2b (20.0 mg, 0.100 mmol) and 2-chloro-6-methylpyridine 6e 
(25.6 mg, 0.200 mmol). The crude product was purified by silica gel chromatography with a 
CombiFlash system (4 g column, 100:0→90:10 hexanes/EtOAc) to give 7e as a yellow solid in 
72% yield (21.0 mg, 0.0723 mmol). The enantiomeric excess was determined by HPLC analysis 
(254 nm, 25 °C) tR 12.2 min (major); tR 17.6 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) 
(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 99:1, 1.0 mL/min] to be 75% ee. [α]D
25
 = 
+171.8° (c 0.74, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 1.63 (s, 3H), 2.43 (ddd, J = 13.8, 11.8, 
5.2 Hz, 1H), 2.51 (s, 3H), 3.29 (ddd, J = 13.8, 3.8, 3.8 Hz, 1H), 4.04 (ddd, J = 11.8, 11.8, 3.8 Hz, 
1H), 4.27 (ddd, J = 11.8, 5.2, 3.8 Hz, 1H), 6.96 – 7.03 (m, 2H), 7.13 (ddd, J = 7.8, 6.7, 1.2 Hz, 
1H), 7.26 – 7.35 (m, 2H), 7.37 (s, 1H), 7.41 (t, J = 7.8 Hz, 1H), 7.71 (d, J = 8.0, 1H). 13C NMR 
(101 MHz, CDCl3) δ 25.0, 25.5, 35.2, 39.6, 52.6, 106.6, 110.6, 118.9, 121.3, 121.9, 123.6, 125.7, 
127.3, 133.9, 137.2, 137.5, 158.4, 159.7, 193.6. HRMS (ESI): Calcd. for C19H19N2O
+
 ([M+H]
+
): 
291.1492, Found: 291.1495. 
 
 (R)-8-(6-Methoxypyridin-2-yl)-8-methyl-7,8-dihydropyrido[1,2-
a]indol-9(6H)-one (7f): Prepared according to the general 
procedure K from 2b (20.0 mg, 0.100 mmol) and 2-chloro-6-
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methoxypyridine 6f (28.8 mg, 0.200 mmol). The crude product was purified by silica gel 
chromatography with a CombiFlash system (4 g column, 100:0→90:10 hexanes/EtOAc) to give 
7f as a light yellow solid in 75% yield (23.1 mg, 0.0754 mmol). The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 12.0 min (major); tR 15.6 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 98:2, 1.0 
mL/min] to be 95% ee. [α]D
23
 = +183.8° (c 0.54, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 1.65 (s, 
3H), 2.46 (ddd, J = 13.8, 12.0, 5.0 Hz, 1H), 3.14 (ddd, J = 13.8, 3.8, 3.0 Hz, 1H), 3.81 (s, 3H), 
3.98 (ddd, J = 12.0, 12.0, 3.8 Hz, 1H), 4.29 (ddd, J = 12.0, 5.0, 3.0 Hz, 1H), 6.57 (dd, J = 8.2, 0.6 
Hz, 1H), 6.78 (dd, J = 7.4, 0.6 Hz, 1H), 7.14 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.26 – 7.36 (m, 2H), 
7.38 (s, 1H), 7.43 (dd, J = 8.2, 7.4 Hz, 1H), 7.72 (ddd, J = 8.2, 1.2, 1.2 Hz, 1H). 
13
C NMR (101 
MHz, CDCl3) δ 24.8, 35.8, 39.5, 52.4, 53.5, 106.4, 109.4, 110.6, 114.5, 121.3, 123.6, 125.8, 
127.4, 134.1, 137.5, 139.6, 158.6, 163.8, 193.2. HRMS (ESI): Calcd. for C19H19N2O2
+
 
([M+H]
+
): 307.1441, Found: 307.1445. 
 
 (R)-8-(4-Methoxypyridin-2-yl)-8-methyl-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one (7g): Prepared according 
to the general procedure K from 2b (20.0 mg, 0.100 mmol) and 2-
chloro-4-methoxypyridine 6g (28.8 mg, 0.200 mmol). The crude product was purified by silica 
gel chromatography with a CombiFlash system (4 g column, 100:0→90:10 hexanes/EtOAc) to 
give 7g as a white solid in 50% yield (15.3 mg, 0.0499 mmol). The enantiomeric excess was 
determined by HPLC analysis (220 nm, 25 °C) tR 11.9 min (major); tR 14.4 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:5, 1.0 
mL/min] to be 86% ee. [α]D
25
 = +17.2° (c 0.46, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 1.63 (s, 
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3H), 2.45 (ddd, J = 13.8, 11.8, 5.1 Hz, 1H), 3.23 (ddd, J = 13.8, 3.2, 3.2 Hz, 1H), 3.74 (s, 3H), 
4.03 (ddd, J = 11.8, 11.8, 3.2 Hz, 1H), 4.28 (ddd, J = 11.8, 5.1, 3.2 Hz, 1H), 6.65 (dd, J = 5.8, 2.4 
Hz, 1H), 6.76 (d, J = 2.4 Hz, 1H), 7.13 (ddd, J = 8.0, 7.0, 0.6 Hz, 1H), 7.28 – 7.35 (m, 2H), 7.39 
(s, 1H), 7.71 (d, J = 8.0 Hz, 1H), 8.38 (d, J = 5.8 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 25.4, 
35.4, 39.6, 52.7, 55.4, 106.8, 108.3, 108.6, 110.7, 121.3, 123.6, 125.9, 127.4, 133.8, 137.6, 150.8, 
162.4, 166.6, 193.3. HRMS (ESI): Calcd. for C19H19N2O2
+
 ([M+H]
+
): 307.1441, Found: 
307.1443. 
 
 (R)-8-Methyl-8-(6-(trifluoromethyl)pyridin-3-yl)-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one (7h): Prepared according 
to the general procedure K from 2b (20.0 mg, 0.100 mmol) and 5-chloro-2-
(trifluoromethyl)pyridine 6h (36.4 mg, 0.200 mmol). The crude product was purified by silica 
gel chromatography with a CombiFlash system (4 g column, 100:0→90:10 hexanes/EtOAc) to 
give 7h as a yellow solid in 80% yield (27.7 mg, 0.0804 mmol). The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 16.1 min (major); tR 33.5 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 
mL/min] to be 99% ee. [α]D
23
 = +65.7° (c 1.03, CHCl3). 
1
H NMR (600 MHz, CDCl3) δ 1.72 (s, 
3H), 2.63 (ddd, J = 14.6, 10.1, 4.8 Hz, 1H), 2.89 (ddd, J = 14.6, 4.8, 4.8 Hz, 1H), 3.99 (ddd, J = 
12.5, 10.1, 4.8 Hz, 1H), 4.35 (ddd, J = 12.5, 4.8, 4.8 Hz, 1H), 7.18 (ddd, J = 8.4, 6.6, 0.6 Hz, 
1H), 7.29 – 7.30 (m, 1H), 7.39 (ddd, J = 8.4, 6.6, 0.8 Hz, 1H), 7.46 (s, 1H), 7.61 (d, J = 8.4 Hz, 
1H), 7.74 (d, J = 8.4 Hz, 1H), 7.78 (dd, J = 8.4, 2.0 Hz, 1H), 8.76 (d, J = 2.0 Hz, 1H). 
13
C NMR 
(151 MHz, CDCl3) δ 25.3, 36.4, 38.9, 48.9, 108.1, 110.6, 120.7 (q, J = 2.7 Hz, 1C), 121.7 (q, J = 
274.0 Hz, 1C), 121.9, 123.9, 126.7, 127.4, 133.0, 136.4, 137.8, 141.2, 147.3 (q, J = 35.0 Hz, 1C), 
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148.6, 191.4. 
19
F NMR (CDCl3, 565 MHz): δ -68.5 (s, 3F). HRMS (ESI): Calcd. for 
C19H16F3N2O
+
 ([M+H]
+
): 345.1209, Found: 345.1213. 
 
 (R)-8-Methyl-8-(thiophen-3-yl)-7,8-dihydropyrido[1,2-a]indol-
9(6H)-one (7i): Prepared according to the general procedure K from 2b 
(20.0 mg, 0.100 mmol) and 3-chlorothiophene 6i (23.8 mg, 0.200 mmol). The crude product was 
purified by silica gel chromatography with a CombiFlash system (4 g column, 100:0→90:10 
hexanes/EtOAc) to give 7i as a light yellow solid in 92% yield (27.2 mg, 0.0924 mmol). The 
enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 23.0 min (major); tR 
27.9 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-
PrOH, 98:2, 1.0 mL/min] to be 94% ee. [α]D
23
 = +84.2° (c 0.55, CHCl3). 
1
H NMR (400 MHz, 
CDCl3) δ 1.63 (s, 3H), 2.55 (ddd, J = 14.0, 11.8, 4.6 Hz, 1H), 2.70 (ddd, J = 14.0, 3.6, 3.6 Hz, 
1H), 3.94 (ddd, J = 11.8, 11.8, 3.6 Hz, 1H), 4.29 (ddd, J = 11.8, 4.6, 3.6 Hz, 1H), 6.96 (d, J = 1.4 
Hz, 1H), 7.04 (dd, J = 5.0, 1.4 Hz, 1H), 7.15 (t, J = 7.4 Hz, 1H), 7.25 – 7.36 (m, 3H), 7.41 (s, 
1H), 7.73 (d, J = 8.1 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 25.8, 37.1, 39.2, 48.1, 107.1, 
110.6, 121.4, 121.6, 123.7, 126.0, 126.1, 126.7, 127.4, 133.5, 137.5, 142.6, 192.6. HRMS (ESI): 
Calcd. for C17H16NOS
+
 ([M+H]
+
): 282.0947, Found: 282.0951. 
 
 (R)-2-Methyl-2-(pyridin-2-yl)-2,3-dihydro-1H-pyrrolizin-1-one (11a): 
Prepared according to the general procedure L from 2m (27.0 mg, 0.199 mmol) 
and 2-bromopyridine 10a (63.1 mg, 0.399 mmol). The crude product was 
purified by silica gel chromatography with a CombiFlash system (4 g column, 100:0→90:10 
hexanes/EtOAc) to give 11a as a light yellow oil in 99% yield (42.0 mg, 0.198 mmol). The 
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enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 10.6 min (major); tR 
13.7 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-
PrOH, 90:10, 1.0 mL/min] to be 97% ee. [α]D
25
 = -136.8° (c 0.89, CHCl3). 
1
H NMR (400 MHz, 
CDCl3) δ 1.77 (s, 3H), 4.24 (d, J = 11.4 Hz, 1H), 5.31 (d, J = 11.4 Hz, 1H), 6.55 (dd, J = 4.0, 2.2 
Hz, 1H), 6.78 (dd, J = 4.0, 1.0 Hz, 1H), 7.09 (m, 1H), 7.16 (ddd, J = 7.2, 4.8, 1.2 Hz, 1H), 7.61 – 
7.69 (m, 2H), 8.51 (ddd, J = 4.8, 1.7, 1.2 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 24.6, 55.8, 
60.0, 109.3, 117.5, 121.5, 122.5, 123.6, 131.4, 137.1, 149.3, 160.7, 191.9. HRMS (ESI): Calcd. 
for C13H13N2O
+
 ([M+H]
+
): 213.1022, Found: 213.1024. 
 
 (R)-2-Methyl-2-(6-methylpyridin-2-yl)-2,3-dihydro-1H-pyrrolizin-1-one 
(11b): Prepared according to the general procedure L from 2m (27.0 mg, 0.199 
mmol) and 2-bromo-6-methylpyridine 10b (68.7 mg, 0.399 mmol). The crude 
product was purified by silica gel chromatography with a CombiFlash system (4 
g column, 100:0→90:10 hexanes/EtOAc) to give 11b as a light yellow oil in 71% yield (32.0 
mg, 0.141 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) 
tR 8.00 min (major); tR 10.2 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 95% ee. [α]D
23
 = -53.2° (c 0.53, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 1.74 (s, 3H), 2.47 (s, 3H), 4.20 (d, J = 11.4 Hz, 1H), 5.41 
(d, J = 11.4 Hz, 1H), 6.54 (dd, J = 4.0, 2.2 Hz, 1H), 6.77 (dd, J = 4.0, 1.0 Hz, 1H), 7.00 – 7.01 
(m, 1H), 7.08 (m, 1H), 7.41 – 7.43 (m, 1H), 7.53 (t, J = 7.6 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 24.89, 24.92, 55.6, 59.9, 109.0, 117.2, 118.3, 121.9, 123.4, 131.5, 137.2, 158.0, 159.8, 
192.3. HRMS (ESI): Calcd. for C14H15N2O
+
 ([M+H]
+
): 227.1179, Found: 227.1179. 
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 (R)-2-(6-Methoxypyridin-2-yl)-2-methyl-2,3-dihydro-1H-pyrrolizin-1-one 
(11c): Prepared according to the general procedure L from 2m (27.0 mg, 0.199 
mmol) and 2-bromo-6-methoxypyridine 10c (75.1 mg, 0.399 mmol). The crude 
product was purified by silica gel chromatography with a CombiFlash system (4 
g column, 100:0→90:10 hexanes/EtOAc) to give 11c as a light yellow oil in 51% yield (24.8 mg, 
0.102 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 
8.92 min (major); tR 11.5 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical 
Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 95% ee. [α]D
23
 = -60.2° (c 0.80, CHCl3). 
1
H 
NMR (400 MHz, CDCl3) δ 1.74 (s, 3H), 3.77 (s, 3H), 4.21 (d, J = 11.2 Hz, 1H), 5.16 (d, J = 11.2 
Hz, 1H), 6.55 (dd, J = 4.0, 2.2 Hz, 1H), 6.60 (dd, J = 8.2, 0.6 Hz, 1H), 6.78 (dd, J = 4.0, 1.0 Hz, 
1H), 7.07 – 7.08 (m, 1H), 7.10 (dd, J = 7.4, 0.6 Hz, 1H), 7.54 (dd, J = 8.2, 7.4 Hz, 1H). 13C 
NMR (101 MHz, CDCl3) δ 23.4, 53.4, 56.1, 59.9, 109.1, 109.5, 113.7, 117.3, 123.2, 131.7, 
139.6, 158.4, 163.5, 191.9. HRMS (ESI): Calcd. for C14H15N2O2
+
 ([M+H]
+
): 243.1128, Found: 
243.1131. 
 
 (R)-2-(5-Fluoropyridin-2-yl)-2-methyl-2,3-dihydro-1H-pyrrolizin-1-one 
(11d): Prepared according to the general procedure L from 2m (27.0 mg, 0.199 
mmol) and 2-bromo-5-fluoropyridine 10d (70.3 mg, 0.399 mmol). The crude 
product was purified by silica gel chromatography with a CombiFlash system (4 
g column, 100:0→90:10 hexanes/EtOAc) to give 11d as a colorless oil in 48% yield (22.0 mg, 
0.0955 mmol). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 
10.1 min (major); tR 12.9 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical 
Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 95% ee. [α]D
25
 = -113.6° (c 0.81, CHCl3). 
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1
H NMR (400 MHz, CDCl3) δ 1.75 (s, 3H), 4.24 (d, J = 11.6 Hz, 1H), 5.29 (d, J = 11.6 Hz, 1H), 
6.56 (dd, J = 4.0, 2.2 Hz, 1H), 6.79 (dd, J = 4.0, 1.0 Hz, 1H), 7.09 – 7.10 (m, 1H), 7.38 (ddd, J = 
8.8, 8.2, 3.0 Hz, 1H), 7.66 (ddd, J = 8.8, 4.0, 0.4 Hz, 1H), 8.34 (d, J = 3.0 Hz, 1H). 
13
C NMR 
(101 MHz, CDCl3) δ 24.9, 55.7, 59.5 (d, J = 1.0 Hz, 1C), 109.5, 117.6, 122.5 (d, J = 5.0 Hz, 1C), 
123.7 (d, J = 2.0 Hz, 1C), 123.9, 131.1, 137.3 (d, J = 24.2 Hz, 1C), 156.5 (d, J = 4.0 Hz, 1C), 
158.9 (d, J = 257.5 Hz, 1C), 191.5. 
19
F NMR (CDCl3, 376 MHz): δ -129.7 (s, 1F). HRMS (ESI): 
Calcd. for C13H12FN2O
+
 ([M+H]
+
): 231.0928, Found: 231.0931.  
 
 (S)-2-Methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-2,3-dihydro-1H-
pyrrolizin-1-one (11f): Prepared according to the general procedure L from 
2m (27.0 mg, 0.199 mmol) and 5-bromo-2-(trifluoromethyl)pyridine 10f (90.3 
mg, 0.399 mmol). The crude product was purified by silica gel 
chromatography with a CombiFlash system (4 g column, 100:0→90:10 hexanes/EtOAc) to give 
11f as a colorless oil in 23% yield (13.0 mg, 0.046 mmol). The enantiomeric excess was 
determined by HPLC analysis (254 nm, 25 °C) tR 21.7 min (major); tR 26.2 min (minor) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 
mL/min] to be 92% ee. [α]D
25
 = -51.9° (c 0.38, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 1.82 (s, 
3H), 4.45 (d, J = 11.8 Hz, 1H), 4.62 (d, J = 11.8 Hz, 1H), 6.63 (dd, J = 4.0, 2.2 Hz, 1H), 6.88 
(dd, J = 4.0, 0.6 Hz, 1H), 7.12 (m, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.89 (dd, J = 8.2, 2.0 Hz, 1H), 
8.68 (d, J = 2.0 Hz, 1H). 
13
C NMR (101 MHz, CDCl3) δ 24.0, 55.9, 57.7, 110.6, 118.5, 120.7 (q, 
J = 2.7 Hz, 1C), 121.7 (q, J = 275.0 Hz, 1C), 124.0, 130.8, 135.5, 141.7, 147.4 (q, J = 35.1 Hz, 
1C), 148.3, 190.2. 
19
F NMR (CDCl3, 376 MHz): δ -68.2 (s, 3F). HRMS (ESI): Calcd. for 
C14H12F3N2O
+
 ([M+H]
+
): 281.0896, Found: 281.0896. 
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4.5.15 Procedure for One-pot Synthesis of (R)-8-(3-Methoxyphenyl)-8-methyl-7,8-
dihydropyrido[1,2-a]indol-9(6H)-one (5d) 
 
 
 
In a nitrogen-filled glovebox, 1-(but-3-en-1-yl)-1H-indole-2-carboxaldehyde (1b) 
(20.0 mg, 0.100 mmol, 1.0 equiv) was added to a 1-dram vial containing solution of 
Ni(COD)2 (1.4 mg, 0.00500 mmol, 0.050 equiv) and IAd (2.0 mg, 0.00600 mmol, 0.060 
equiv) in mesitylene (0.5 mL).  The vial was sealed with a PTFE/silicone-lined septum cap 
and removed from the glovebox. The reaction mixture was stirred at 165 °C in an oil bath 
for 10 h. The vial was removed from the oil bath and allowed to cool to room temperature. 
The reaction mixture was allowed to stir in air at room temperature for 5-10 min. The vial 
was taken inside the glove box and Ni(COD)2 (5.6 mg, 0.0200 mmol, 0.20 equiv), (R)-
BINAP (15.0 mg, 0.0240 mmol, 0.24 equiv), NaOtBu (19.3 mg, 0.200 mmol, 2.0 equiv), 1-
chloro-3-methoxybenzene (4d) (28.6 mg, 0.200 mmol, 2.0 equiv), and toluene (0.5 mL) 
were added. The vial was sealed and removed from the glovebox. The reaction mixture was 
stirred at 65 °C in an oil bath for 48 h.  The vial was removed from the oil bath and allowed 
to cool to room temperature.  The reaction mixture was filtered through a short plug of silica 
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gel (eluting with 20 mL of 3:2 hexanes:EtOAc). The crude reaction mixture was 
concentrated under reduced pressure. The crude product was purified with a CombiFlash 
system with 10% ethyl acetate in hexanes as eluent to give (R)-8-(3-methoxyphenyl)-8-
methyl-7,8-dihydropyrido[1,2-a]indol-9(6H)-one (5d) as a light yellow solid in 70% yield 
(21.5 mg, 0.0704 mmol). The enantiomeric excess was determined by HPLC analysis (254 
nm, 25 °C) tR 30.6 min (major); tR 41.2 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) 
(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 99:1, 1.0 mL/min] to be 98% ee. [α]D
24
 = 
+125.4° (c 0.92, CHCl3). 
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CHAPTER 5  
 
NICKEL PHOSPHIDE (Ni2P) NANOCRYSTAL CATALYZED HYDROGENATION OF 
PHENYLACETYLENE 
 
Chapter would be modified for publication 
 
Avipsa Ghosh, Himashi Andaraarachchi, Javier Vela* and Levi M. Stanley* 
5.1 Abstract 
Hydrogenation of phenylacetylene catalyzed by Ni2P nanocrystals at 100 °C with 40 
bar H2 is reported. The model reaction is studied with both hollow and solid Ni2P 
nanocrystals in two different solvents (1,4-dioxane and 1-propanol). Recycling studies in 
both solvents demonstrated increase in catalytic activity of Ni2P nanocrystals over reaction 
cycles. Structural characterization of recycled Ni2P nanocrystals via powder XRD, TEM and 
XPS analyses revealed reduction in the size of hollow nanoparticles along with the 
formation of Ni(II) species after the hydrogenation reaction. Systematic characterization of 
Ni2P nanocrystals isolated after each reaction throughout the lifetime of the recycling study 
(in both 1,4-dioxane and 1-propanol) has been demonstrated using powder XRD, TEM and 
XPS analyses. Hydrogenation of phenylacetylene in 1,4-dioxane catalyzed by Ni2P 
nanocrystal has been recycled up to 8 times without any significant loss in reactivity. 
However, hydrogenation of phenylacetylene in 1-propanol catalyzed by Ni2P nanocrystal 
demonstrated steady drop in the yield of product over recycling. Use of NiCl2 as precursor 
for synthesis of Ni2P nanocrystal generated a mixture of solid and hollow Ni2P nanocrystal, 
while Ni(OAc)2 precursor exclusively forms hollow Ni2P nanocrystal having smaller 
particle size as compared to the ones synthesized from NiCl2. These smaller, hollow Ni2P 
nanocrystals obtained from Ni(OAc)2 as nickel precursor, has been shown to be catalytically 
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more active than the mixture of solid and hollow Ni2P nanocrystals as synthesized from 
NiCl2 as nickel precursor. 
5.2 Introduction 
Nanocatalysis has been a subject of extensive interest because of the novel catalytic 
properties associated with nanostructures, including highly enhanced reactivity and selectivity of 
nanoparticle catalysts as compared to their bulk counterparts.
1
 The intrinsic properties of a metal 
nanoparticle are a function of its size, shape, composition, crystallinity, and structure.
2
 In order 
to utilize the power of these nanocatalysts to their true potential, a detailed understanding of the 
origin of their enhanced performance is required. Many experimental studies on nanocatalysts 
have focused on correlating catalytic activity with particle size.
3
 While particle size is an 
important consideration, many other factors such as geometry, composition, shape, oxidation 
state, and chemical/physical environment can play a role in determining nanocrystals reactivity.
4
 
However, the exact relationship between these parameters and nanocrystal catalytic performance 
may be system dependent, and is yet to be determined for many nanoscale catalysts. Thus, in the 
last two decades, considerable effort has been dedicated to the systematic investigation of the 
influence of the nanoparticle preparation method, size, shape, and nanoparticle-metal oxide 
support interaction on catalytic performance.
2, 3, 4
 
Metal phosphides (MPs)
5
 are a class of materials with various compositions and ratios 
that show fascinating properties in magnetic, electronic, and catalytic applications due to their 
specific structural properties. During last few decades, their catalytic properties have garnered 
extensive research interest. For instance, several studies have shown that transition metal 
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phosphides (e.g., MoP, CoP, Fe2P, and Ni2P) display high activity toward hydrodesulfurization 
(HDS)
6
 and hydrodenitrogeneration (HDN) reactions.
4a
  
The nickel-rich phosphides,
7
 having a metallic character, have been used as 
heterogeneous catalysts mainly in hydrotreating reactions. An early use of bulk Ni2P was 
reported for the reduction of nitrobenzene,
8
 but was not studied further. Reports during the 1980s 
demonstrated that phosphorus-containing amorphous nickel catalysts exhibited attenuated 
hydrogenation activities compared with nickel, due to the electron-withdrawing effect of the 
phosphorus on the nickel. In the next decade, efforts concentrated on the crystallized phases, as a 
wide variety of nickel phosphides were constructed, with stoichiometry ranging from Ni3P to 
NiP3.
9
 Their oxidation states and electronic properties strongly relied on the Ni/P ratio.
10
 Among 
the Ni-rich phases (Ni3P, Ni12P5, Ni5P4, and Ni2P), the Ni2P phase has been studied most 
extensively, particularly due its higher stability upon sulfur exposure, thus making it an efficient 
catalyst for hydrodesulfurization processes.
11
  
Recently, Ni2P nanocrystals have been studied in the context of selective hydrogenation 
of alkynes. Mezailles, Sanchez, Corma and coworkers in 2012 reported that well-defined 25 nm 
Ni2P nanoparticles act as a colloidal catalyst for the chemoselective hydrogenation of terminal 
and internal alkynes.
12
 In this study, cis-alkenes were obtained as products under mild reaction 
conditions (6 bar H2, 85 °C) with good yield (up to 95%) and selectivity (up to 99%). The 
authors noted that the phosphorus inserted in the Ni-P nanoparticles was critical for the 
selectivity of the nanocatalyst.  
Last year, He, Wei and coworkers reported a new synthetic strategy for the fabrication of 
various alumina supported nickel phosphides (Ni12P5, Ni2P, and NiP2) with particle size ranging 
from 5 to 15 nm via a two-step procedure: preparation of supported Ni particles from layered 
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double hydroxide precursors, followed by a further reaction with a certain amount of red 
phosphorus.
13
 They evaluated the activity of these alumina supported metal phosphides toward 
selective hydrogenation of phenylacetylene and the Ni2P/Al2O3 catalyst was found to exhibit 
higher selectivity to styrene (up to 88%) than Ni12P5/Al2O3 (48%), NiP2/Al2O3 (66%), and 
Ni/Al2O3 (1%) catalysts. EXAFS and in situ IR measurements revealed that the incorporation of 
P increases the bond length of Ni−Ni, which imposes a key influence on the adsorption state of 
alkene intermediates: as the Ni−Ni bond length extends to 0.264 nm, the alkene intermediate 
undergoes di-π(C=C) adsorption, facilitating its desorption and the resulting enhanced 
selectivity. They further noted that electron transfer occurs from Ni to P, as confirmed by 
EXAFS, XPS, and in situ CO-IR experiment, in which the positively charged Ni reduces the 
desorption energy of alkene and thus improves the reaction selectivity. 
In this study, we demonstrate a systematic study on the effects of phase, size, shape, 
oxidation state and preparation method of Ni2P nanocrystals on its catalytic activity toward 
hydrogenation of phenylacetylene. We further discuss the effect of recycling on the catalyst 
surface through characterization of recycled Ni2P nanocrystals via powder XRD, TEM AND 
XPS analyses. 
 
5.3 Results and Discussion 
5.3.1 Nanocrystalline Ni2P synthesized from NiCl2 and Ni(OAc)2 
Nanocrystalline Ni2P was synthesized by injecting an organophosphite precursor into a solution 
containing a nickel(II) source (chloride and acetate) and oleylamine in 1-octadecene (ODE) at 
275 °C.
9
 The phase, size and shape of the isolated nickel phosphide nanocryatals were 
determined using powder X-ray diffraction (XRD) and transmission electron microscopy (TEM). 
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Nickel phosphide nanocrystals synthesized from both nickel chloride and nickel acetate showed 
formation of Ni2P through XRD analysis (Table 5.1). TEM images revealed that Ni2P obtained 
from nickel acetate are hollow particles with 29 ± 6 nm diameter and Ni2P obtained from nickel 
chloride showed bimodal distribution with the presence of both solid (14 ± 3 nm) and hollow 
particles (58 ± 5 nm).  
Figure 5.1 represents the unit cell of Ni2P. The crystal structure of Ni2P is similar to that 
of Fe2P with space group P62m. The hexagonal unit cell contains two types of Ni atoms: Ni(I) of 
tetrahedral coordination and Ni(II) of square pyramidal coordination. There are two surfaces, 
Ni3P2 and Ni3P1 terminated. 
Table 5.1 Selected properties of nanocrystalline Ni2P synthesized from NiCl2 and Ni(OAc)2 
as Ni(II) precursors 
Entry Ni(II) 
precursor 
Shape Size (nm) XPS 
TEM XRD 
1 NiCl2 Solid 14 ± 3 17 ± 4 Ni2P 
Hollow 58 ± 5 
2  Ni(OAc)2 Hollow 29 ± 6 17 ± 2  Ni2P 
 
 
Figure 5.1 Unit cell of Ni2P nanocrystal 
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5.3.2 Shape- and Size-dependant catalytic activity of Ni2P nanocrystals toward 
hydrogenation of plenylacetylene 
To test the catalytic activity of Ni2P nanocrystals, we conducted hydrogenation 
reactions of phenylacetylene in presence of 30 mol% Ni2P (solid+hollow nanocrystals, 
synthesized from NiCl2) and 40 bar hydrogen pressure at 100 °C for 14 h in two different 
solvents (1,4-dioxane and 1-propanol) (Table 5.2). The hydrogenation reaction carried out in 
1,4-dioxane formed 23% styrene and 5% ethylbenzene (28% total yield with 4.6:1 
selectivity for styrene:ethylbenzene). To test if the Ni2P nanocrystals used in trial 1 could be 
recycled for another reaction, we isolated the crystalline Ni2P from the reaction mixture by 
centrifugation and subjected it to another hydrogenation reaction under identical reaction 
conditions. Trial 2 in 1,4-dioxane showed formation of 63% styrene and 7% ethylbenzene 
thus increasing the total yield (a+b) to 69% and selectivity towards styrene to 9:1. Due to 
the apparent increase in catalytic activity of Ni2P on recycling, we further recycled the same 
Ni2P for one more trial (trial 3). In trial 3, we observed formation of 47% styrene and 20% 
ethylbenzene thus reducing the selectivity toward formation of styrene to 2.3:1.  
A similar trend in activity of Ni2P was observed when the hydrogenation of 
phenylacetylene was carried out in 1-propanol as solvent under otherwise identical reaction 
conditions. While trial 1 in 1-propanol formed 34% styrene and 4% ethylbenzene (38% total 
yield with 8.5:1 selectivity for styrene:ethylbenzene), the total yield in trial 2 was increased 
to 71%. However, selectivity of the reaction decreased with formation of an almost equal 
mixture of styrene and ethylbenzene. Selectivity was completely lost in trial 3 as ethyl 
benzene was generated as the only product in 72% yield. 
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Table 5.2 Hydrogenation of phenylacetylene catalyzed by Ni2P (solid+hollow) 
 
Trial 1,4-Dioxane 1-Propanol 
Conv (%) Total yield 
(a+b) (%) 
a:b Conv (%) Total yield 
(a+b) (%) 
a:b 
1 40 28 4.6:1 99 38 8.5:1 
2 99 69 9:1 99 71 1:1.1 
3 99 67 2.3:1 99 72 0:1 
 
To confirm the integrity of the catalyst after three trials, XRD, TEM and XPS 
analyses of the isolated solid catalysts were performed and their results are tabulated in 
Table 5.3. Nanocrystals isolated after trial 3 in both 1,4-dioxane and 1-propanol were 
confirmed to be Ni2P by XRD analyses (Figure 5.3). Analysis of TEM images still showed 
bimodal distribution comprised of solid and hollow particles in both cases (Figure 5.2). 
However, the hollow particles present in Ni2P nanocrystals isolated from reactions in both 
1,4-dioxane and 1-propanol showed reduced particle size (Table 5.3, compare entries 2 and 
3 with entry 1). Moreover, XPS analyses (Figure 5.4, Table 5.4) indicated presence of Ni
2+
 
species on the catalyst surface along with Ni2P (Table 5.3, see entries 2 and 3). 
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Table 5.3 Selected properties of nanocrystalline Ni2P before and after hydrogenation 
reaction of phenylacetylene 
Entry Ni2P Shape Size (nm) XPS (Oxidation 
state)  
TEM XRD 
1 Before trial 1 Solid 14 ± 3 17 ± 4 Ni2P 
Hollow 58 ± 5 
2  After trial 3 
(1,4-dioxane) 
Solid 17  ± 2  21 ± 2 Ni2P, Ni
2+
 
Hollow 37 ± 6  
3 After trial 3 
(1-propanol) 
Solid 16 ± 3 22 ± 6 Ni2P, Ni
2+
 
Hollow 40 ± 7 
 
 
Figure 5.2 TEM images of A) Ni2P B) Ni2P after trial 3 in 1,4-dioxane C) Ni2P after trial 3 
in 1-propanol 
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Figure 5.3 Powder XRD patterns of A) Ni2P B) Ni2P after trial 3 in 1,4-dioxane C) Ni2P 
after trial 3 in 1-propanol 
 
 
Figure 5.4 XPS of A) Ni2P B) Ni2P after trial 3 in 1,4-dioxane C) Ni2P after trial 3 in 1-
propanol 
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Table 5.4 Chemical state-Binding energy (eV) correlation chart 
Chemical State Binding Energy Ni 2p3/2 (eV) Binding Energy P 2p3/2 (eV) 
Ni2P 852.9 -- 
NiO 853.7 -- 
Ni(OH)2 855.6 -- 
Metal phosphide -- ~129 
Metal phosphate -- ~133 
 
5.3.3 Systematic study of Ni2P nanocrystals through recycling reactions: Effect of 
recycling on shape, size and oxidation state of Ni2P nanocrystals 
To investigate the impact of shape of the Ni2P nanocrystals on its catalytic activity, 
we conducted hydrogenation reactions of phenylacetylene in the presence of 30 mol% Ni2P 
nanocrystals (hollow nanocrystals, synthesized from Ni(OAc)2) and 40 bar hydrogen 
pressure at 100 °C for 14 h in two different solvents (1,4-dioxane and 1-propanol) (Table 
5.5). In both solvents, 1,4-dioxane and 1-propanol, Ni2P nanocrystal was recycled for 8 
times.  
Trials 1 and 2 of the hydrogenation of phenylacetylene in 1,4-dioxane generated a 
mixture of styrene and ethylbenzene (entries 1 and 2). While styrene was the major product 
in first trial, ethyl benzene was the major product (89% yield) in trial 2 (1:15 styrene: 
ethylbenzene). In trial 3 through trial 8, ethyl benzene was formed as the only product in 
consistently high yields (83-89% yields).  
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Table 5.5 Recyclability of Ni2P nanocrystal (hollow nanocrystals, synthesized from 
Ni(OAc)2) catalyst in hydrogenation of phenylacetylene 
 
Trial 1,4-Dioxane 1-Propanol 
Conv (%) Total yield 
(a+b) (%) 
a:b Conv (%) Total yield 
(a+b) (%) 
a:b 
1 99 55 6.9:1 99 58 3.8:1 
2 99 95 1:15 99 96 0:1 
3 99 87 0:1 99 77 0:1 
4 99 86 0:1 99 68 0:1 
5 99 85 0:1 99 68 0:1 
6 99 83 0:1 99 63 0:1 
7 99 83 0:1 99 55 0:1 
8 99 89 0:1 99 59 0:1 
 
Hydrogenation of phenylacetylene in 1-propanol in the presence of hollow, 
nanocrystalline Ni2P generated 46% styrene and 12% ethylbenzene in the first trial (58% 
total yield, 3.8:1 styrene:ethylbenzene). In trial 2 through trial 8, the hydrogenation of 
phenylacetylene yielded ethylbenzene as the only product. While ethylbenzene was formed 
in 96% yield in trial 2, the yield of the product decreased progressively from 96% to 55% 
from trial 2 through trial 8.  
To investigate any modification of the hollow, nanocrystalline catalyst surface during 
recycling, we conducted multiple identical hydrogenation reactions of phenylacetylene in 
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the presence of hollow Ni2P catalysts in both 1,4-dioxane and 1-propanol. Nanocrystalline 
Ni2P catalysts were isolated after each trial from trial 1 through trial 4 for reactions in both 
solvents (Table 5.6 & Table 5.8) and the isolated Ni2P catalysts were subjected to XRD, 
TEM and XPS analyses. The results of TEM, PXRD, XPS analyses of Ni2P nanocrystals 
isolated after trials 1 through 4 in 1,4-dioxane are tabulated in Table 5.7. The results of 
TEM, PXRD, XPS analyses of Ni2P nanocrystals isolated after trials 1 through 4 in 1-
propanol are tabulated in Table 5.9. Analysis of TEM images of Ni2Ps isolated from 
reactions in both 1,4-dioxane and 1-propanol demonstrated sole presence of hollow Ni2P 
(Figures 5.5 & 5.8, Tables 5.7 & 5.9). However, these hollow Ni2P nanocrystals isolated 
after reactions in 1,4-dioxane and 1-propanol showed reduced particle size (Tables 5.7 & 
5.9). Moreover, XPS analyses indicated presence of Ni
2+
 species along with Ni2P in the 
nanocrystals isolated after hydrogenation reaction (Table 5.7, refer Table 5.4 for chemical 
state-binding energy correlation chart). 
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Table 5.6 Hydrogenation of phenyl acetylene in 1,4-dioxane  
 
Entry Trial Conv (%) a (%) b (%) Total Yield 
(%) 
a:b 
1 1 99 49 6 55 8.2:1 
 
 Ni2P isolated after trial 1 is subjected to PXRD, TEM and XPS analyses 
 
Entry Trial Conv (%) a (%) b (%) Total Yield 
(%) 
a:b 
2 1 99 67 3 70 22:1 
2 99 0 84 84 0:1 
 
 Ni2P isolated after trial 2 is subjected to PXRD, TEM and XPS analyses 
 
Entry Trial Conv (%) a (%) b (%) Total Yield 
(%) 
a:b 
3 1 99 46 16 62 2.9:1 
2 99 0 88 88 0:1 
3 99 0 86 86 0:1 
 
 Ni2P isolated after trial 3 is subjected to PXRD, TEM and XPS analyses 
 
Entry Trial Conv (%) a (%) b (%) Total Yield 
(%) 
a:b 
4 1 99 63 12 75 5.3:1 
2 99 0 89 89 0:1 
3 99 0 88 88 0:1 
4 99 0 85 85 0:1 
 
 Ni2P isolated after trial 4 is subjected to PXRD, TEM and XPS analyses 
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Table 5.7 Selected properties of nanocrystalline Ni2P before and after hydrogenation 
reaction of phenylacetylene in 1,4-dioxane 
Entry Ni2P Shape Size (nm) XPS (Oxidation 
state)  
TEM XRD 
1 Before trial 1 Hollow 29 ± 6 17 ± 2 Ni2P 
2  After trial 1  Hollow 27 ± 3 12 ± 1 Ni2P, Ni
2+
 
3 After trial 2  Hollow 28 ± 4 15 ± 1 Ni2P, Ni
2+
 
4 After trial 3 Hollow 22 ± 4 10 ± 1 Ni2P, Ni
2+
 
5 After trial 4 Hollow 28 ± 5 12 ± 1 Ni2P, Ni
2+
 
 
 
Figure 5.5 TEM images of A) Ni2P B) Ni2P after trial 1 C) Ni2P after trial 2 D) Ni2P after 
trial 3 E) Ni2P after trial 4 in 1,4-dioxane  
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Figure 5.6 Powder XRD patterns of A) Ni2P B) Ni2P after trial 1 C) Ni2P after trial 2 D) 
Ni2P after trial 3 E) Ni2P after trial 4 in 1,4-dioxane 
 
Figure 5.7 XPS of A) Ni2P B) Ni2P after trial 1 C) Ni2P after trial 2 D) Ni2P after trial 3 E) 
Ni2P after trial 4 in 1,4-dioxane 
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Table 5.8 Hydrogenation of phenyl acetylene in 1-propanol 
 
 
Entry Trial Conv (%) a (%) b (%) Total Yield 
(%) 
a:b 
1 1 99 44 15 59 3:1 
 
 Ni2P isolated after trial 1 is subjected to PXRD, TEM and XPS analyses 
 
Entry Trial Conv (%) a (%) b (%) Total Yield 
(%) 
a:b 
2 1 99 41 25 66 1.6:1 
2 99 0 80 80 0:1 
 
 Ni2P isolated after trial 2 is subjected to PXRD, TEM and XPS analyses 
 
Entry Trial Conv (%) a (%) b (%) Total Yield 
(%) 
a:b 
3 1 99 45 8 53 5.6:1 
2 99 0 70 70 0:1 
3 99 0 66 66 0:1 
 
 Ni2P isolated after trial 3 is subjected to PXRD, TEM and XPS analyses 
 
Entry Trial Conv (%) a (%) b (%) Total Yield 
(%) 
a:b 
4 1 99 43 10 53 4.3:1 
2 99 0 81 81 0:1 
3 99 0 66 66 0:1 
4 99 0 62 62 0:1 
 
 Ni2P isolated after trial 1 is subjected to PXRD, TEM and XPS analyses 
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Table 5.9 Selected properties of nanocrystalline Ni2P before and after hydrogenation 
reaction of phenylacetylene in 1-propanol 
Entry Ni2P Shape Size (nm) XPS (Oxidation 
state)  
TEM XRD 
1 Before trial 1 Hollow 29 ± 6 17 ± 2 Ni2P 
2  After trial 1  Hollow 30 ± 7 15 ± 1 Ni2P, Ni
2+
 
3 After trial 2  Hollow 28 ± 4 15 ± 2 Ni2P, Ni
2+
 
4 After trial 3 Hollow 27 ± 4 13 ± 1 Ni2P, Ni
2+
 
5 After trial 4 Hollow 24 ± 4 11 ± 2 Ni2P, Ni
2+
 
 
 
Figure 5.8 TEM images of A) Ni2P B) Ni2P after trial 1 C) Ni2P after trial 2 D) Ni2P after 
trial 3 E) Ni2P after trial 4 in 1-propanol  
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Figure 5.9 Powder XRD patterns of A) Ni2P B) Ni2P after trial 1 C) Ni2P after trial 2 D) 
Ni2P after trial 3 E) Ni2P after trial 4 in 1-propanol 
5.4 Conclusions 
In conclusion, we have studied hydrogenation of phenylacetylene catalyzed by Ni2P 
nanocrystals at 100 °C with 40 bar H2 as a function of size and shape of Ni2P nanocrystals in 
1,4-dioxane and 1-propanol. Recycling studies in both solvents demonstrated an increase in 
catalytic activity of Ni2P nanocrystals toward hydrogenation of phenylacetylene over 
reaction cycles. Structural characterization of recycled Ni2P nanocrystals via powder XRD, 
TEM and XPS analyses revealed reduction in the size of hollow nanoparticles along with 
the formation of Ni(II) species after hydrogenation reaction. Systematic characterization of 
Ni2P nanocrystals isolated after each reaction throughout the lifetime of the recycling study 
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(in both 1,4-dioxane and 1-propanol) has been completed using powder XRD, TEM and 
XPS analytical techniques and in most cases, reduction in size of the hollow Ni2P 
nanocrystal has been observed after hydrogenation of phenylacetylene reactions. 
Hydrogenation of phenylacetylene in 1,4-dioxane catalyzed by Ni2P nanocrystal has been 
recycled up to 8 times without any significant loss in reactivity. However, hydrogenation of 
phenylacetylene in 1-propanol catalyzed by Ni2P nanocrystal demonstrated steady drop in 
the yield of product over recycling. Use of NiCl2 as precursor for synthesis of Ni2P 
nanocrystal generated a mixture of solid and hollow Ni2P nanocrystal, while Ni(OAc)2 
precursor exclusively forms hollow Ni2P nanocrystal having smaller particle size as 
compared to the ones synthesized from NiCl2. These smaller, hollow Ni2P nanocrystals 
obtained from Ni(OAc)2 as nickel precursor, has been shown to be catalytically more active 
than the mixture of solid and hollow Ni2P nanocrystals as synthesized from NiCl2 as nickel 
precursor. 
5.5 Experimental details 
5.5.1 Materials 
Nickel(II) chloride hexahydrate, triphenylphosphite were purchased from Strem 
chemicals; 1-octadecene (ODE, 90%) and oleylamine (80−90%) from Acros organics; and 
nickel(II) acetate, phenyl acetylene, styrene, ethyl benzene and dodecane from Sigma-Aldrich. 
All compounds were used as received and handled under an inert (dry N2 or Ar) atmosphere 
inside a glovebox or with a Schlenk line. 
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5.5.2 Nanocrystal synthesis 
5.5.2.1 Phosphite addition solution. Inside a glovebox filled with dry N2, 0.11 mL of P(OPh)3 
was thoroughly dissolved in ODE (1.00 g, 1.27 mL). 
5.5.2.2 General procedure for nanocrystal synthesis. Inside a three-neck flask, NiCl2·6H2O 
(26 mg, 0.10 mmol) or Ni(OAc)2 (18 mg, 0.10 mmol), oleylamine (270 mg, 1.00 mmol, 
0.33 mL), and ODE (5.00 g, 6.34 mL) were degassed under vacuum at 80 °C for 1 h, refilled 
with Ar, and heated to 275 °C. After 5 min, the organophosphite addition solution was 
quickly injected and stirred at this temperature for 1 h. The mixture was allowed to cool to 
room temperature, and nanocrystalline products were isolated by washing with toluene for 
two times and centrifugation at 4900 rpm for 5 min. 
5.5.4 Structural characterization 
Powder X-ray Diffraction (XRD) was measured using Cu Kα radiation on a Scintag 
XDS-2000 diffractometer. Transmission Electron Microscopy (TEM) was conducted on carbon-
coated copper grids using a FEI Technai G2 F20 field emission scanning transmission electron 
microscope (STEM) at 200 kV (point-to-point resolution <0.25 nm, line to line resolution <0.10 
nm). Particle dimensions were measured manually and/or with ImageJ for >50−100 particles. 
Averages are reported ± one standard deviation. 
5.5.3 Procedure for hydrogenation of phenylacetylene catalyzed by Ni2P nanocrystals 
5.5.3.1 General procedure. In a nitrogen-filled glovebox, Ni2P nanocrystals (13.4 mg, 0.090 
mmol, 0.30 equiv), phenylacetylene (30.7 mg, 0.300 mmol, 1.00 equiv), a magnetic stirring 
bar, and 1,4-dioxane (1.0 mL) or 1-propanol (1.0 mL) were added to a 20 mL vial. The vial 
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was sealed with a PTFE septum and removed from the glovebox. The septum was pierced 
with a 20-gauge needle and quickly placed in a pressure reactor. The pressure reactor was 
sealed and pressurized with hydrogen gas at 40 bar. The pressure reactor was placed in a 
pre-heated oil bath at 100 °C and the reaction mixture was stirred at the same temperature 
for 14 h. The pressure reactor was removed from oil bath after 14 h of stirring and cooled to 
room temperature. Once it reached room temperature, the hydrogen gas was released and the 
reaction vial was removed from the reactor. Dodecane (22.6 µL, 0.30 mmol) was added to 
the reaction mixture as an internal standard. 3.0 mL 1,4-dioxane or 1-propanol was added to 
the reaction mixture and stirred at room temperature for 5 min. The reaction mixture was 
centrifuged for 15 min at 5000 rpm and the supernatant liquid was injected for gas 
chromatographic (GC) analysis. The conversion of phenylacetylene and yields of styrene 
and ethylbenzene were calculated from the relative area of dodecane and analyte using a GC 
calibration curve. 
5.5.3.2 Procedure for recycling reactions. In a nitrogen-filled glovebox, Ni2P nanocrystals 
(13.4 mg, 0.090 mmol, 0.30 equiv), phenylacetylene (30.7 mg, 0.300 mmol, 1.00 equiv), a 
magnetic stirring bar, and 1,4-dioxane (1.0 mL) or 1-propanol (1.0 mL) were added to a 20 
mL vial. The vial was sealed with a PTFE septum and removed from the glovebox. The 
septum was pierced with a 20-gauge needle and quickly placed in a pressure reactor. The 
pressure reactor was sealed and pressurized with hydrogen gas at 40 bar. The pressure 
reactor was placed in a pre-heated oil bath at 100 °C and the reaction mixture was stirred at 
the same temperature for 14 h. The pressure reactor was removed from oil bath after 14 h of 
stirring and cooled to room temperature. Once it reached room temperature, the hydrogen 
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gas was released and the reaction vial was removed from the reactor. Dodecane (22.6 µL, 
0.30 mmol) was added to the reaction mixture as an internal standard. 3.0 mL 1,4-dioxane or 
1-propanol was added to the reaction mixture and stirred at room temperature for 5 min. The 
reaction mixture was centrifuged for 15 min at 5000 rpm and the supernatant liquid was 
injected for gas chromatographic (GC) analysis. The conversion of phenylacetylene and 
yields of styrene and ethylbenzene were calculated from the relative area of dodecane and 
analyte using a GC calibration curve. The solid catalyst was further washed with 3.0 mL 
solvent twice and isolated by centrifugation at 5000 rpm for 15 min. After removing the 
supernatant liquid, solid nanocrystals were used as catalyst for the next reaction in the same 
vial.  
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CHAPTER 6  
 
CONCLUSIONS AND OUTLOOK 
 
About 59% of the U.S FDA approved unique small-molecule drugs possess nitrogen 
heterocycles. These nitrogen heterocycles are currently used to treat human disease ranging 
from cancer to diabetes to microbial infections. The prevalence of nitrogen heterocycles in 
medicinally important compounds continues to drive research into strategies to form new 
heterocyclic scaffolds and methods that streamline the syntheses of complex heterocycles. 
To this end, we have developed catalytic, enantioselective intramolecular 
hydroacylation of N-vinylindole-2-carboxaldehydes in the presence of a readily accessible 
rhodium catalyst and form chiral, non-racemic dihydropyrroloindolones in high yields with 
excellent enantioselectivities. These reactions encompass a broad range of N-vinylindole-2-
carboxaldehydes bearing a variety of aryl and alkyl substituents on the olefin moiety and 
substitution throughout the indole core. In addition, catalyst loadings can be lowered to 0.2 
mol % with only modest impact on the yield and no impact on the enantioselectivity of the 
hydroacylations. This methodology could be extended to hydroacylations of N-allylindole- 
and N-allylpyrrole-2-carboxaldehydes in construction of six-membered rings that generates 
dihydropyridoindolones and dihydroindolizinones in moderate to high yields with excellent 
enantioselectivities. This study represents a rare example of alkene hydroacylation to 
generate nitrogen heterocycles and, to our knowledge, is only the first report of 
enantioselective alkene hydroacylation to generate chiral, non-racemic nitrogen 
heterocycles. More importantly, these hydroacylation reactions can be extended to the 
formation of six-membered nitrogen heterocycles in the absence of chelating functionality 
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within the substrates or introduced through additives. Additionally, these 
dihydropyrroloindolone and dihydropyridoindolone products can be readily transformed to 
dihydropyrroloindoles and dihydropyridoindoles that are core structures present in a variety 
of natural products and biologically relevant compounds. We believe the ability to form 
nitrogen heterocycles and medium-sized rings by alkene hydroacylation in the absence of 
chelation assistance will be of great interest to the chemistry community, and the knowledge 
gained on catalyst design principles will extend to additional systems and will significantly 
expand the classes of ketones accessible by alkene hydroacylation. 
We have also demonstrated the first enantioselective model synthesis of the 2,3-
dihydro-1H-pyrrolo[1,2-a]indole core present in the putative structure of yuremamine. The 
2,3-dihydro-1H-pyrrolo[1,2-a]indole core containing three contiguous stereogenic centers 
was synthesized in 39% overall yield and 96% ee in 5 steps. The model synthesis leverages 
enantioselective, rhodium-catalyzed hydroacylation of an N-vinylindole-2-carboxaldehyde 
as the key step in the installation of the stereochemical triad. The ketone functionality 
present in the hydroacylation product served as a synthetic handle for the installation of 
additional stereogenic centers with precise control of absolute and relative stereochemistry. 
Progress toward enantioselective synthesis of the putative structure of yuremamine is also 
reported, and the enantioselective synthesis of a densely functionalized 
dihydropyrroloindolone core that maps onto its structure has been demonstrated in 26% 
yield and 97% ee over 8 steps. The synthetic strategy is likely to be amenable to synthesis of 
other natural products containing a 2,3-dihydro-1H-pyrrolo[1,2-a]-indole core and 
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highlights the utility of enantioselective hydroacylation reactions in the construction of 
complex molecular scaffolds. 
Despite many advances over the past decades, enantioselective synthesis of quaternary 
stereogenic centers remains a significant synthetic challenge. In 2011, 12% of the top 200 
prescription drugs sold in United States contained quaternary stereogenic centers and majority of 
these compounds are synthesized from naturally occurring compounds (steroids, opioids, taxane 
and diterpenoids) with the natural product precursor providing the quaternary stereogenic 
centers. To this end, we have developed a catalytic strategy that combines alkene hydroacylation 
with enantioselective α-(hetero)arylation reactions that construct a wide variety of nitrogen-
containing heterocyclic ketones bearing α-chiral quaternary stereogenic centers. The first step in 
the sequential protocol involves intramolecular nickel-catalyzed hydroacylations of N-
homoallylindole- and N-homoallylpyrrole-2-carboxaldehydes to form α-substituted six-
membered heterocyclic ketones or N-heterocyclic carbene (NHC)-catalyzed hydroacylations to 
form α-substituted five-membered heterocyclic ketones with absolute exo-selectivity. The 
racemic five- and six-membered products of Ni- and NHC-catalyzed hydroacylation reactions 
are readily transformed into heterocyclic ketones containing an α-chiral quaternary stereogenic 
center by enantioselective Ni-catalyzed α-(hetero)arylation reactions. The chiral, non-racemic 
products of sequential alkene hydroacylation and α-(hetero)arylation reactions are formed in 
moderate-to-high yields with excellent enantioselectivities. In contrast to the previous studies on 
nickel-catalyzed α-arylation involving carbocyclic ketone starting materials, the identity of the 
precatalyst for Ni-catalyzed α-(hetero)arylation is dictated by the identity of the α-substituted 
five- or six-membered heterocyclic ketone starting material. We also demonstrate a one-pot 
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protocol for sequential alkene hydroacylation and α-arylation that generates the heterocyclic 
ketone product in good yield and high enantioselectivity. Due to the potential to further 
functionalize the remaining carbonyl moiety, we believe that this sequence of reactions is poised 
to serve as a strategic approach to the synthesis of complex chiral heterocycles possessing 
benzylic quaternary stereocenters. 
In the final chapter, we have outlined a systematic study on the effects of phase, size, 
shape, oxidation state and preparation method of Ni2P nanocrystals on its catalytic activity 
toward hydrogenation of phenylacetylene. We have further discussed the effect of recycling on 
the catalyst surface through characterization of recycled Ni2P nanocrystals via powder XRD, 
TEM and XPS analyses. 
 
